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 ABSTRACT 
PHARMACOKINETIC MODELING OF  
99MTC-HMPAO IMAGES OF  
ISOLATED PERFUSED  
RAT LUNGS 
 
 
Katherine Barry, B.S. 
Marquette University, 2017 
 
The single-photon emission tomography (SPECT) imaging biomarker 
technetium-labeled hexamethylpropyleneamine oxime (99mTc-HMPAO) exists in two 
forms, the oxidized, cell-permeable form and the reduced, cell-impermeable form. Recent 
studies revealed that the lung uptake of 99mTc-HMPAO increases early in rat models of 
human acute lung injury. Lung uptake of 99mTc-HMPAO is the net result of multiple 
cellular and vascular processes, many of which can vary with acute illness. Thus, when a 
change in the lung uptake of 99mTc-HMPAO is detected, it is unclear how much of this 
change is due to alteration in the activity of the targeted cellular process versus alteration 
of some other process(es).  
The objective was to investigate the pharmacokinetics of 99mTc-HMPAO uptake in 
isolated perfused rat lungs and identify the dominant vascular and tissue processes 
involved in that uptake. Rats were anesthetized, and the lungs were excised and connected 
to an isolated perfused lung ventilation-perfusion system. 99mTc-HMPAO (1.5 mCi) was 
injected into the pulmonary arterial cannula, and a time-sequence of images was acquired. 
Imaging was repeated using a range of pump flow rates, perfusate protein concentrations, 
and before and after lung treatment with the glutathione-depleting agent diethyl maleate 
(DEM).  
A pharmacokinetic (PBPK) model for the pulmonary disposition of 99mTc-
HMPAO was developed and used for quantitative interpretation of the 99mTc-HMPAO 
lung time-activity curves. DEM decreased 99mTc-HMPAO lung uptake, consistent with a 
dominant role of lung GSH content in 99mTc-HMPAO uptake. The PBPK model was used 
to assess the sensitivity of 99mTc-HMPAO lung uptake to changes in flow rate, plasma 
protein concentration, capillary perfusion kinematics, lung 99mTc-HMPAO input function, 
and microvascular permeability.   
The approach we developed allows for evaluation of the dominant factors that 
determine 99mTc-HMPAO lung uptake, separation of the contributions of pulmonary 
processes from systemic processes, and application of this knowledge to in vivo studies. 
The approach can be extended to other biomarkers. These results may be important for 
clinical application of 99mTc-HMPAO as a means for early detection of acute lung injury 
and for assessing the efficacy of novel therapies. 
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Chapter 1: Introduction 
1.1 Background and significance 
 Single-photon emission tomography (SPECT) is a clinical nuclear tomographic 
imaging modality that utilizes a radiolabeled biomarker targeted either to a specific organ 
or to the product of a particular biological process. For SPECT, a gamma-emitting 
isotope is attached to a targeted ligand. A typical SPECT scan then involves 
administration of the radiolabeled biomarker, commonly by intravenous injection (iv), 
followed by acquisition of a set of planar images.  Subsequently, the image data is 
reconstructed to obtain a three-dimensional volume describing the amount of uptake of 
the biomarker at each voxel within the volume. Typically, the images are viewed by a 
radiologist for detection and/or classification of a pathologic condition. However, beyond 
visual interpretation, the images often lend themselves to quantification in order to 
ascertain physiologic parameters that may indicate the extent of the disease, e.g. tumor 
size and its change over time.  By acquiring SPECT data with a particular biomarker at a 
sequence of time points, a time-sequence of images is obtained leading to dynamic data 
that can be analyzed to quantify key pathways involved in the disease process.  The 
utility of a given biomarker for probing a given biological function depends on the 
sensitivity and specificity of its uptake and retention to changes in the targeted biological 
process [41].  
The SPECT imaging biomarker technetium-labeled hexamethylpropyleneamine 
oxime (99mTc-HMPAO) was originally used for measuring brain perfusion because of its 
prolonged retention in a flow-dependent distribution pattern [27]. 99mTc-HMPAO exists 
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in two forms, the oxidized, cell-permeable form and the reduced, cell-impermeable form 
[32]. The uptake of the oxidized form is dependent on its rate of diffusion across the cell 
membrane. Once it crosses the cell membrane and enters the cells, the oxidized form can 
either diffuse back to the blood or convert to its reduced, cell-impermeable form, which is 
retained within the tissue cells. The intracellular conversion and retention of HMPAO is 
dependent in part on the oxidoreductive state of the tissue and the tissue’s intracellular 
glutathione (GSH) content [9, 32]. Andersen et al. also demonstrated this dependence by 
showing the linear correlation between GSH concentration and the disappearance of 
lipophilic HMPAO [1]. GSH is an antioxidant that protects endothelial cells from 
oxidant-mediated damage [33]. The cellular concentration of GSH increases in response 
to oxidative stress, as demonstrated in previous studies using various rat models of acute 
lung injury (ALI) [7, 22, 33].  
In order to determine the role of GSH in the conversion of HMPAO, diethyl 
maleate (DEM), a known glutathione-depleting agent, is added to the perfusate. DEM 
depletes GSH by conjugating with it to form a thioether conjugate [6]. When GSH levels 
are substantially depleted, the rate of conversion of HMPAO is much slower and is likely 
dominated by other sources such as vascular permeability and mitochondrial dysfunction 
[6, 9, 30, 32]. 
The lung uptake of HMPAO is the net result of multiple cellular and vascular 
processes, including cardiac output, plasma and tissue GSH content, plasma protein 
binding, uptake by other organs, capillary endothelial permeability, mitochondrial and/or 
cytosolic redox status, and HMPAO lung input function. All of these cellular and 
vascular processes can vary with acute illness. In addition, the blood fraction of the lung 
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biomarker signal can be significant because of the lung’s high blood to parenchyma ratio. 
Thus, when a change in the lung uptake of HMPAO is detected, it is unclear how much 
of this change is due to alteration in the activity of the targeted cellular process induced 
by the disease pathology compared to alteration of some other process(es) (e.g. cardiac 
output, vascular permeability, input function) [9, 27].  
Due to the complexity of the lung uptake and retention of 99mTc-HMPAO, a 
physiologically based pharmacokinetic (PBPK) model is essential for mechanistic and 
quantitative interpretation of imaging data. PBPK models are derived from physiology 
and anatomy and provide the ability to simulate the introduction of a drug into the body, 
transport, and the uptake and metabolism of the drug in various organs [12]. Previous 
studies [27, 30, 32] have utilized compartmental PBPK models to quantitatively interpret 
imaging data of the brain. Compartmental models utilize ordinary differential equations 
under the assumption of instantaneous, well-mixed compartments. However, 
instantaneous mixing likely does not occur in the lung as blood moves very rapidly 
through it. Thus, a spatially distributed model, which relaxed the assumption of rapid 
mixing, was developed and used to interpret kinetic imaging data [3, 29]. The spatially 
distributed model accounted for spatial concentration gradients, and hence the resulting 
governing equations are in the form of partial differential equations. 
In order to clinically use 99mTc-HMPAO as a method for assessing lung 
pathology, the sensitivity and specificity of uptake to changes in cardiac output, GSH 
content, vascular permeability, lung input function, and other cellular processes, must be 
evaluated. The isolated perfused lung (IPL) preparation along with computational 
modeling are advantageous in this regard. The IPL preparation provides a means for 
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readily and knowingly manipulating the vascular and tissue processes hypothesized to 
determine lung uptake of 99mTc-HMPAO, including the targeted cellular process. In 
addition, IPL studies permit us to separate the contributions of pulmonary processes from 
systemic processes to the lung uptake of 99mTc-HMPAO and apply this knowledge to in 
vivo studies. The unique, open-design of our micro-SPECT system allows us to perform 
IPL studies as well as in vivo imaging studies with enhanced spatial resolution and high 
sensitivity.  
Acute lung injury (ALI), one of the most common causes of admission to the 
intensive care unit, is a rapidly progressing hypoxic lung failure following a direct or 
indirect injury to the pulmonary parenchyma or vasculature [31].  Common causes of 
ALI include sepsis, pneumonia, shock, and major trauma [28]. Acute Respiratory 
Distress Syndrome (ARDS) is the most severe form of ALI, affecting approximately 
200,000 patients per year in the U.S. alone and carrying a 30-40% mortality rate [28, 35]. 
This high mortality rate is due in part to a lack of clinical means for early detection and 
effective therapies. Ventilation with high fractions of oxygen (hyperoxia) is a common 
therapy for ARDS; however, prolonged exposure to hyperoxia can impair lung function 
[14]. Thus, development of clinical means for early detection and novel therapies for 
ALI/ARDS are urgently needed. 
Recently, Audi et al. demonstrated a significant increase in 99mTc-HMPAO lung 
uptake in rats exposed to hyperoxia (>95% O2 for 24 hrs), a well-established model of 
clinical ARDS [15, 37, 40]. Those results suggest the potential utility of 99mTc-HMPAO 
as an early indicator of ARDS prior to clinical evidence of injury [6]. However, clinical 
application of HMPAO requires further understanding of the dominant cellular and 
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vascular processes that determine the uptake and retention of 99mTc-HMPAO in normal 
and diseased lungs.  
The primary objective of this thesis was to investigate the pharmacokinetics of 
99mTc-HMPAO uptake in isolated perfused rat lungs.  This involves the development of a 
spatially distributed PBPK model for mechanistic and quantitative interpretation of lung 
99mTc-HMPAO images. This included identifying the dominant vascular and cellular 
processes that determine the lung uptake of 99mTc-HMPAO and estimating the parameters 
descriptive of each of these processes. The second objective was to determine the 
usefulness of the isolated perfused lung preparation for quantifying changes in 99mTc-
HMPAO lung uptake in rats exposed to hyperoxia (>95% O2 for 24 hrs).  The outcomes 
from this thesis are important for the clinical application of 99mTc-HMPAO as means for 
early detection of ARDS and for assessing the efficacy of novel therapies.  
 
1.2 Literature review 
As described below, several studies have evaluated the uptake of 99mTc-HMPAO 
in different organs, and computational modeling has been used as a tool for quantitative 
interpretation of resulting imaging data [6, 7, 9, 10, 11, 12, 14, 15, 17, 20, 21, 24, 27, 30, 
32, 37, 39, 40].  
  Altered 99mTc-HMPAO lung uptake has been reported in subclinical lung injury 
due to chemotherapy and radiation injury, in the absence of perfusion impairment or 
roentgenographic abnormalities. For instance, Suga et al. performed a study measuring 
the uptake of 99mTc-HMPAO as a marker of lung injury in two irradiation rabbit models 
and in chemotherapy patients [39]. The irradiation studies involved either injecting a low 
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dose of oleic acid or exposing rabbits to 50 Gy of radiation. Both are models of minimal 
lung injury to the pulmonary endothelium, which is believed to be an early event in the 
development of lung disease. Suga et al. also investigated the uptake of 99mTc-HMPAO in 
patients who had received chemotherapy or radiotherapy for lung cancer. Both animal 
models and the study involving the chemotherapy patients showed enhanced lung uptake 
of 99mTc-HMPAO, suggesting that 99mTc-HMPAO could be a sensitive marker of early 
and subclinical lung injury [39]. 
  Hang et al. also performed a study to measure the uptake of 99mTc-HMPAO in the 
lung [21]. They assessed pulmonary vascular endothelium damage in diffuse infiltrative 
lung disease (ILD), a group of disorders characterized by various types of cellular or 
extracellular infiltrates that affect the lung parenchyma, but do not impact the airway. 
The study involved a control group of patients without ILD, and a group of patients with 
ILD. All of the patients were given a dose of 99mTc-HMPAO and scanned 10 minutes 
after injection. The patients with ILD showed a significantly higher uptake than the 
control group, proving that 99mTc-HMPAO imaging may be a method for objectively 
assessing and detecting injury in ILD patients prior to detection using conventional 
clinical tools [21]. 
 Altered 99mTc-HMPAO lung uptake has also been reported in rat lungs exposed to 
high concentrations of O2 (hyperoxia) and in those treated with the endotoxin 
lipopolysaccharide (LPS), both well-established models of human ALI [15, 37, 40]. Audi 
et al. investigated the role of 99mTc-HMPAO lung uptake as a preclinical marker of lung 
injury in these two models. Despite the lack of structural and functional changes observed 
in the lungs, there was an increase in 99mTc-HMPAO uptake at both 24 hours (134%) and 
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48 hours (172%) of hyperoxia exposure and at 24 hours (188%) after LPS (1 mg/kg, IT) 
treatment. Audi et al. also measured a significant increase in the vascular endothelial 
filtration coefficient (Kf) at 48 hours, but no significant change at 24 hours. Diethyl 
maleate (DEM), a known glutathione-depleting agent, was injected (1 g/kg BW i.p.) in 
both models to determine the role of glutathione (GSH) in the enhanced 99mTc-HMPAO 
lung uptake. In both injury models, DEM greatly reduced the uptake of 99mTc-HMPAO as 
compared to normoxic rats (Figure 1.1). The DEM effect suggests a key role for 
hyperoxia- and LPS-induced increase in lung tissue GSH in the enhanced lung uptake of 
99mTc-HMPAO [6]. These results suggest the potential utility of 99mTc-HMPAO as a 
clinical means for early detection of ALI, prior to clinical evidence of injury. 
 
Figure 1.1. Lung uptake of 99mTc-HMPAO increases with exposure to 95% O2 and 
decreases with DEM [6]. 
 
 Rats exposed to 100% O2 die within 64-72 hours from lung injury [15]. Audi et al. 
evaluated the role of intracellular GSH in lung retention of 99mTc-HMPAO in two rat 
models with increased or decreased sensitivity to lethal (100% O2) exposure. For the first 
model, rats were exposed to 60% oxygen (O2) for 7 days, which increases the sensitivity 
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of the rats to subsequent exposure to lethal 100% O2 (susceptible rats). For the second 
model, rats were exposed to >95% O2 for 2 days followed by 24 hours in room air. This 
pre-exposure protocol induces tolerance in rats to subsequent exposure to 100% O2, in 
that if these rats (tolerant rats) are transferred to 100% O2, they can survive for extended 
periods of time. For those studies, 99mTc-HMPAO was injected intravenously in 
anesthetized rats and planar images were acquired. The results demonstrate that exposure 
to elevated O2 conditions leads to an increase in 99mTc-HMPAO retention with a 
substantially larger increase in the tolerant rats than susceptible rats. GSH is believed to 
be a dominant factor in the conversion of 99mTc-HMPAO from its lipophilic to 
hydrophilic form and its retention in the lungs. Audi et al. also determined that factors 
other than GSH content contribute to the lung retention of 99mTc-HMPAO [9]. 
 Tolerance to lethal 100% O2 can also be induced in rats by pre-exposing them to 
sub-lethal 85% O2 for 5-7 days. Clough et al. evaluated changes in the lung uptake of 
99mTc-HMPAO and 99mTc-duramycin, a SPECT biomarker for cell death, in rats exposed 
to 85% O2 for up to 21 days [14]. The objective of that study was to evaluate the potential 
of these two radiotracers for distinguishing the injury (days 1-7) and tolerance (days 7-
21) phases of prolonged exposure to sub-lethal 85% O2. Rats were exposed to 85% O2 for 
2, 4, 7, 14, or 21 days. Clough et al. found an increase in both 99mTc-HMPAO and 99mTc-
duramycin (a SPECT biomarker of endothelial cell death) uptake out to 7 days due to 
increases in the lung tissue redox status and cellular apoptosis or necrosis, respectively. 
However, during the tolerance phase there was no further change in 99mTc-HMPAO lung 
uptake, but 99mTc-duramycin uptake decreased back to normal levels. These results prove 
that these two biomarkers could be useful for differentiating the early inflammatory phase 
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of hyperoxia-induced ALI from the subsequent tolerance phase [14]. 
  Recently, Audi et al. demonstrated the potential utility of SPECT imaging with 
99mTc-HMPAO and 99mTc-duramycin to assess the efficacy of inhaled hydrogen (H2) gas 
as a potential therapy for ALI [17, 24]. They demonstrated increased lung uptake of 
99mTc-HMPAO and 99mTc-duramycin in a time-dependent manner in rats exposed to 98% 
O2 (balance N2) for up to 60 hours. Audi et al. also demonstrated the reduction of 99mTc-
HMPAO and 99mTc-duramycin uptake by 120% and 70%, respectively, in rats exposed to 
98% O2 + 2% H2 compared to rats exposed to hyperoxia (98% O2 + 2% N2) alone. These 
results suggest that H2 reduced hyperoxia-induced oxidative stress, consistent with 
measured tissue GSH concentrations in rat lungs exposed to hyperoxia or hyperoxia + H2 
[7]. 
  Compartmental models have been used in a number of studies for quantitative 
interpretation of 99mTc-HMPAO imaging data [23, 26, 27, 30, 32]. In a study by Lassen et 
al., 99mTc-HMPAO was injected into the internal carotid artery and SPECT cameras 
recorded its retention in the brain [27]. Lassen et al. developed a model of the brain in 
order to quantitatively interpret the imaging data. The first region of the model was the 
lipophilic tracer in the blood, which was not well-mixed. The second region was a well-
mixed compartment representative of the lipophilic tracer in the brain. The third 
compartment was the hydrophilic form retained in the brain. 99mTc-HMPAO was assumed 
to move freely between the first and second regions by diffusion and from the second 
compartment to the third by conversion from the lipophilic to the hydrophilic form [27]. 
This model may not be appropriate for the lung uptake of the lipophilic, oxidized form of 
99mTc-HMPAO since the lung has a relatively high blood flow rate and hence the 
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assumption of rapid mixing is not appropriate. 
  Neirinckx et al. also proposed a compartmental model based on the intracellular 
reaction of 99mTc-HMPAO with GSH in the brain [32]. 99mTc-HMPAO was added to rat 
brain homogenates. DEM was then added to deplete the GSH content (160 to 16 μM). 
The model consisted of two compartments that represented the freely diffusible, 
lipophilic form and the nondiffusible, hydrophilic form. The tissue distribution of 99mTc-
HMPAO showed a pattern dominated by blood flow [32]. The conversion rate in the 
presence of DEM decreased significantly from 0.12 min-1 to 0.012 min-1. Similar to 
Lassen’s model [27], Neirinckx’s model may not be appropriate for the rapid lung uptake 
of the lipophilic, oxidized form of 99mTc-HMPAO since it assumes rapid mixing of 99mTc-
HMPAO in the vascular and tissue compartments.  
  Matsuda et al. [30] utilized the model developed by Lassen et al. [27] to directly 
determine the rate constants and the cerebral blood flow (CBF) values in the human 
brain. They found an increase in initial back-diffusion of 99mTc-HMPAO in regions of 
high flow compared to those of lower flow. They also found consistency between the 
experimentally determined rate constant values and those reported by Lassen et al. [27] 
Matsuda et al. used a parameter estimation analysis of the time-activity data, in which 
they directly fit the data to the solution of the four-compartment kinetic model equations, 
to determine the rate constants and CBF values [30]. To the best of my knowledge, no 
computational model, compartmental or otherwise, has been developed for quantitative 
evaluation of the lung uptake of 99mTc-HMPAO or any other SPECT biomarker. 
  Several studies have evaluated the pharmacokinetics of SPECT tracers, including 
99mTc-HMPAO, in the isolated perfused heart [10, 20, 23, 29]. Kusuoka et al. and 
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Imahashi et al. focused on the myocardial kinetics of BMS181321 and HL91, 
respectively, in various oxygen levels and perfusion states, specifically normoxic, 
hypoxic, ischemic, and stunned states [23, 26]. Their studies involved isolated perfused 
rat hearts, which were hearts that had been excised and attached to a blood-perfusion 
system. Kusuoka et al. compared the kinetics of BMS181321 to those of 99mTc-HMPAO 
and 6-meythl propyleneamine oxime (PAO-6-Me) and found the time-activity curve of 
BMS181321 was very similar to 99mTc-HMPAO and PAO-6-Me in normoxic lungs and 
that retention was higher for all tracers in hypoxic myocardium than in normoxic [26]. 
They also found that the retention of 99mTc-HMPAO in the heart was not significantly 
different among normoxic, hypoxic, and ischemic myocardium. The results suggest that 
BMS181321 is trapped in the ischemic myocardium due to metabolism, similar to the 
trapping of 99mTc-HMPAO in the brain, and due to the nitroimidazole portion of the 
compound [26]. Imahashi et al. performed a similar study using 99mTc-4,9-diaza-
3,3,10,10-tetramethyldodecan-2,11-dione dioxime (99mTc-HL91) and a three-
compartment model to analyze the normoxic and hypoxic data [23]. Similar to Kusuoka 
et al., they found an increased retention in hypoxic hearts. Using the three-compartment 
model, Imahashi et al. discovered an intracellular trapping mechanism that is dependent 
on the level of oxygen bubbling through the perfusate, suggesting 99mTc-HL91 as a probe 
for measuring the severity of hypoxia [23]. 
  Fukushima et al. used the isolated heart preparation to evaluate the 
pharmacokinetics of 210Thallium (Tl), 99mTc-tetrofosmin (Tf), and 99mTc-sestamibi (MIBI) 
under normal and acute ischemia-reperfusion conditions [20]. The rat hearts were 
subjected to normal flow conditions, mild ischemia (no flow for 15 minutes), and severe 
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ischemia (no flow for 30 minutes) followed by administration of the SPECT tracers, and 
25 minutes of tracer washout. For quantitative interpretation of the resulting imaging 
data, they proposed a one-compartment model to describe the kinetics of each of these 
perfusion tracers and found that severe ischemia caused a decrease in the myocardial 
flow rate from the vascular space [20]. Ayalew et al. used a similar approach to 
investigate the role of cellular metabolic disorders on the decreased uptake of 201Tl and 
99mTc-MIBI with SPECT during low-flow ischemia or stunning in isolated perfused 
hearts [10]. Using this experimental and computational approach, both Fukushima et al. 
and Ayalew et al. were able to easily manipulate specific experimental parameters, such 
as the flow needed to induce ischemia. To the best of my knowledge, the studies 
performed for this thesis are the first for evaluating the pharmacokinetics of any SPECT 
biomarkers in isolated perfused lungs. 
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Chapter 2: Experimental Methods 
2.1 Materials 
HMPAO (Ceretec®) was purchased in kit form from GE Healthcare (Arlington 
Heights, IL). Diethyl maleate (DEM) and other reagent grade chemicals were purchased 
from Sigma-Aldrich (St. Louis, MO). 
 
2.2 Rat treatments 
Adult male adult Sprague-Dawley rats (300-400 g) were used for this study. Rats 
were placed in a sealed, temperature controlled, acrylic 59 L chamber (33.0 × 58.3 × 30.5 
cm) and exposed to room air (normoxia, n = 11) or >95% oxygen (hyperoxia, n = 3) for 
24 hours. Within the chamber, carbon dioxide (CO2) levels were maintained at <0.5%, 
and temperature was maintained at 20-22°C. The rats were exposed to a 12:12 hours 
light-dark cycle. The O2 and CO2 levels were monitored to ensure the desired O2 
concentration was achieved. This protocol has been approved by the Institutional Animal 
Care and Use Committees of the Veterans Affairs Medical Center and Marquette 
University (Milwaukee, WI).  
 
2.3 Isolated perfused rat lung preparation 
Each rat was weighed and anesthetized with sodium pentobarbital (40-50 mg/kg) 
and a midline sternotomy was performed (see Appendix A.2). Heparin was injected into 
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the right ventricle and cannulas were placed in the pulmonary artery via the right 
ventricle, in the pulmonary vein via the left ventricle, and in the trachea. The lungs were 
then removed and attached to the ventilation-perfusion system using the pulmonary artery 
and trachea cannulas (Figure 2.1). Pressure transducers were used to monitor the pressure 
in the airway and the pulmonary artery. 
 
 
Figure 2.1. Experimental setup for the isolated perfused lung system. The lung is 
attached to the system via the trachea cannula and the pulmonary arterial cannula. The 
lung is perfused at a rate of 40 breaths/min. Krebs-Ringer bicarbonate perfusate (with 3% 
or 5% bovine serum albumin (BSA)) will be pumped from the reservoir through the 
pulmonary artery at a rate of 5-15 mL/min.  
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2.4 Micro-SPECT system  
The micro-SPECT system used is composed of a gamma ray camera with a 
square detection area of 4.5 inches on each side. The camera has a single-crystal NaI(Tl) 
scintillator, a 15-mm thick quartz light guide, and a 3x3 array of 1.5-in diameter 
Hamamatsu photomultiplier tubes with high quantum efficiency and gain. A parallel-hole 
collimator (hexagonal with 1.7 mm diameter holes and 2.54 cm thickness) was placed in 
front of the camera for image formation. The stage and camera operations were 
controlled using LabVIEW on a PC workstation. An energy threshold of 140 keV was 
used to reject scatter known to cause error in the images.  
 
2.5 Planar imaging of isolated perfused rat lung 
The isolated perfused lung was suspended vertically and attached to the single 
pass ventilation-perfusion system via the arterial and trachea cannulas (Figure 1). Prior to 
attachment, the perfusion system was primed with Krebs-Ringer bicarbonate perfusate 
containing (in mM) 4.7 KCl, 2.51 CaCl2, 1.19 MgSO4, 2.5 KH2PO4, 118 NaCl, 25 
NaHCO3, and 5.5 glucose, with 3% or 5% bovine serum albumin (BSA). The arterial 
cannula was attached to the pump outlet and the trachea cannula was attached to a rodent 
ventilator (15% O2, 6% CO2, balance N2) set at 40 breaths/minute. The parallel-hole 
collimator, which abutted the front of the camera, was positioned as close as possible to 
the lung (~4 cm).  
The perfusate was maintained at 37°C and equilibrated with 16% O2, 6% CO2, 
and balanced with N2, resulting in PO2, PCO2, and pH of ~105 Torr, 40 Torr, and 7.4, 
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respectively. The lung was ventilated with the previously mentioned gas mixture and 
with end-inspiratory and end-expiratory airway pressures of ~6 and 3 mmHg, 
respectively. The pulmonary arterial and venous pressures were referenced to 
atmospheric pressure at the level of the left atrium. The analog signal was amplified by 
the Hugo Sachs Elecktronik Harvard Apparatus amplifier and then converted to a digital 
signal and monitored and recorded using the DataQ Instruments DI-710 A/D converter. 
The pressure data was monitored and recorded using the WinDaq Data Acquisition 
software at a frequency of 13.3 Hz per channel. The perfusate was pumped from the 
reservoir through the pulmonary artery and into the lung at a flow rate of 5 ml/min, 10 
ml/min, or 15 ml/min. Each lung was perfused with the perfusate for several minutes, 
until the lung was evenly blanched, and the venous effluent was clear of visible blood.  
HMPAO was conjugated with pertechnetate (TcO4-) according to the kit 
directions to form 99mTc-HMPAO. A bolus of 99mTc-HMPAO (1.5 mCi in 0.2 ml) was 
loaded into an injection loop positioned upstream from the arterial cannula. The injection 
loop contained two parallel segments of tubing. The bolus was loaded into the stagnant 
segment of tubing, while perfusate flowed through the other segment. Just prior to the 
injection and at the end of expiration, the ventilator was stopped. Dynamic planar images 
were acquired every second for 1-2 minutes (depending on the flow rate) using 
LabVIEW, the micro-SPECT data acquisition software. The first ~5 seconds of 
acquisition were used to establish a baseline before 99mTc-HMPAO was injected. The 
solenoid valve in the injection loop was then activated to permit the flow of 99mTc-
HMPAO into the lung, without changing the pressure or flow. The solenoid valve 
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diverted the lung inflow path of perfusate from the tube segment containing perfusate to 
the parallel segment containing the bolus.  
To determine the dominant cellular processes that account for the lung uptake and 
retention of 99mTc-HMPAO, various inhibitors and precursors (Section 2.6) were also 
added to the perfusate flowing through the lung without changing the pressure or flow. 
Between injections the lung was ventilated. After completion of the series of 
experimental injections, the lung with the attached cannulas was removed from the 
perfusion system and placed in a lead pig. The pig was stored in the specimen refrigerator 
for 72 hours (99mTc has a half-life of ~6 hrs) until the radioisotope decayed to safe levels. 
The wet weight was obtained, and the lung was placed in the oven for three days to dry. 
Then the dry weight was obtained. 
 
2.6 Experimental protocols 
 After the lung was suspended, but prior to 99mTc-HMPAO injection, a calibration 
phantom containing ~4 mCi of technetium-99m was imaged. The calibration phantom 
was placed next to the lung, approximately the same distance from the collimator as the 
lung. The calibration phantom was used to calculate the percent of 99mTc-HMPAO taken 
up by the lung.  Following this calibration procedure, one or more of the following 
protocols were carried out in each of the lungs. 
 
- Evaluation of the sensitivity of 99mTc-HMPAO lung uptake to perfusate flow rate 
Using 3% BSA perfusate, bolus injections of 99mTc-HMPAO were performed at 
flow rates of 5 mL/min, 10 mL/min, and 15 mL/min. This was done to determine the 
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impact of flow rate on the lung time-activity curve since changes in cardiac output can 
occur with ALI/ARDS and other lung injuries/diseases. In particular, changes in flow 
rate can provide information about the rate of diffusion (PS product) of the oxidized 
form of 99mTc-HMPAO between perfusate and tissue.  
 
- Impact of bovine serum albumin (BSA) percentage in perfusate on the lung 
uptake of 99mTc-HMPAO 
To determine the effect of protein in the perfusate on the uptake and retention of 
99mTc-HMPAO, bolus injections of 99mTc-HMPAO were made using perfusate 
containing either 3% or 5% BSA with a flow of 10 mL/min. 99mTc-HMPAO binds with 
protein which decreases the amount of free 99mTc-HMPAO available for cellular uptake 
[2].  
 
- Impact of diethyl maleate (DEM) on the lung uptake of 99mTc-HMPAO 
To determine the impact of GSH on the uptake and retention of 99mTc-HMPAO, a 
glutathione (GSH)-depleting agent, known as DEM, was added to the perfusate, (6 
mM) and allowed to pass through the lung for 10 minutes prior to bolus injections and 
imaging. The resulting time activity curves provide information needed to identify the 
values of the rate constants of the GSH-dependent and independent pathways in the 
PBPK model.  
 
- Impact of mitochondrial uncoupler pentachlorophenol (PCP) or mitochondrial 
complex IV inhibitor potassium cyanide (KCN) on the lung uptake of HMPAO 
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To determine the role of various mitochondrial complexes on the uptake and 
retention of 99mTc-HMPAO, PCP (3 mM) or KCN (2 mM) was added to the perfusate 
and allowed to pass through the lung for 2 minutes. Bolus injections of 99mTc-HMPAO 
were then carried out with the flow rate set at 10 mL/min. 
  
 20 
Chapter 3: Data Analysis 
3.1 Image analysis 
For a given bolus injection, the files of the acquired planar images were converted 
to .img format files (Appendix C.2) and imported into ImageJ (Appendix C.3) to extract 
the time activity curves (TACs) of the arterial inlet, lung, and venous outlet. In ImageJ, 
the Generate_TAC plug-in was used to create the TAC from the planar images. To that 
end, regions of interest (ROIs) were manually outlined on a summed image of all the 
dynamic planar images (Figure 3.1). These ROIs were for the lung input, the lung output, 
and the lung. The lung ROI mask was then superimposed on the sequence of 99mTc-
HMPAO images and used to calculate the mean counts per pixel within the lung region 
for each time frame. The ROI files were then imported into MATLAB to view the 
resulting curves. For each curve, the pre-injection baseline activity level corresponding to 
the first ~5 seconds was subtracted from the curve to account for any residual 99mTc-
HMPAO from the previous injection. The curve was then normalized to the injected dose 
to obtain the TAC in units of mean counts/pixel/s/injected dose within each ROI. 
Representative examples of an arterial, lung, and venous TAC are shown in Figure 3.2. 
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Figure 3.1. Summed ImageJ image of the three regions of interest (ROIs), namely lung 
input (1), lung output (2) and lung (3). 
  
Figure 3.2. Normalized lung input, lung output, and lung TACs from a normoxic lung 
following a 0.2 ml, 1.4 mCi bolus injection of 99mTc-HMPAO.  The left axis is for the 
input and output TACs, whereas the right axis is for the lung TAC. The experiment was 
performed with F = 10 ml/min and 3% BSA.  
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3.2 Physiologically-based pharmacokinetic (PBPK) model 
The lung uptake and retention of 99mTc-HMPAO on passage through the 
pulmonary circulation could be affected by various cellular and vascular processes, 
including cardiac output, blood and tissue glutathione (GSH) content, plasma protein 
binding, uptake by other organs, capillary endothelial permeability, mitochondrial and/or 
cytosolic redox status, and the lung 99mTc-HMPAO input function. Thus, when a change 
in the lung uptake of 99mTc-HMPAO is detected, it is not clear from the measured TACs 
how much of this change is due to alteration in the activity of the targeted cellular process 
(lung tissue GSH content) versus alteration of some other process(es) (e.g. cardiac output, 
vascular permeability, lung 99mTc-HMPAO input function). In order to use 99mTc-HMPAO 
as a method for early ALI detection or early detection of pulmonary oxidative stress, we 
need to identify and quantify the dominant cellular and vascular processes that determine 
the lung uptake of 99mTc-HMPAO and the sensitivity of the measured TACs to a change 
in each of these processes.  To that end, we developed a distributed in time and space 
physiologically-based pharmacokinetic (PBPK) model and used it for quantitative 
interpretation of the measured lung TACs, including estimation of the values of the 
model parameters descriptive of these processes. The following are the model 
assumptions:  
• Injected 99mTc-HMPAO is 100% in the oxidized form. 
• No uptake of 99mTc-HMPAO on passage through the arterial or venous sections of 
the pulmonary circulation since their vascular surface area is relatively small 
compared to that of the capillary or microvascular region of the pulmonary 
circulation. 
 23 
• No bolus dispersion on passage through the arterial and venous regions of the 
pulmonary circulation [27].  
• All reactions are reversible, but they are significantly faster in the forward 
direction than in the reverse direction. Thus, the reverse reaction rate constants are 
assumed to be zero on the time scale of the data acquisition period for a given 
injection. 
• The GSH-dependent rate of 99mTc-HMPAO reduction in the vascular region is 
assumed to be zero, unless exogenous GSH is added to the perfusate. 
• Convection occurs only within the vascular region.  
• Transport in the extravascular or tissue region occurs only by diffusion.  
• No axial diffusion in the capillary region due to the large Peclet number, the ratio 
of the convection flux to diffusion flux [8]. 
• Instantaneous radial diffusion in the capillary region due to the relatively small 
capillary radius [8].  
There is ample evidence that the lung uptake of 99mTc-HMPAO is relatively fast 
on passage through the pulmonary circulation [6, 27, 32]. This suggests that the 
assumption of well-mixed compartments made by existing models for 99mTc-HMPAO 
pharmacokinetics may not be appropriate, especially since the lung capillary perfusion is 
highly heterogeneous with some pathways having short transit times and others having 
long transit times [8]. To address this issue, a distributed in time and space PBPK model 
for the pulmonary disposition of 99mTc-HMPAO was developed. This model relaxes the 
assumption of well-mixed compartments and accounts for the perfusion heterogeneity of 
the pulmonary capillary region.  
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Figure 3.3. Distributed in time and space PBPK model of the dominant lung processes 
involved in the uptake and retention of 99mTc-HMPAO on passage through the pulmonary 
circulation. The model consists of two regions, the vascular (blood) region and the 
surrounding extravascular (cell/tissue) region. Figure 3.3a represents the capillary region 
as a series of non-interacting elements with an overall distribution of transit times, hc(t) 
(Figure 3.3b). Figure 3.3c shows a single capillary element of the PBPK model.  
 
The model consists of conducting arteries and veins as well as the capillary region 
where biomarker uptake occurs. Each capillary element (Figure 3.3c) consists of a 
vascular region and its surrounding tissue region.  
After passing through the conducting arteries, 99mTc-HMPAO enters the capillary 
region of the lung. Within the vascular region, the free oxidized form of 99mTc-HMPAO 
participates in rapidly equilibrating interactions with albumin (BSA) in the perfusate and 
either converts to its reduced form via a GSH-dependent process (k1[GSH]b) and exits the 
lung or diffuses across the cell membrane into the tissue region surrounding the 
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capillaries. This is consistent with the fact that the free oxidized form of 99mTc-HMPAO 
has an octanol-water partition of ~83 (as compared with 0.006 for the reduced form) [9]. 
The uptake of 99mTc-HMPAO is dependent on its rate of diffusion (PS) across the cell 
membrane. Once 99mTc-HMPAO crosses the cell membrane and enters the tissue region, 
it can either convert from the oxidized to the reduced form via a GSH-dependent 
(k2[GSH]c) or GSH-independent pathway (k3[RH]) and be retained, or it can diffuse back 
into the vascular region of the capillaries.  
Both the oxidized and the reduced forms of 99mTc-HMPAO pass through the 
conducting veins by convection. Similar to the arteries, the veins are represented by a 
shifted impulse response function (Section 3.2.2).  
The interactions described above result in temporal and spatial variation in the 
concentrations of the oxidized and reduced forms of HMPAO in the vascular and tissue 
regions. The following set of partial differential equations (Eqns. 3.1-3.4) were obtained 
using mass balance and mass action.  
![#$]&!' +𝑊 ![#$]&!* = ,-.& /[𝑄]1 − [#$]&345[6]789: − 𝑘4[𝐺𝑆𝐻]? / [#$]&345[6]789:  (3.1) 
![@]&!' + 𝑊 ![@]&!* = 𝑘4[𝐺𝑆𝐻]? / [#$]&345[6]789:   (3.2) 
![#]A!' = ,-.A / [#$]&345[6]789 − [𝑄]1: − [𝑄]1𝑘B[𝐺𝑆𝐻]1 − [𝑄]1𝑘C[𝑅𝐻]1  (3.3) ![@]A!' = [𝑄]1𝑘B[𝐺𝑆𝐻]1 + [𝑄]1𝑘C[𝑅𝐻]1   (3.4) 𝐾F = GHIGI      (3.5) [𝑄$]? = [𝑄]? + [𝐵] = [𝑄]? K1 + [,]M8N		    (3.6)  
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The complete derivation of these equations and additional assumptions can be 
found in Appendix A. The above equations assume rapidly equilibrating interactions 
between the oxidized form of HMPAO in the vascular region and P, which is the BSA 
concentration in the perfusate. B is the form of HMPAO bound to BSA, [𝑄$]P is the total 
vascular concentration of both the free and bound forms of oxidized HMPAO, k4 and k-4 
are the association and dissociation rate constants of the oxidized form of HMPAO with 
BSA, respectively, and Kd is the equilibrium dissociation constant. Kd was estimated by 
optimizing the 3% BSA curve with the [P]/Kd as a free parameter. Kd was then calculated 
from the estimated ratio and [P] = 3% and set as a fixed parameter.  
 
3.2.1 Whole-organ distributed in time and space model 
The above partial differential equations are for a single capillary element. To 
account for the effect of capillary perfusion kinematics on the lung uptake of 99mTc-
HMPAO, an organ model was constructed that accounts for the distribution of pulmonary 
capillary transit times, hc(t), and for the arterial and venous conducting vessels [8]. 
The lung is assumed to consist of N parallel, non-interacting capillary elements, 
each with a different transit time. The distribution of pulmonary capillary transit times, 
hc(t), is the result of capillaries with different lengths, flows, cross-sectional areas, or any 
combination of these. For a given capillary transit time distribution, hc(t), let  
  𝐻Q = ∆'B (ℎ1 K𝑡Q − ∆'B N + ℎ1 K𝑡Q + ∆'B N)    (3.7) 
    ∑ 𝐻Q = 1X*QY4       (3.8) 
where Hi is the flow-weighted fraction of capillaries with transit time ti, and Hi is 
calculated for N different capillary transit times [8]. All capillaries are exposed to the 
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same flow and capillary input function, Cin(t), under the assumption of random coupling 
conditions between the conducting vessels and exchanging vessels [8].  Figure 3.4 shows 
a capillary transit time distribution with µ = 2.5 s and 𝜎B	= 0.5 s2. 
 
 
Figure 3.4. (Top) Capillary transit time distribution hc(t) generated using a gamma 
variate function with a mean transit time of 2.5 s and a variance of 0.5 s2. (Bottom) The 
weighted curve (Hi) is the fraction of capillaries with transit time 𝑡Q 	= 	𝑖	 × 	𝑑𝑡; Hi is 
calculated form hc(t) with dt = 0.005 sec (𝑁𝑥	 = 	1 𝑑𝑥⁄ = 973 capillaries, where dx is the 
step-size in the x-direction). 
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For each capillary, the governing PDEs were solved numerically using the finite 
difference method (see Appendix A for derivation) with the following initial (t = 0) and 
boundary (x = 0) conditions (Eqns. 3.9 and 3.10-3.11, respectively), where Qa is the lung 
input function (Cin(t)) convolved with the shifted impulse response function) representing 
the pulmonary arteries. 𝑄?(0, 𝑥) = 𝑄1(0, 𝑥) = 𝑅?(0, 𝑥) = 𝑅1(0, 𝑥) = 0   (3.9) 𝑄?(𝑡, 0) = 𝑄c       (3.10) 𝑄1(𝑡, 0) = 𝑅?(𝑡, 0) = 𝑅1(𝑡, 0) = 0    (3.11) 
Two different methods were used to solve the resulting finite difference equations 
for the different capillaries [8]. The first method (Method A) solves the partial differential 
equations for N capillaries with different transit times 𝑡Q = 𝑖∆𝑡, where ∆t is an arbitrary 
step size and i = 1, …, N, as shown in Figure 3.5. The capillary outflow concentrations 
for the oxidized and the reduced form of 99mTc-HMPAO in the tissue and blood were then 
obtained by summing (performing a mass balance) the solutions at the output of the N 
capillaries with the output of each capillary weighted by its corresponding Hi. The lung 
time-activity curve is then the cumulative difference between the input, represented by 
the gamma variate function, and the venous outflow curves at each time point [8]. 
 
Figure 3.5. Method A: N parallel pathways corresponding to N capillaries with different 
mean transit times (tCi where i = 1, …, N) and Cin(t) capillary input function [8]. 
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The second method (Method B) solves the governing differential equations for a 
single capillary with the longest mean transit time, tN, as shown in Figure 3.6. By solving 
for the longest mean transit time, the capillary can then be segmented by dt to 
approximate the range of capillary transit times. Because the model produces a continuity 
wave that travels only in the positive z (axial) direction, the time-concentration functions 
at all z locations along this maximum mean transit time capillary can be interpreted as 
individual outflow concentration curves from capillaries with transit times corresponding 
to the z locations. This can be seen in Figure 3.6 where the concentration at the ith node 
of the maximum transit time corresponds with the outflow concentration time curve for a 
capillary of transit time 𝑡Q = 𝑖	 × 	𝑑𝑡 [8]. 
 
Figure 3.6. Method B solves the model partial differential equations for the capillary with 
the longest transit time. Ci corresponds to the outflow concentration for each capillary 
with a transit time falling between the minimum and maximum transit time. Hi is the 
flow-weighted fraction of capillaries with transit time t [8].  
 
 
Figure 3.7 shows a comparison of the results of both methods used to solve the 
finite difference equations. Method A and B produce virtually the same concentration 
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curves; however, Method B is computationally more efficient [8], and hence was used for 
fitting the model solution to data and for estimating the values of model parameters. 
Both the oxidized and the reduced form of 99mTc-HMPAO pass through the 
conducting veins by convection. Similar to the arteries, the veins are represented by a 
shifted impulse response function. Hence the lung output is the capillary outflow 
concentration-time curves convolved with the venous shifted impulse function. 
  
Figure 3.7. Simulated organ output time activity curves with the governing differential 
equations solved using Method A and Method B. 
 
3.2.2. Lung input curve, capillary transit time distribution, and the mean transit 
times of the arterial and venous regions of the pulmonary vasculature  
 
 
In order to solve the governing differential equations of the PBPK model and to 
estimate the values of the model parameters, the lung input function, the capillary transit 
time distribution (hc(t)), and the arterial and venous mean transit times must be specified.   
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To determine the lung input curve to be used in the model, a gamma variate 
function (Equation 3.12) was fit to the experimental lung inlet TAC where 
𝐶Qe(𝑡) = f 0, 𝑡g ≤ 0(𝑡 − 𝑡g)3ijkj9l4𝑒𝑥𝑝	(− ('l'o)(pj qr )), 𝑡g > 0   (3.12) 
and µ is the mean transit time, s2 is the variance, and t0 is a time shift. Figure 3.8 shows a 
representative example of a measured and model-fit input curve obtained at F = 10 
ml/min. This was carried out in MATLAB using the lsqcurvefit function that uses the 
Levenberg-Marquardt procedure to perform the optimization. The resulting gamma 
variate function was used as the lung input function (Cin(t)) in the PBPK model for the 
corresponding 99mTc-HMPAO bolus injection. 
 
Figure 3.8. Fit of a gamma variate function to the measured lung inlet TAC following the 
bolus injection of 99mTc-HMPAO. The resulting gamma variate function was used as the 
lung input function (Cin(t)) for the PBPK model. 
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For the model, the capillary transit time distribution, hc(t), was represented using a 
gamma variate function (Equation 3.13) with mean transit time (𝜇1) and variance (𝜎B1) 
equal to previously measured values reported by Ramakrishna et al. [36].  
ℎ1(𝑡) = f 0, 𝑡 ≤ 0(𝑡)3iAjkjA9l4𝑒𝑥𝑝	(− (')(pjA qAr )), 𝑡 > 0    (3.13) 
where 𝜇1 = 2.45 ± 0.37 (SE) s, and 𝜎B1  = 4.05 ± 0.63 s2 when F = 10 ml/min.  
To obtain the functional forms of hc(t) at flows of 5 and 15 ml/min, hc(t) at 10 
ml/min was rescaled by dividing time by the ratio of the new flow (5 ml/min or 15 
ml/min) to 10 ml/min and by multiplying its amplitude by the ratio of the new flow rate 
to 10 ml/min as shown in Figure 3.9.   
  
Figure 3.9. Gamma variate functions representing the capillary vascular transit time 
distribution (hc(t)) at flows of 5, 10, and 15 ml/min. 
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Under the assumption of no vascular dispersion in the arterial and venous regions 
of the vasculature, the arterial and venous transit time distributions at 10 ml/min were 
each represented with a shifted impulse function with the shift equal to 50% of the 
difference between the total vascular (4.18 ± 0.26 s) and the capillary mean transit times 
[36], i.e. for F = 10 ml/min the arterial and venous shifts are each 0.87 s.  These times 
were scaled as described above for flows of 5 and 15 ml/min. Note that for each section 
of the vascular bed, the volume is the product of the total mean transit time (arteries, 
capillaries, and veins) and the flow rate.   
 
3.3. Estimation of values of the model parameters 
Knowing the mean transit time and variance of the lung input curve, the shifts of 
the arterial and venous impulse functions, and the capillary transit time distribution (hc(t)) 
(Section 3.2.2), the remaining unknown model parameters (Table 3.1) were then 
estimated by fitting the model solution to lung TACs. Nonlinear regression was used to 
fit the model solution to measured 99mTc-HMPAO TACs pre- and post-DEM 
simultaneously.  
 
Table 3.1 Unknown model parameters  
Parameter Symbol Units 
Permeability surface area product PS ml/s 
Extravascular volume Vc ml 
Rate constant for GSH-dependent reduction 
of HMPAO in the tissue region k2[GSH]c s
-1 
Rate constant for GSH-independent reduction 
of HMPAO in the tissue region k3[RH] s
-1 
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For a given lung, the % uptake of the injected dose of 99mTc-HMPAO was 
estimated by normalizing both the mean of the lung TAC data and the measured 
calibration phantom data for that day by the amount injected and multiplying them by 
their respective ROI areas. For the lung TAC data, the pre-injection baseline activity 
level, corresponding to the first ~5 seconds, was subtracted from the curve to account for 
any residual 99mTc-HMPAO from the previous injection. The lung TAC data was then 
divided by the calibration phantom data to obtain the percent uptake. This process was 
performed for both pre- and post-DEM data. 
The correlation matrix was used to measure the dependency between the 
estimated values of the model parameters. If the correlation coefficient (in absolute 
value) between any two parameters is > 0.95, the two corresponding parameters are 
considered to be highly correlated, and hence cannot be independently estimated since a 
change in one can be compensated for by a change in the other. The model fit to the data 
was evaluated using the sum of squared differences (Eqn. 3.14). The 95% confidence 
intervals were also obtained as measures of confidence in the estimated values of the 
model parameters (Eqn. 3.15).  𝑆𝑢𝑚	𝑜𝑓	𝑠𝑞𝑢𝑎𝑟𝑒𝑑	𝑑𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒𝑠 = 𝑆𝑆𝐷 =	∑ (𝑚𝑜𝑑𝑒𝑙Q − 𝑑𝑎𝑡𝑎Q)BXQY4  (3.14) 𝜃 	± 𝑠{(𝑋𝑋)l4} 	× 	𝑡(𝑁 − 𝑃;	B)     (3.15) 
where {(𝑋𝑋)l4}  is equal to the jth diagonal element of the matrix (𝑋𝑋)l4 and X is 
equal to the Jacobian matrix, which is one of the outputs of the MATLAB function 
lsqcurvefit. 
The sensitivity function, Sj, was used to reveal the portion of the data that is sensitive 
to a change in the jth model parameter, qj, (Eqn. 3.16). 
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𝑆 = !()! Y	     (3.16) 
where η(θ) is the lung TAC with values of the model parameters (𝜃) set to those that best 
fit the model solution to the data (𝜃). 
 The PBPK model provides a foundational platform for investigating the 99mTc-
HMPAO uptake and retention properties in the lung. The estimated model parameters can 
be used to infer changes in key cellular processes that may incur with lung injury or 
disease. However, in clinical settings, the use of the model may not be feasible, yet the 
lung TAC and its shape may still provide useful physiological information. Thus, in all of 
the experiments we also quantified the lung steady-state uptake by defining it to be the 
mean of the last data points where the lung TAC has reached a steady-state. 
Summary 
The following steps summarize the procedure for analyzing a set of lung input and lung 
TACs obtained prior to and following the addition of DEM to the perfusate. 
1. Acquire time sequence of images. 
2. Use ImageJ to draw ROIs and obtain the lung TACs. 
3. In MATLAB, normalize the curves to the amount injected and shift the baseline 
to 0. 
4. Fit the 99mTc-HMPAO input curve to a gamma variate to obtain the mean and 
variance of the lung input curve. 
5. Using the fitted input curve values and the published capillary transit time 
distribution values, simultaneously fit two independent curves using nonlinear 
regression to obtain the model parameters and the lung steady-state uptake value. 
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Chapter 4: Experimental Results 
Lungs from normoxic (control, N = 11) rats and rats exposed to >95% O2 for 24 
hrs (hyperoxia, N = 3) were imaged. Table 4.1 includes the body weights, lung wet and 
wet/dry weights at the end of the imaging protocol, and arterial pressures at perfusate 
flow rate of 10 ml/min. The pre- and post-exposure body weights for hyperoxic (>95% 
O2) lungs were not significantly different (p = 0.578, paired t-test). The normoxic and 
hyperoxic wet weights, post-exposure body weights, wet/dry weight ratios, and arterial 
pressures were also not significantly different (t-test, p = 0.941, p = 0.633, p = 0.220, and 
p = 0.590, respectively). These results are consistent with those reported by Crapo et al. 
and Audi et al. [6, 15]. All reported results are for normoxic rats unless otherwise 
indicated. 
 
Table 4.1 Rat body weights and lung wet and dry weights  
Treatment 
Pre-
exposure 
body weight 
(g) 
Post-
exposure 
body 
weight (g) 
Wet 
weight (g) 
Wet to dry 
weight 
ratio 
 
Arterial 
Pressure 
(mmHg) 
Normoxic 
(N) N/A 
352 ± 7 
(11) 
1.22 ± 0.04 
(11) 
4.90 ± 0.13 
(11) 
5.46 ± 0.62 
(8) 
Hyperoxic 
(N) 
344 ± 7 
(3) 
346 ± 10 
(3) 
1.22 ± 0.04 
(3) 
5.10 ± 0.08 
(3) 
4.72 ± 0.76 
(3) 
Values are mean ± S.E. N is the number of rats. Arterial pressures are for flow rate of 10 
ml/min. 
 
 
The resulting imaging data are presented as time-activity curves (TACs) from 
lung inlet, lung, and lung outlet ROIs. The activity of each of the measured TACs was 
normalized to the mCi of technetium or 99mTc-HMPAO injected, and the resulting 
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normalized activity was shifted to have a baseline of zero. For a given lung, the resulting 
TACs following a bolus injection of 99mTc-HMPAO are exemplified in Figure 4.1 as 
depicted earlier. As expected, the lung output TAC is more dispersed and has a longer 
mean transit time as compared to the input TAC, consistent with the dispersion of the 
injected 99mTc-HMPAO bolus as it passes through the pulmonary circulation and with the 
heterogeneity of lung perfusion kinematics [8, 36]. The lung TAC consists of a 
throughput portion that dominates the early part of the curve and tissue uptake and 
retention portion that dominates the later, steady-state portion of the curve. The steady-
state portion of the lung TAC is consistent with the fact that the reduced form is tissue 
impermeable. Results show that at 10 ml/min and 3% BSA perfusate, 35.9 ± 4.73% (SE, 
N = 8) of the injected dose was retained in the lung tissue during a single pass through 
the pulmonary circulation of normoxic lungs, consistent with the relatively high 
lipophilicity of the oxidized form of 99mTc-HMPAO.  
  
Figure 4.1. Normalized lung input, lung output, and lung TACs from a normoxic lung 
following the injection of a 0.2 ml, 1.4 mCi bolus of 99mTc-HMPAO with 3% BSA and 
flow rate of 10 ml/min. The left axis is for the input and output TACs, whereas the right 
axis is for the lung TAC. 
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Experiments were performed at flow rates of 5, 10, and/or 15 ml/min to determine 
the effect of flow on the lung uptake of 99mTc-HMPAO. As Figure 4.2 shows, the lung 
uptake of 99mTc-HMPAO, as measured by the steady-state value of the 99mTc-HMPAO 
lung TAC, was inversely related to the flow rate. This is consistent with the fact that as 
the flow rate increases, the lung mean transit time decreases and hence time available for 
99mTc-HMPAO uptake during passage through the lung decreases. The effect of flow rate 
on the lung uptake of 99mTc-HMPAO suggests that although the lung uptake appears to be 
relatively fast, it is not flow-limited and hence steady-state uptake is sensitive to a change 
in flow.  Decreasing the flow from 10 to 5 ml/min resulted in a significant increase 
(~55%, paired t-test, p <0.001) in steady state lung uptake (2.74 ± 0.27 (SE, N = 8) at 10 
ml/min vs. 4.30 ± 0.30 (N = 8) at 5 ml/min) using 3% BSA perfusate. Increasing the flow 
rate from 10 ml/min (2.70 ± 0.27, N = 5) to 15 ml/min (2.33 ± 0.15, N = 5) resulted in a 
small but not statistically significant decrease (~13%, paired t-test, p = 0.324) in lung 
steady-state uptake. Potential reasons for the insignificant effect of increasing the flow 
rate from 10 to 15 ml/min on the lung uptake of 99mTc-HMPAO are included in the 
Discussion Chapter. 
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Figure 4.2. Representative 99mTc-HMPAO lung TACs obtained following bolus 
injections at 5, 10, and 15 ml/min (3% BSA perfusate) in a normoxic lung.   
 
The effect of bovine serum albumin (BSA) concentration in the perfusate on the 
lung uptake of 99mTc-HMPAO was evaluated with the flow rate set at 10 ml/min. The 
results shown in Figure 4.3 suggest that increasing the BSA concentration from 3% (2.74 
± 0.27, N = 8) to 5% (1.92 ± 0.19, N = 7) resulted in a significant decrease (~30%, p = 
0.034, unpaired t-test) in 99mTc-HMPAO lung uptake in isolated perfused lungs. This is 
consistent with a decrease in the fraction of the injected lipophilic form of 99mTc-HMPAO 
that is available for uptake on passage through the lung as BSA concentration increases.  
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Figure 4.3. Representative lung TACs obtained following bolus injection of 99mTc-
HMPAO in a normoxic lung perfused with either 3% or 5% BSA perfusate at 10 ml/min.  
 
The contribution of lung tissue glutathione (GSH) content to the lung uptake and 
retention of 99mTc-HMPAO was evaluated by adding DEM (6 mM), a known GSH-
depleting agent, to the perfusate with the flow rate set at 5 or 10 ml/min (Figure 4.4).  At 
5 ml/min, DEM decreased (paired t-test, p = 0.004) the 99mTc-HMPAO steady-state 
uptake by 62% (4.46 ± 0.42 pre-DEM vs. 1.66 ± 0.14 post-DEM, N = 4). Similarly, at 10 
ml/min, DEM decreased (paired t-test, p = 0.009) the 99mTc-HMPAO lung steady-state 
uptake by 67% (2.93 ± 0.49 pre-DEM vs. 0.98 ± 0.17 post-DEM, N = 4).  These results 
are consistent with a dominant role for lung tissue GSH in the lung uptake and retention 
of 99mTc-HMPAO on passage through the pulmonary circulation, and with the potential 
utility of 99mTc-HMPAO as an index of lung tissue GSH content in intact functioning 
lungs and in vivo.  
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Figure 4.4. Representative lung TACs acquired following bolus injections of 99mTc-
HMPAO pre- and post-lung treatment with DEM (6 mM in perfusate) at flow rates of 5 
ml/min (top) and 10 ml/min (bottom).  
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4.1 Computational modeling results  
For each lung, the arterial input was estimated from the input TAC following the 
bolus injection of 99mTc-HMPAO with the flow rate set at 10 ml/min. As described in the 
Data Analysis chapter (Chapter 3), a gamma variate function was fit to the input 99mTc-
HMPAO curve and used as the arterial input (Figure 3.8) of the oxidized form of 99mTc-
HMPAO for solving the governing differential equations and for estimating the model 
parameters.  
With the lung input function and transit time distributions of the arterial, capillary, 
and venous section of the pulmonary circulation known, the next step was estimation of 
the values of the other model parameters. To that end, for each lung two lung TACs (pre- 
and post-DEM) were fit simultaneously (as exemplified in Figure 4.5) to estimate the 
values of the unknown model parameters (Table 4.2) as described in Chapter 3. 
Simultaneous fitting of multiple TACs was needed to break the correlation between the 
model parameters. Table 4.2 shows the estimates of the model parameters and measures 
of precision of these estimates, specifically using the 95% confidence intervals along 
with the correlation matrix. The results in Table 4.2 show that simultaneous fitting of 
lung TACs measured with and without the lung treatment with DEM improved the ability 
of the nonlinear least squares algorithm to estimate the model parameters. This is 
indicated by the relatively low correlation coefficients between the various model 
parameters.   
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Figure 4.5. Example of the simultaneous model fit of the lung TACs following 99mTc-
HMPAO bolus injection pre- and post-DEM treatment with a flow rate of 10 ml/min in a 
normoxic lung.  The GSH-dependent pathway (k2[GSH]c) was set to 0 in the model for 
the post-DEM TAC. 
 
 
 
Table 4.2. Estimated values of the kinetic model parameters from lungs of normoxic rats 
and measures of precision of these estimates. 
    Measures of Precision of Model Parameter Estimates 
N = 4 rats 
Estimated 
model 
parameters 
95% 
Confidence 
interval 
Correlation matrix 
PS 
(ml/sec) 1.78 ± 0.62 2.00 ± 0.84 1    
k2[GSH]c 
(s-1) 0.07 ± 0.003 0.01 ± 0.002 
-0.23 ± 
0.02 1   
k3[RH] (s-1) 0.04 ± 0.005 0.01 ± 0.002 
0.39 ± 
0.01 0.09 ± 0.02 1  
Vc (ml) 1.98 ± 0.36 0.281 ± 0.05 
-0.34 ± 
0.04 0.48 ± 0.024 -0.78 ± 0.02 1 
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An example of the sensitivity functions S(t), normalized to the maximum value of 
the Jacobian for each of the model parameters, is shown in Figure 4.6. The sensitivity 
function may be used to identify the portion of the data that is sensitive to a change in a 
given model parameter. Figure 4.6 shows the early transit portion of the lung TAC is 
sensitive to a change in value of PS, where the steady-state portion of the lung TAC is 
more sensitive to a change in the values of k2[GSH]c and k3[RH].   
Results from rats exposed to hyperoxia were compared to those from normoxic 
rats. Lung uptake of 99mTc-HMPAO, as measured by the steady-state lung TAC value 
(using F = 10 ml/min and 3% BSA perfusate) was not significantly different (t-test, p = 
0.261) between isolated perfused lungs from normoxic (2.74 ± 0.27, N = 8) and 
hyperoxic (2.79 ± 0.16, N = 3) rats (>95% O2 for 24 hrs).  
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Figure 4.6. Normalized sensitivity functions, S(t), for model parameters for pre-DEM 
(top) and post-DEM (bottom). 
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 Chapter 5: Simulations 
Simulations were performed to confirm consistency of the model with lung 
physiology and to verify consistency between the behavior of the model and our 
understanding of 99mTc-HMPAO pharmacokinetic uptake and retention in the lung. 
Performing such simulations allowed us to isolate each of the parameters and determine 
their contribution to the lung time activity curve (TAC). The simulations were used to 
evaluate the sensitivity of the lung TAC to a change in the following parameter values: 
lung vascular transit time distribution, flow rate, permeability surface area product (PS), 
tissue glutathione-dependent reduction rate constant (k2[GSH]c), alternative pathway 
reduction rate constant (k3[RH]), input curve transit time distribution, and concentration 
of albumin (% BSA) in the perfusate.  
 
5.1 Forward simulations 
In order to determine the impact of the model parameters on the shape of the lung 
TAC, an input concentration curve, Cin(t), and a vascular distribution of transit times were 
constructed. For a flow rate of 10 ml/min, a gamma variate function with a mean transit 
time of 2.5 s and variance of 4.0 s2 was used to represent the capillary transit time 
distribution, hc(t), as described in Ramakrishna et al. [36]. The movement of 99mTc-
HMPAO through the arteries or veins is represented with a shifted impulse function, with 
the shift equal to half of the difference (1.0 s) between the vascular mean transit time and 
the capillary mean transit time. Similarly, an input concentration curve with a mean 
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transit time of 4.0 s and a variance of 7.0 s2 was constructed using a gamma variate 
function. These values were chosen to be consistent with experimental isolated perfused 
rat lung data and were used to generate a base-case curve for each of the simulations. The 
other input parameters for the base curve were: flow rate = 10 ml/min, 3% BSA in the 
perfusate, k2[GSH]c = 0.07 s-1, PS = 2.0 ml/sec, and k3[RH] = 0.04 s-1. The PS, k2[GSH]c, 
and k3[RH] values fell within the range of parameter values determined using nonlinear 
regression to fit the lung TACs as described in the Data Analysis chapter (Chapter 3). 
The PBPK model was then solved using these parameter values to simulate lung TACs 
under a range of experimental conditions.  
 
5.1.1 Changes in capillary mean transit time  
Simulations were performed to determine the impact of the lung capillary transit 
time distribution (hc(t)) on the shape of the lung TAC. Changes in capillary transit time 
and capillary volume have previously been reported for hyperoxic and other lung injuries. 
Thus, to interpret a lung TAC it is important to account for potential changes in capillary 
volume and mean transit time. 
Initially, for the base curve, the model was run using a capillary mean transit time 
of µ = 2.5 s and a variance of s2 = 4.0 s2. Subsequently, the procedure was repeated with 
µ and s2 increased or decreased by 50%. Note that the arterial and venous time shifts and 
the relative dispersion of the capillary transit time distribution, 𝑅𝐷 = 	 pq, remained 
constant in these simulations. In order to account for the change in capillary volume, the 
permeability-surface area product (PS) was changed when hc(t) was changed since a 
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proportional change in the capillary mean transit time of A results in a proportional 
change of A2/3 in the surface area “S” in PS.  
The resulting lung TACs from the forward model simulation are shown in Figure 
5.1 where the blue solid line represents the base curve. Here we see that as µ increases, 
the peak of the curves increases and shifts to the right, and the steady-state value 
increases. The resulting steady-state values of the 50% increase, baseline, and 50% 
decrease curves are 2.73, 2.64, and 2.32 respectively. Here a 50% increase in µ results in 
a 3% increase in steady-state while a 50% decrease in µ corresponds with a 12% decrease 
in steady-state.  
These results are consistent with the notion that an increase in capillary mean 
transit time corresponds to 99mTc-HMPAO remaining in the capillary volume for a longer 
time. This results in more opportunity for uptake into the extravascular region of the lung 
and hence more 99mTc-HMPAO retention as evidenced by the increased steady-state 
values. 
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Figure 5.1. Effect of changing the mean transit time by 50% on the shape of the lung 
time activity curve. The relative dispersion (RD) is held constant. 
 
5.1.2 Changes in flow rate 
Acute lung injury has been reported to cause a substantial reduction in cardiac 
output and blood pressure in patients, especially when accompanied with vital 
mechanical ventilation [35, 38]. In order to determine the impact of flow rate on the lung 
TAC in the model, the flow rate through the lung was increased or decreased by 50% 
from its base value of 10 ml/min. In these simulations, the capillary volume and the 
volumes of the arteries and veins were held constant. In order to account for the impact of 
the different flows rates (5 ml/min and 15 ml/min) on the input concentration curve 
(Cin(t)) and hc(t), the mean transit time was rescaled by multiplying the mean, µ, by the 
ratio (A) of the base flow rate (10 ml/min) to the new flow rate (5 ml/min or 15 ml/min) 
and by multiplying the variance by A2 to construct the appropriate Cin(t) curve. The time 
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shift of the shifted impulse functions for the arteries and veins was also multiplied by A to 
account for the effect of flow rate on the mean transit times of the arteries and veins.  
The resulting lung TACs from the forward model simulation are shown in Figure 
5.2. The resulting steady-state values of the 5, 10, and 15 ml/min curves are 4.23, 2.64, 
and 1.92 respectively. These values correspond with a 27% decrease and a 60% increase 
in steady-state for the 50% increase and 50% decrease cases, respectively.   
An increase in flow rate leads to a decrease in the steady-state value because 
99mTc-HMPAO flows more quickly through the lung vasculature resulting in less time for 
uptake into the extravascular space. This results in less uptake and hence retention of 
99mTc-HMPAO in the tissue. For lower flow rates, however, the steady-state value is 
increased because there is more time for 99mTc-HMPAO uptake and retention. Decreasing 
the flow rate to 5 ml/min doubles the mean transit time, whereas increasing the flow to 15 
ml/min decreases the mean transit time by only 33.3%.  
 
Figure 5.2. Effect of changing the flow by 50% on the shape of the lung time activity 
curve. 
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5.1.3 Changes in membrane permeability 
Previous studies have shown that at 24 hours of hyperoxia (>95% O2) there is no 
increase in vascular permeability. However, at 48 hours of hyperoxia exposure there is a 
significant increase (more than ~200%) in the pulmonary vascular endothelial filtration 
coefficient, a correlate of the permeability in the permeability-surface area product (PS) 
[6]. 
In order to determine the effects of a change in PS on the lung TACs, simulations 
were performed using an initial PS of 2.0 ml/sec. The simulation was then repeated with 
a 50% increase (PS = 3.0 ml/sec) and decrease (PS = 1.0 ml/sec) in PS.  
The resulting TAC curves are shown in Figure 5.3 where the solid blue line 
represents the base value. The resulting steady-state values are 2.46, 2.64, and 2.71 when 
PS is 1.0, 2.0, and 3.0 ml/sec, respectively. This corresponds with a 3% increase and an 
7% decrease from the base case.  
Changes in permeability can occur when endothelial cells, that form the barrier 
between the capillary and the lung tissue, are injured or die, such as that which occurs 
with apoptosis. Apoptosis occurs when the lungs are exposed to hyperoxic conditions 
(>95% O2 for 24 hours or longer) which may lead to increased uptake of 99mTc-HMPAO. 
Due to the relatively high diffusion of 99mTc-HMPAO across the membrane at the base PS 
value, the increase in steady-state value is not linearly proportional to the increase in PS.  
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Figure 5.3. Increasing and decreasing the permeability-surface area product (PS) by 50% 
leads to a 3% increase and a 7% decrease in the steady-state values, respectively. 
 
5.1.4 Changes in GSH-dependent reduction rate constant (k2[GSH]c) 
Simulations were also performed to determine the effect of lung tissue GSH 
content on the uptake and retention of 99mTc-HMPAO.  Previous studies from our 
laboratory have shown that the conversion of 99mTc-HMPAO from the lipophilic to the 
hydrophilic state, and thus the retention of 99mTc-HMPAO, is strongly dependent on the 
concentration of glutathione (GSH) in the lung tissue [6, 9, 14]. The relevance of GSH 
was determined using diethyl maleate (DEM), a known GSH-depleting agent. The results 
show a significant decrease in the lung uptake and retention of 99mTc-HMPAO in the 
presence of DEM. These results suggest the GSH-dependent process contributes more to 
the retention of 99mTc-HMPAO than other processes [9]. Neirinckx et al. also reported the 
importance of GSH for the in vivo conversion of 99mTc-HMPAO to its hydrophilic form 
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and retention in the brain. The reaction of 99mTc-HMPAO with GSH is assumed to be the 
major rate-determining step for the conversion of lipophilic, diffusible 99mTc-HMPAO to 
its hydrophilic, nondiffusible form [32]. 
To determine the effect of GSH on the uptake and retention of 99mTc-HMPAO we 
changed the rate constant (k2[GSH]c) by 50%. The resulting lung TACs from the forward 
model simulation are seen in Figure 5.4. The 50% increase in GSH results in a 20% 
increase in the steady-state value, and the 50% decrease results in a 24% decrease in the 
steady-state value. The resulting lung TAC steady-state values for k2[GSH]c = 0.035, 
0.07, and 0.105 s-1 are 2.00, 2.64, and 3.16, respectively.  
These results suggest that as GSH content increases, as is the case when rats are 
exposed to hyperoxia (>95% O2), there is an increase in the uptake and retention of 99mTc-
HMPAO. However, as GSH content decreases, there is less 99mTc-HMPAO uptake and 
retention because there is less GSH available for conversion of the lipophilic form of 
99mTc-HMPAO to its hydrophilic form. The simulations also suggest that the change in 
lung TAC steady-state value is not proportional to a change in k2[GSH]c.  
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Figure 5.4. Increasing or decreasing the glutathione (GSH) tissue rate constant by 50% 
results in steady-state values of 3.16 and 2.00, respectively.  
 
5.1.5 Changes in input curve mean transit time 
The shape of the 99mTc-HMPAO input curve is dependent on multiple factors 
including the volume of the 99mTc-HMPAO bolus, the rate of its injection, and the exact 
site in the image of the pulmonary arterial cannula at which it is measured. In 
experiments, the volume of the bolus must be large enough that the input curve can be 
acquired at a sufficient sampling rate (1 sample per second) to capture the 99mTc-HMPAO 
rapidly changing front portion of the curve. Also, the curve must be dispersed enough 
that the bolus resides within the capillaries for a sufficiently long time so that the 
resulting TAC contains relevant information. Thus, we were interested in determining the 
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effect that changes in the shape of the input curve might have on the resulting lung TAC 
and steady-state value.  
Simulations were performed to determine the impact of the input curve mean 
transit time on the shape of the lung TAC. The input curve was modeled as a shifted 
gamma-variate function with a mean transit time of µ = 4.0 s and a variance of s2 = 7.0 
s2. Subsequently, the procedure was repeated with µ and s increased or decreased by 
50%. Note that the relative dispersion of the input curve transit time distribution, 𝑅𝐷 =	pq, remained constant in these simulations.  
The resulting TAC curves from the forward model simulation are shown in Figure 
5.5 where the blue solid line represents the base curve. Here we see that as the input 
curve becomes more dispersed but with the same mass injected, µ increases, the peak of 
the lung TACs decreases, and the curve becomes more dispersed, but the steady-state 
value remains constant.  
The decrease in the peak and the increase in the dispersion of the curve (yellow 
curve) is due to a decrease in the concentration of 99mTc-HMPAO but with a 
corresponding increase in residence time in the capillary region. Similarly, when the 
concentration increases due to a decrease in the input bolus volume, the peak increases 
and the curve becomes less dispersed (orange curve). 
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Figure 5.5. Increasing the input curve mean transit time by 50% results in an increase in 
the peak and a decrease in the mean transit time.  
 
5.1.6 Changes in GSH-independent rate constant (k3[RH]) 
When GSH is depleted there is an alternate pathway for 99mTc-HMPAO 
conversion that dominates the process. The rate of conversion for the GSH-independent 
pathway is much slower than for the GSH-dependent pathway at normal tissue GSH 
concentrations [32]. Although, the GSH-independent factors have not been clearly 
identified, there is evidence that mitochondrial dysfunction and/or endothelial amine 
metabolism dysfunction may be contributors [9]. 
In order to determine the effect of the GSH-independent rate constant on the 
retention of 99mTc-HMPAO, the GSH-dependent rate constant (k2[GSH]c) was set to 0. 
The GSH-independent rate constant (k3[RH]) was then increased and decreased by 50%. 
0 10 20 30 40 50 60 70 80
Time (sec)
0
1
2
3
4
5
6
7
8
Co
un
ts
/p
ixe
l/m
Ci
 In
je
ct
ed
Input mean = 50% decrease
Input mean = 4.0 s
Input mean = 50% increase
 57 
Initially k3[RH] was 0.04 s-1. The forward model simulations were performed with k3[RH] 
= 0.02, 0.04, and 0.06 s-1.  
The 50% increase in k3[RH] led to a 40% increase in the steady-state value, and 
the 50% decrease in k3[RH] led to a 46% decrease in the steady-state value. The resulting 
steady-state values for the 50% increase, base value, and 50% decrease are 1.68, 1.20, 
and 0.65, respectively. The resulting lung TACs can be seen in Figure 5.6 where we 
observe that the peak of the curves did not change as k3[RH] was changed.  
 
Figure 5.6. Effect of increasing or decreasing the GSH-independent pathway rate 
constant when GSH is depleted.  
  
5.1.7 Changes in albumin concentration in the perfusate 
Bovine serum albumin (BSA) is a key component of the perfusate used in isolated 
perfused lung experiments. However, there is evidence that 99mTc-HMPAO binds to 
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protein in the blood and thus may influence its uptake in the lung. Andersen et al. 
performed a study in which 99mTc-HMPAO was mixed with either pure saline or saline 
containing 10% albumin [1]. They found the value of initial extraction across the blood 
brain barrier was significantly lower in the presence of albumin and suggested this was 
due to the binding of the lipophilic 99mTc-HMPAO with the albumin protein [1, 2]. 
In order to determine the effect of perfusate albumin concentration on the lung 
TAC, the albumin concentration was changed in the simulation. The resulting steady state 
values 2.11, 2.64, and 3.52, correspond with the 50% increase, 3% BSA, and 50% 
decrease cases, respectively. This corresponded to a 20% decrease and a 33% increase 
from the base case of 3%.  Note that the resulting TACs in Figure 5.7 suggest that as 
albumin concentration increases, the peak of the lung TAC decreases, and the curves 
become less dispersed.  
These results correspond with the results of the study by Andersen et al. [2]. As 
the albumin concentration increases, the 99mTc-HMPAO available for uptake and 
retention decreases because more binds with the albumin. Conversely, decreasing the 
percent of albumin in the perfusate, results in an increase in the uptake and retention of 
99mTc-HMPAO because more is available to diffuse across the capillary membrane.  
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Figure 5.7. Increasing or decreasing the albumin by 50% results in a 20% decrease and a 
33% increase, respectively, in the steady-state value. 
 
5.2 Estimation of the values of the model parameters 
In Section 5.1, we used the model to forward simulate lung TACs to determine 
the effect of the key model parameters on the shape of the curves and their steady-state 
values. The model can also be used in an inverse fashion; given a lung TAC what set of 
key model parameters generated that curve?  Thus, nonlinear least squares regression was 
used to fit the model to the lung time activity curve and estimate the key unknown 
parameter values (PS, k2[GSH]c, k3[RH], and Vc).   
In the results below, we first simulated lung TACs using the following parameter 
values: flow = 10 ml/min, 3% BSA, k2[GSH]c = 0.04 s-1, PS = 2.0 ml/sec, and k3[RH] = 
0.07 s-1, Vc = 2.0, input mean = 4.0 s and variance = 7.0 s2, and capillary mean = 2.5 s and 
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variance = 4.0 s2. Then normally distributed random noise with mean = 0 and standard 
deviation = 0.03 ´ maximum value of the lung TAC was added to the curve. 
In order to determine the identifiability of the key model parameters from the lung 
TACs, we used nonlinear least squares to fit the model to the simulated TACs. This was 
implemented in MATLAB using the lsqcurvefit function that uses the Levenberg-
Marquardt procedure to perform the optimization.  The model was fit to the simulated 
noisy curve where PS, k2[GSH]c, k3[RH], and Vc were the free parameters.  The procedure 
was then repeated using different initial estimates of these parameters.  
Figure 5.8 shows an example of a simulated curve and its resulting model fit 
referred to as Trial 1. In this case the model curve did a good job capturing the behavior 
of the solution, however as shown in Table 5.1 the estimated parameter values had 
relative error of up to 80%. When the regression was repeated using different initial 
guesses, the model time-activity curves were nearly identical, but trials with different 
initial guesses yielded different parameter estimates.   
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Figure 5.8. A single curve at a flow of 10 ml/min was generated to simulate the data. The 
curve was then fit using the model to recover the key parameter values (PS, k2[GSH]c, 
k3[RH], and Vc). 
 
 
Table 5.1. Single curve parameter estimation 
  True Trial 1 Trial 2 Trial 3 
PS (ml/sec) 2.0 12.26 2.54 4.18 
k2[GSH]c (s-1) 0.07 0.10 0.08 0.04 
k3[RH] (s-1) 0.04 0.01 0.04 0.07 
 
The inability of the model to consistently recover the true parameter values, yet 
still obtain good model fits, suggests that there is strong correlation between the 
parameters. In other words, there is a range of different parameter combinations that will 
all yield equally good model fits, making it impossible to identify the true parameter 
values. This is illustrated in the forward model simulations in Section 5.1 where we 
observe that a change in k2[GSH]c results in nearly identical changes to the shape of the 
TAC as does a change to k3[RH]. Thus, we cannot expect the model fitting procedure as 
0 20 40 60 80
Time (sec)
0
1
2
3
4
5
6
7
Co
un
ts
/p
ixe
l/m
Ci
 In
je
ct
ed Data
Simulation fit
 62 
presented to uniquely recover k2[GSH]c and k3[RH].  
To break the correlation, we simulated a pair of TACs intended to represent those 
that would be acquired prior to the administration of DEM (k2[GSH]c = GSH-dependent 
rate constant = 0.07 s-1) and following DEM (k2[GSH]c = 0, since GSH is assumed to be 
completely depleted). The model was then fit to the two TACs simultaneously to 
determine if the parameters could be recovered reliably. The fitting was performed as 
described above except that k2[GSH]c was hard-coded to be 0 for the post-DEM curve, 
but was free for the pre-DEM curve (Figure 5.9).  We performed five trials each with 
different initial conditions to obtain the mean parameter estimates shown in Table 5.2. 
The small standard deviation of the distribution of parameter estimates suggests that this 
approach will provide reliable parameter estimates when analyzing experimental data. 
 
 
Figure 5.9. Model fitting results using two TACs simulated to represent pre- and post-
DEM acquisitions. The two curves were fit simultaneously to break the correlation 
between parameters. 
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Table 5.2. Parameter estimation using pre- and post-DEM TACs.  
N = 5 
Simulations TRUE MEAN S.D. 
PS (ml/sec) 2 2.08 0.43 
k2[GSH]c (s-1) 0.07 0.07 0.01 
k3[RH] (s-1) 0.04 0.04 0.01 
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Chapter 6: Discussion 
We have developed an experimental and computational approach for mechanistic 
and quantitative evaluation of the pharmacokinetics of SPECT biomarkers such as 99mTc-
HMPAO in the isolated perfused rat lung. The approach allows for the evaluation of the 
dominant factors that determine the lung uptake of 99mTc-HMPAO, separation of the 
contributions of pulmonary processes from systemic processes to the lung uptake of 
99mTc-HMPAO, and application of this knowledge to in vivo studies. To the best of our 
knowledge, this is the first study of the pharmacokinetics of any SPECT biomarkers in 
isolated perfused lungs.  
In addition, the proposed PBPK model is the first to account for the spatial and 
temporal variations in the concentration of 99mTc-HMPAO on passage through the 
pulmonary circulation. The model relaxes the assumption of well-mixed compartments 
that existing models for 99mTc-HMPAO pharmacokinetics in other organs make, which 
may not be appropriate for lipophilic compounds such as 99mTc-HMPAO, especially since 
the lung capillary perfusion is highly heterogeneous with some pathways having short 
transit times and others having long transit times [36]. The model also accounts for the 
effect of capillary perfusion heterogeneity on the lung uptake of 99mTc-HMPAO. The 
results confirm the utility of 99mTc-HMPAO for probing tissue glutathione (GSH) content 
in intact functioning lungs and in vivo.  
Besides the immediate application to 99mTc-HMPAO pulmonary pharmacokinetics, 
the proposed experimental and PBPK modeling approach could be readily modified for 
evaluating key cellular processes in lung injury models, for assessing the efficacy of 
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treatment on targeted lung cellular processes, for quantifying the uptake of other 
biomarkers in the lung or other organs (e.g., heart), or for analyzing data from other 
functional imaging modalities (e.g., MRI, PET).  
Experimental and model results suggest that, in addition to lung tissue GSH 
content, the lung uptake of 99mTc-HMPAO is sensitive to a change in cardiac output (flow 
rate) and plasma protein concentration, both of which could change with lung disease 
[19]. Additional results revealed the sensitivity of the lung uptake to perfusate GSH 
concentration. Preliminary results in Figure 6.1 show the effect of adding exogenous 
GSH (20 µM) to the perfusate on the lung uptake of 99mTc-HMPAO. This GSH 
concentration is close to that reported for blood plasma of normoxic rats [4]. The addition 
of exogenous GSH to the perfusate decreased the lung uptake of 99mTc-HMPAO, most 
likely due to a decrease in the fraction of 99mTc-HMPAO that entered the lung in the 
oxidized form. Thus, a change in plasma GSH led to a change in 99mTc-HMPAO lung 
uptake independent of a change in lung tissue GSH content. Both plasma and tissue GSH 
content can be altered by lung and liver injury [6, 34]. For instance, Payabvash et al. 
demonstrated a 35% decrease in mouse plasma GSH concentration 24 hours after 
treatment with lipopolysaccharide (5 mg/kg, i.p.), which is known to cause lung injury 
[34]. This change in plasma GSH concentration could result in a change in the lung 
uptake of 99mTc-HMPAO independent of a change in lung tissue GSH content [6]. 
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Figure 6.1. Lung TACs following the bolus injection of 99mTc-HMPAO in the same lung 
with 3% BSA perfusate (10 ml/min) with or without exogenous GSH (20 µM).  
 
For the PBPK model, the capillary transit time distribution, hc(t), was represented 
with a gamma variate function with a mean transit time and variance values set to 
previously estimated values by Ramakrishna et al. for a control rat lung at 10 ml/min 
[36]. Previous studies have shown that acute lung injury, including hyperoxia-induced 
lung injury, could alter lung capillary volume and hc(t) [5, 15]. Hence, an approach for 
estimating hc(t) for a given lung before or after imaging would be useful. Fully reduced 
99mTc-HMPAO is hydrophilic and hence can be assumed to behave as an intravascular 
indicator on passage through the pulmonary circulation. Thus, one potential approach for 
estimating hc(t) for a given lung would be to reduce 99mTc-HMPAO by mixing it with a 
high concentration of exogenous GSH, and then injecting a bolus of the reduced 99mTc-
HMPAO and measuring lung input and output TACs. The lung vascular transit time 
distribution, hv(t), can then be estimated as the gamma variate function that, when 
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convolved with the lung input TAC, best fits the lung output TAC. Figure 6.2 shows 
lung, input, and output TACs following the bolus injection of the reduced form of 99mTc-
HMPAO at 10 ml/min. To reduce 99mTc-HMPAO, it was incubated with 0.1 M GSH for 3 
min prior to injection. Additional studies would be needed to make sure that the 
concentration of GSH used and the incubation time with GSH was sufficient to fully 
reduce 99mTc-HMPAO.  hc(t) can then be represented by a gamma variate function with 
mean transit time equal to half of the mean transit time of hv(t) and variance equal to that 
of hv(t), under the assumption that most of the lung perfusion heterogeneity is due to the 
heterogeneity of the capillary transit times [36]. 
 
Figure 6.2. Lung, input, and output TACs following the bolus injection of the reduced 
form of 99mTc-HMPAO at a flow rate of 10 ml/min (3% BSA). 
 
For a given flow rate, 99mTc-HMPAO uptake depends on the capillary mean transit 
time and hence, on capillary volume. The longer the capillary mean transit time, the more 
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time is available for 99mTc-HMPAO lung uptake on passage through the pulmonary 
circulation. Since the pulmonary vasculature consists of distensible blood vessels whose 
diameters and hence volumes are dependent on the intravascular pressure, increasing 
flow rate increases the intravascular pressure and hence distends the vessels and increases 
their vascular volume. As such, increasing the flow rate to 15 ml/min would be expected 
to increase the lung vascular volume as compared to that at 10 ml/min, and decreasing the 
flow rate to 5 ml/min would decrease the vascular volume as compared to that at 10 
ml/min. This could explain the smaller than predicted decrease in 99mTc-HMPAO lung 
uptake as the flow rate was increased from 10 ml/min to 15 ml/min. The effect of flow 
rate on the lung vascular volume could be mitigated by adjusting the venous pressure to 
minimize the change in microvascular pressure, (arterial pressure + venous pressure)/2, 
as the flow rate is changed. 
Experimental results show that prior to the addition of DEM, 32 ± 4% of the 
injected 99mTc-HMPAO was taken up and retained in the lung, but post-DEM only 14 ± 
4% of the injected 99mTc-HMPAO was taken up and retained in the lung on passage 
through the isolated perfused rat lung with the flow rate set to 10 ml/min. The pre-DEM 
fraction is much larger than the 7.4 ± 4.9% (SE) lung retention in vivo reported by 
Neirinckx et al. [32]. This difference is largely due to the large difference between the 
pump flow rate (10 ml/min) and the resting cardiac output (300 ml/min/kg) for a rat 
reported by Flaim and Zelis [18]. Thus, the cardiac output for a 350-g rat would be 
around 105 ml/min. Using the estimated model parameters in Table 4.2, the model 
predicted 99mTc-HMPAO lung uptake at a flow rate of 105 ml/min was ~6% (Figure 6.3), 
which is close to that measured in vivo, and hence a validation of the proposed model.  
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The presence of GSH in blood plasma (~20 µM), which can partially reduce 
99mTc-HMPAO prior to entering the lungs, can reduce the fraction of the injected 99mTc-
HMPAO that is entering the lungs in the oxidized form. For a flow rate of 105 ml/min, 
model simulations (Figure 6.3) show that decreasing the fraction of the injected 99mTc-
HMPAO entering the lungs in the oxidized form from 100% to 90% had little (~10%) 
effect (decreased from 6.0% to 5.4%) on the fraction of injected 99mTc-HMPAO retained 
in the lungs.  
 
Figure 6.3. Model simulation comparing the retention of 100% oxidized 99mTc-HMPAO, 
90% oxidized, 10% reduced 99mTc-HMPAO, 80% oxidized, 20% reduced 99mTc-HMPAO, 
and 70% oxidized, 30% reduced 99mTc-HMPAO at a flow of 105 ml/min. 
 
 
The early transit portion of the lung TAC following the bolus injection of 99mTc-
HMPAO is determined to a large extent by the shape of the lung input 99mTc-HMPAO 
curve. For the present study, the lung input TAC following the injection of an 99mTc-
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HMPAO bolus injection was used to determine the lung input function. As Figure 6.4 
shows, the 99mTc-HMPAO input TAC is noisy. A smoother version of this TAC could be 
obtained by increasing the mCi injected. Thus, for a subset of the lungs studied, we 
injected a bolus of high-dose (3-4 mCi) technetium. As Figure 6.4 shows, the resulting 
lung TAC curve is less noisy (higher signal to noise ratio) as compared to that for the 
99mTc-HMPAO bolus injection and is representative of the 99mTc-HMPAO lung input 
curve, Cin(t).   
 
Figure 6.4. Input TACs for a bolus of high dose technetium (blue) and boluses of 99mTc-
HMPAO. 
 
Simultaneous fitting of the lung TACs pre- and post-DEM improved the 
estimability of the model parameters as reflected by the correlation matrix and the 
confidence intervals (Table 4.2). As expected, the estimated value of the GSH-dependent 
rate constant (k2[GSH]c) was larger than the GSH-independent-rate constant (k3[RH]), 
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since GSH plays a dominant role in the lung uptake and retention of 9mTc-HMPAO. The 
permeability-surface area product, PS, for oxidized 99mTc-HMPAO was large (1.78 ± 0.62 
ml/s) relative to the flow rates (5-15 ml/min) consistent with the high lipophilicity of the 
injected oxidized form of 99mTc-HMPAO [9].  
For the present study, the lung was under zone 2 conditions during the bolus 
injection of 99mTc-HMPAO since the venous effluent pressure was atmospheric pressure 
and hence, lower than the lung’s end expiratory pressure (2-3 mmHg). As such, the lung 
vascular volume and vascular mean transit time were most likely smaller than those 
under in vivo conditions (zone 3 conditions). One approach to mitigate this issue and 
reduce its potential impact on the lung uptake of 99mTc-HMPAO would be to raise the 
lead-enclosed venous effluent reservoir to ensure that the venous effluent pressure is 
greater than or equal to the end expiratory pressure.  
Previous in vivo studies showed a significant increase (~134%) in the lung uptake 
of 99mTc-HMPAO in rats exposed to hyperoxia (>95% O2) for 24 hrs as compared to lung 
uptake in normoxic rats [6, 7]. Preliminary results in the present study show no 
significant difference in 99mTc-HMPAO uptake in isolated perfused lungs from normoxic 
and hyperoxic lungs perfused at 10 ml/min. There are several potential reasons for the 
lack of significant increase in the lung uptake of 99mTc-HMPAO in isolated perfused 
lungs from hyperoxic rats compared to normoxic rats. Lung tissue GSH content is 
determined by a complex network of lung and non-lung processes that control GSH 
synthesis, metabolism, and GSH plasma concentration [16]. For instance, organs such as 
the liver and kidneys play a key role in determining the plasma GSH concentration, and a 
change in the activity of the cell surface enzyme g-glutamyl transpeptidase (GGT), which 
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provides precursors for GSH cellular synthesis by breaking down extracellular GSH, can 
also alter lung tissue GSH [25]. Knickelbein et al. showed that rat exposure to hyperoxia 
(>95% O2) for 48 hrs more than doubled the lung activity and expression of the enzyme 
GGT, which plays an important role in regulating lung tissue GSH content [25]. By 
isolating the lungs from the rest of the body, it is possible that this somehow negatively 
impacted lung tissue GSH content in hyperoxic rats and contributed to the difference in 
99mTc-HMPAO uptake in hyperoxic lungs in vivo as compared to that in insolated 
perfused lungs. Another possible reason for this difference is potential washout or loss of 
some of the lung tissue GSH from hyperoxic lungs as a result of single-pass perfusion ex-
vivo. However, Berggren et al. showed that ex-vivo perfusion of rat lungs with amino-
acid free perfusate for 60 min reduced lung tissue GSH content by only 20-30% [13]. 
One possible way to mitigate this potential loss of lung tissue GSH during ex vivo 
perfusion would be to perfuse the lungs with perfusate that includes cysteine, which is an 
amino acid precursor for GSH synthesis. Berggren et al. showed that the addition of 
cysteine (100 µM) was sufficient to replenish 60% of the lung tissue GSH content within 
60 min in lungs from DEM-treated (i.p.) rats. Preliminary results in Figure 6.5 show that 
the addition of cysteine (1 mM) to the perfusate had no significant effect on 99mTc-
HMPAO lung uptake in isolated perfused lungs. Another possible reason for the lack of 
significant increase in the lung uptake of 99mTc-HMPAO in isolated perfused lungs from 
hyperoxic rats is that the plasma GSH concentration is lower in hyperoxic rats as 
compared to that in normoxic rats. A lower plasma GSH in hyperoxic rats would increase 
the fraction of 99mTc-HMPAO in the oxidized form that is available for uptake on passage 
through the lungs. Model simulations show that decreasing the % of injected 99mTc-
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HMPAO in the oxidized form from 100% to 90% resulted in a 10% decrease in the lung 
uptake at 10 ml/min and at 105 ml/min. Payabvash et al. demonstrated a 35% decrease in 
mouse plasma GSH concentration 24 hrs after treatment with lipopolysaccharide (LPS, 5 
mg/kg, i.p.), which is known to cause lung injury [34]. Thus, a change in plasma GSH 
leads to a change in 99mTc-HMPAO lung uptake independent of a change in lung tissue 
GSH content. This LPS-induced decrease in plasma GSH content could account for some 
of the LPS-induced increase in 99mTc-HMPAO lung uptake 24 hours after rat treatment 
with LPS (1 mg/kg, IT) [6].  Additional studies would be needed to assess the impact of 
hyperoxia on blood plasma GSH and amino acids content.  
One of the differences between in vivo imaging studies and isolated perfused 
lungs (IPL) imaging studies is that for the IPL studies the lung ventilation was stopped at 
end expiration during the bolus injection of 99mTc-HMPAO to minimize the effect of 
ventilation on the measured TACs. Differences in lung tidal volume and lung volume in 
vivo between normoxic and hyperoxic lungs, which are not accounted for in the IPL 
studies, could result in differences in tissue density per pixel, which in turn could result in 
apparent differences in the lung uptake of 99mTc-HMPAO per pixel. This could contribute 
to the lack of significant increase in the lung uptake of 99mTc-HMPAO in IPLs from 
hyperoxic rats as compared to that from normoxic rats. This could be assessed by 
repeating the IPL 99mTc-HMPAO imaging studies with the lung ventilation stopped at end 
inspiration instead of end expiration. Differences in blood protein content, cardiac output, 
and uptake by other organs between normoxic and hyperoxic lungs could also contribute 
to the increase in the lung uptake of 99mTc-HMPAO in hyperoxic rats as compared to that 
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in normoxic rats. Additional studies are needed to assess such differences and are beyond 
the scope of this thesis project. 
 
 
Figure 6.5. Lung TACs following bolus injections of 99mTc-HMPAO with and without 
the addition of cysteine (1 mM) to the 3% BSA perfusate.  
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Glossary:  
Symbol Definition 
µ Mean transit time of a gamma variate function (s) 
s2 Variance of a gamma variate function (s2) 
t0 Time shift for a gamma variate function (s) 
µin Mean of the lung input function (s) 
s2in    Variance of the lung input function (s2) 
µc Mean of the capillary transit time distribution (s) 
s2c Variance of the capillary transit time distribution (s2) 
Cin(t) Lung input function 
hc(t) Capillary transit time distribution 
F Flow rate (ml/s) 
PS Permeability surface area product (ml/s) 
[Q]a Concentration of the diffusible, oxidized form of HMPAO in the arteries 
[Q]v Concentration of the diffusible, oxidized form of HMPAO in the veins 
[R]v Concentration of the nondiffusible, reduced form of HMPAO in the veins 
[R]b (t,x) Concentration of the nondiffusible, reduced form of HMPAO in the 
capillaries at time t and distance x from the capillary inlet (x = 0) 
[R]c(t,x) Concentration of the nondiffusible, reduced form of HMPAO in the lung 
tissue at time t and distance x from the capillary inlet (x = 0) 
[Q]b(t,x) Concentration of free (not bound to albumin), oxidized form of HMPAO in 
the capillaries at time t and distance x from the capillary inlet (x = 0) 
[Q]c(t,x) Concentration of the diffusible, oxidized form of HMPAO in the lung 
tissue at time t and distance x from the capillary inlet (x = 0) 
W Convective transport velocity, flow per cross-sectional area 
[P] Concentration of bovine serum albumin (BSA) in the perfusate (% BSA by 
mass) 
Kd Dissociation rate constant, ratio of inverse to forward rate constants for 
albumin binding (% BSA by mass) 
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[B] Concentration of the bound form of the oxidized form of HMPAO in the 
vascular region 
Vb Vascular volume (ml) 
Vc Extravascular volume (ml) 
k1 Rate constant for GSH-dependent reduction of HMPAO in the vascular 
region (M-1s-1) 
k2 Rate constant for GSH-dependent reduction of HMPAO in the tissue 
region (M-1s-1) 
k3 Rate constant for GSH-independent reduction of HMPAO in the tissue 
region (M-1s-1) 
k4 Association rate constant of binding of the oxidized form of HMPAO with 
perfusate BSA (%BSA-1s-1) 
k-4  Dissociation rate constant of the binding of the oxidized form of HMPAO 
with perfusate BSA (s-1) [Q]P [B] + [Q]b = Total vascular concentration of the free and BSA-bound 
oxidized HMPAO  
[RH] Concentration of the unknown reactant (M) 
[GSH]b   Concentration of glutathione in the vasculature (M) 
[GSH]c   Concentration of glutathione in the tissue (M) 
 
 81 
Appendix A: Detailed Derivation of Physiologically Based 
Pharmacokinetic (PBPK) Models 
 
 
A.1 Distributed in time and space model: single capillary element 
The model accounts for the vascular and cellular processes that determine the 
lung uptake and retention of 99mTc-HMPAO, including capillary perfusion kinematics. 
Several assumptions were made.  
• The hydrophilic reduced form of 99mTc-HMPAO is confined to the vascular 
region, whereas the lipophilic oxidized form of 99mTc-HMPAO can diffuse out of 
the capillary region and into the extravascular region.  
• Instantaneous radial diffusion within the vascular and tissue regions. 
• There is no uptake of 99mTc-HMPAO in the pulmonary arteries or veins.  The 
endothelial surface area of arteries and veins are relatively small compared to that 
of the pulmonary capillary endothelium surface area in which diffusion could 
occur.  
• There is no dispersion of the injected bolus in the arteries or veins. Thus, in the 
model the transit time distributions of the arteries and the veins are represented by 
shifted impulse functions.   
• All reactions are reversible, but they are significantly faster in the forward 
direction than in the reverse reaction, so the reverse reaction rate constants are 
assumed to be zero. 
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• The forward reaction of 99mTc-HMPAO with glutathione (GSH) in the vasculature 
is also zero because no GSH is added to the perfusate. 
• Within the vascular region, the free (i.e. not albumin bound) oxidized form of 
99mTc-HMPAO participates in rapidly equilibrating interactions with perfusate 
albumin (BSA). 
• The free oxidized form of 99mTc-HMPAO is converted to the reduced form via a 
GSH-dependent and a GSH-independent process. 
 
A.1.1 Species balance equations 
Based on the above assumptions and Figure A.1, the general equations describing 
the disposition of 99mTc-HMPAO on passage through a single capillary can be derived 
using mass balance, mass action, and Fick’s law of diffusion. In Figure A.1, Q(x, t) and 
R(x, t) represent the oxidized (diffusible) and reduced (non-diffusible) indicators at a 
distance x from the capillary inlet (x = 0) and at time t.  For a control volume of distance 
Dx and radius r, J(x, t) is the rate of mass entering the control volume at time t, and 
J(x+Dx, t) is the rate of mass leaving the control volume at time t. Using mass balance, 
the rate of change of mass per unit time for an intravascular tracer (Cv) or probe is 
expressed as 
!F.∗(*,',)!' = 𝐴1𝐽(𝑥, 𝑡, 𝑟) − 𝐽(𝑥 + ∆𝑥, 𝑡, 𝑟)    (A.1) 
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Figure A.1. Mass flux through a capillary unit. 
where Ac is the cross-sectional area and 𝑑𝑉 =	∆𝑥𝐴1 is the differential volume of the 
control volume. Dividing the above equation by dV and taking the limit as ∆𝑥 approaches 
0, 
!(*,',)!' = 𝑙𝑖𝑚∆*→g K	 (*,',)∆* −  (*5∆*,',)∆* N    (A.2) 
We arrive at, 
!!' = − ! !*      (A.3) 
where J is composed of a convection flux term and a diffusion term, which follows Fick’s 
law of diffusion. 𝐽 = 	 𝐽1¡e¢£1'Q¡e + 𝐽FQ¤¤¥¦Q¡e = 𝑊 ∗ 𝐶¢ − 𝐷 FF*   (A.4) 
The diffusion term is negligible, however, due to the large Peclet number (𝜑). 𝜑 = ¨©ª« = ©jª«'̅A    (A.5) 
The Peclet number is the ratio between convection flux and diffusion flux where W = 
velocity = F/Ac, L = length of vasculature, 𝑡1̅ = capillary mean vascular transit time, and 
D = diffusion coefficient (~10-7 cm2/sec). Therefore,  
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𝐽 = 𝐽1¡e¢£1'Q¡e = 𝐶¢ ∗ ­®A = 𝐶¢(𝑥, 𝑡) ∗ 𝑊   (A.6) 
Substituting Eqn. A.6 into Eqn. A.4, we arrive at 
!!' + 𝑊 !!* = 0				𝑜𝑟				 !!' = −𝑊 !!*    (A.7) 
These same principles used for the reference indicator can be applied to a diffusible 
indicator (C1).  𝐴1∆𝑥 !¯!' = 𝐹 ∗ 𝐶4(𝑥, 𝑡) − 𝐹 ∗ 𝐶4(𝑥 + ∆𝑥, 𝑡) − 𝑃𝑆* ∗ ∆𝑥 ∗ 𝐶4 + 𝑃𝑆* ∗ ∆𝑥 ∗ 𝐶B (A.8) !¯!' = 𝑊 ∗ (𝐶4(𝑥, 𝑡) − 𝐶4(𝑥 + ∆𝑥, 𝑡)) − ,-«®A (𝐶4 + 𝐶B)  (A.9) 
where 𝑆* = surface area per unit length, 𝑆 = 𝑆*𝐿 = surface area, 𝐿 = capillary length = 	.A®A, P is the permeability of the endothelium, and Vb is the vascular volume.  Hence, !¯!' +𝑊 !¯!* = ,-.A (𝐶B − 𝐶4)    (A.10) 
where PS is the so-called permeability-surface area product, which is a measure of the 
rate of diffusion of the diffusible indicator between the vascular and tissue regions. 
The same approach can be used to derive the equation for the extravascular 
indicator:  
!j!' = ,-.A (𝐶4 − 𝐶B)  (A.11) 
where Vc is the extravascular or tissue volume.  
Similarly, using the law of mass action and mass balance, the rate of change in the 
masses of the oxidized and reduced forms of 99mTc-HMPAO in the vascular and tissue 
regions can be derived.  
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Figure A.2. Pharmacokinetic model of the dominant lung processes involved in the 
uptake and retention of 99mTc-HMPAO within the vascular (Vb) and extravascular (Vc) 
space. 
 
The spatial and temporal variations in the concentration of the oxidized form of 99mTc-
HMPAO ([Q]b) in the vascular region is described by Eqn. A.12. 
!([#]&®A∆*)!' + [𝑄]?𝑊𝐴1 = 𝐴1∆𝑥(𝑃𝑆([𝑄]1 − [𝑄]?) − 𝑘4[𝐺𝑆𝐻]?[𝑄]?) (A.12) 
Divide both sides of the equation by 𝐴1∆𝑥, ![#]&!' +𝑊 [#]&!* = ,-.& ([𝑄]1 − [𝑄]?) − 𝑘4[𝐺𝑆𝐻]?[𝑄]?  (A.13) 
Similarly, the reactions for the oxidized form of 99mTc-HMPAO in the tissue 
([Q]b), the reduced form of 99mTc-HMPAO in the blood ([R]b), and the reduced form of 
99mTc-HMPAO in the tissue ([R]c) are described by 
!([#]A®A∆*)!' = 𝐴1∆𝑥(𝑃𝑆([𝑄]? − [𝑄]1) − 𝑘B[𝐺𝑆𝐻]1[𝑄]1 − 𝑘C[𝑅𝐻]1[𝑄]1) (A.14) ![#]A!' = ,-.A ([𝑄]? − [𝑄]1) − 𝑘B[𝐺𝑆𝐻]1[𝑄]1 − 𝑘C[𝑅𝐻]1[𝑄]1  (A.15) !([@]&®A∆*)!' + [𝑅]?𝑊𝐴1 = 𝐴1∆𝑥(𝑘4[𝐺𝑆𝐻]?[𝑄]?)  (A.16) ![@]&!' + 𝑊 [@]&!* = 𝑘4[𝐺𝑆𝐻]?[𝑄]?  (A.17) 
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!([@]A®A∆*)!' = 𝐴1∆𝑥(𝑘B[𝐺𝑆𝐻]1[𝑄]1 + 𝑘C[𝑅𝐻]1[𝑄]1)   (A.18) ![@]A!' = 𝑘B[𝐺𝑆𝐻]1[𝑄]1 + 𝑘C[𝑅𝐻]1[𝑄]1   (A.19) 
The assumption of rapidly equilibrating binding between the free oxidized form 
and the perfusate albumin leads to the following equation,  [𝑄]?[𝑃]𝑘² = [𝐵]𝑘l² (A.20) 
where Q is the oxidized form of 99mTc-HMPAO, R is the reduced form of 99mTc-HMPAO, 
k1[GSH]b is the vascular GSH-dependent rate constant, k2[GSH]c is the extravascular 
GSH-dependent rate constant, k3[RH] is the extravascular GSH-independent rate 
constant, P is the percent albumin, and B is the bound form of 99mTc-HMPAO.  𝐾F = GHIGI  (A.21) 
Kd is the equilibrium dissociation constant, k4 and k-4 are the oxidized 99mTc-HMPAO and 
perfusate BSA association and dissociation rate constant, respectively. The total ([𝑄$]?) 
vascular concentration of the oxidized form of 99mTc-HMPAO is the sum of the free and 
bound forms of 99mTc-HMPAO. [𝑄$]? = [𝑄]? + [𝐵] = [𝑄]? K1 + [,]M8N  (A.22) 
Substituting Eqn. A.22 into Eqns. A.13, A.15, and A.17, results in  
![#$]&!' +𝑊 ![#$]&!* = ,-.& /[𝑄]1 − [#$]&345[6]789: − 𝑘4[𝐺𝑆𝐻]?( [#$]&345[6]789)  (A.23) ![@]&!' + 𝑊 ![@]&!* = 𝑘4[𝐺𝑆𝐻]?( [#$]&345[6]789)  (A.24) 
![#]A!' = ,-.A / [#$]&345[6]789 − [𝑄]1: − [𝑄]1𝑘B[𝐺𝑆𝐻]1 − [𝑄]1𝑘C[𝑅𝐻] (A.25) 
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A.1.3 Finite Difference Equations 
For each capillary, the governing system of partial differential equations (Eqns. 
A.19, A.23, A.24, and A.25) were solved numerically using the finite difference method. 
The forward difference was used for time and the backward difference was used for 
space. The finite difference equation for the oxidized form of 99mTc-HMPAO in the blood 
was derived as follows,  
#$&(*,'5∆')l#&(*,')∆' = −𝑊#$&(*,')l#$&(*l∆*,')∆* + ,-B.& (𝑄1(𝑥, 𝑡) + 𝑄1(𝑥 − ∆𝑥, 𝑡) −
#$&(*,')l#$&(*l∆*,')45 678 ) − G¯[³-´]&B µ#$&(*,')5#$&(*l∆*,')45 678 ¶ (A.26) 𝑊 = ∆*∆· (A.27) ∆𝑧 = ©'̅A , 𝐿 = 1 (A.28) 𝑡1 = ∆'∆· (A.29) 
𝑄$?(𝑥, 𝑡 + ∆𝑡) − 𝑄$?(𝑥 − ∆𝑥, 𝑡) = − ∆'∆·'A 𝑄$?(𝑥, 𝑡) − 𝑄$?(𝑥 − ∆𝑥, 𝑡) + ,-B.& µ𝑄1(𝑥, 𝑡) +
𝑄1(𝑥 − ∆𝑥, 𝑡) − #$&(*,')l#$&(*l∆*,')45 678 ¶ − G¯[³-´]&∆'B µ#$&(*,')5#$&(*l∆*,')45 678 ¶ (A.30) 
𝑄$?(𝑥, 𝑡 + ∆𝑡) = 𝑄$?(𝑥 − ∆𝑥, 𝑡) + ,-∆'B∗.& µ𝑄1(𝑥, 𝑡) + 𝑄1(𝑥 − ∆𝑥, 𝑡) − #$&(*,')l#$&(*l∆*,')45 678 ¶ −
G¯[³-´]&∆'B µ#$&(*,')5#$&(*l∆*,')45 678 ¶ (A.31) 
The finite difference equations for the oxidized form of 99mTc-HMPAO in the tissue, the 
reduced form of 99mTc-HMPAO in the blood, and the reduced form of 99mTc-HMPAO in 
the tissue were derived in a similar manner. They are as follows 
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𝑄1(𝑥, 𝑡 + ∆𝑡) = 𝑄1(𝑥, 𝑡) + ,-∗∆'B∗.A µ#$&(*,')5#$&(*l∆*,')45 678 ¶ − 𝑄1(𝑥, 𝑡) − 𝑄1(𝑥 − ∆𝑥, 𝑡)) 	−G¹[@´]∆'B (𝑄1(𝑥, 𝑡) + 𝑄1(𝑥 − ∆𝑥, 𝑡)) − Gj[³-´]A∆'B (𝑄1(𝑥, 𝑡) + 𝑄1(𝑥 − ∆𝑥, 𝑡)) (A.32) 
𝑅?(𝑥, 𝑡 + ∆𝑡) = 𝑅?(𝑥 − ∆𝑥, 𝑡) + G¯[³-´]&∆'B µ#$&(*,')5#$&(*l∆*,')45 678 ¶ (A.33) 𝑅1(𝑥, 𝑡 + ∆𝑡) = 𝑅1(𝑥, 𝑡) + G¹[@´]∆'B 𝑄1(𝑥, 𝑡) + 𝑄1(𝑥 − ∆𝑥, 𝑡) + Gj[³-´]&∆'B 𝑄1(𝑥, 𝑡) +𝑄1(𝑥 − ∆𝑥, 𝑡) (A.34) 
 
A.1.4 Boundary and initial conditions 
The boundary conditions (x = 0) are  	𝑄1(0, 𝑥) = 	𝑅?(0, 𝑥) = 	𝑅1(0, 𝑥) = 0   (A.35) 𝑄?(0, 𝑥) = 𝑄c(𝑡) (A.36) 
where Qa(t) is the shifted impulse response function representing the pulmonary artery. 
The initial conditions (t = 0) are  𝑄?(0, 𝑥) = 	𝑄1(0, 𝑥) = 	𝑅?(0, 𝑥) = 	𝑅1(0, 𝑥) = 0   (A.37) 
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Appendix B: Running an Experiment 
B.1 LabVIEW initialization and data acquisition 
Turn on the power to the gamma cameras by first turning on the low voltage 
power and then turning on the high voltage power. To turn off the power, reverse the 
order. The camera should be turned on ~1 hour prior to use. Connect one end of the cable 
to the top right port on the SPECT camera system and the other end to the port marked 
“G” on the PC workstation computer. 
To acquire SPECT data, start by initializing the gamma cameras. To do this, run 
the “Imager Control System.vi” program found on the Desktop in the Learning folder 
(Learning > BenTriCam > LMBuffer > TriCam.lib > ImagerControlSystem.vi). Once the 
GUI is open click “Data Acquisition” in the “Setup” column. Keep the window that pops 
up open (you may collapse it). Next click the “Imager” button in the “Setup” column. 
Adjust the number of cameras and CPU’s used for the study and hit the “OK” button (in 
the dynamic experiments this should be 0). Then click “Initialize Camera(s)” in the 
“Setup” column. Keep the window that pops up open as well (you may also collapse it). 
Click the “Electronics’ Offsets” button in the “Setup” column, after which click “stop” 
then “run continuously” (the icon at the top left of the window). Click the button at the 
bottom “Close Window” numerous times and ensure that the sum is around 0. Then, 
close the window. 
To begin recording data:  
• Click “Dynamic Acquisition” in the Actions column. 
• Type in the number of frames and the integration time.  
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• Specify the storage path.  
• Type the name of the file in the “Root Filename” box. The projection data will 
then be saved to the file specified in the storage path in “list-mode” format.  
• Click “Exit” after the data acquisition and close the “Dynamic Acquisitions” 
box. Between each data acquisition open one image of the recently acquired 
data (see Appendix C.1). 
• Close this image. 
• Repeat the data recording steps for ~5 seconds to obtain background data. If 
the numbers that appear are inconsistent with the numbers that should be 
acquired (i.e. if previously you were obtaining counts of ~10,000 and during 
the background acquisition you obtain counts of ~50), unplug the cable 
connecting the camera to the computer and restart the program.  
 
B.2  Lung removal and safety procedures 
B.2.1 Lung removal 
After the experiment, place the lungs with the attached cannulas in a lead pig 
lined with a red hazardous waste bag and cover with the lead lid. Radioactivity will be 
present in the cannulas and lungs. Label the pig with a yellow radioactive waste sticker 
containing the date and radioisotope used. Store the pig in the specimen refrigerator until 
the radioisotope has decayed to safe levels (72 hrs or 12 half-lives for 99mTc labeled 
compounds). After the radioisotope has decayed, obtain the wet weight of the lung, then 
dry the lungs in the oven and obtain the dry weight. 
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B.2.2 General safety procedure 
§ All working areas should be covered with absorbent paper. 
§ Lab coats, body badges, and ring badges should be worn at all times. 
§ Gloves should be worn when in contact with the radio-tracer. 
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Appendix C: Data Processing 
C.1 Converting planar data from list-mode to image format 
• Under the “Show” column, click “generate image”. This will open another 
window. From this window click run (represented by the forward arrow).  
• Find the Calibration folder located on the Desktop in the “Learning” folder.  
• From the “Learning” folder, select “BenTriCam”, “calibrations”, 
“calibrations5_31_16”, “mdrf_files”, “Lut2.dat”, “mean.dat”, and 
“winLimits.dat.  
• Select the data file you wish to view by finding the file containing the 
acquired data and select the file (ending in .dat).  
• Name the output image (ending in .img) and click “OK”. Another window 
will appear. When you finish viewing the image, click “Quit” at the bottom 
left.  
• Click “Cancel” in the “Choose an existing image file” window. Then close the 
“gen_image.vi” window.  
• Click “Generate image” again (if the box is still highlighted green) and close 
the window. 
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C.2 Converting dynamic data from list-mode to image format 
 In order to view the series of dynamic images in ImageJ, the data must be 
converted to the .img format. To convert the files:  
• Copy the files to the folder “ListModetoImages”.  
• Copy the document “ListModeToProjections.out” to each subfolder containing 
data that needs to be processed.  
• Open the folder in the command terminal.  
• Type “make” to build the project. Then type “./listModeToProjections.out” and a 
sequence of requirements for continuing will appear. It will say <mdrf_dim> 
<wid> <output_dim> etc. Type “./listModeToProjections.out” again followed by 
the mdrf_file dimension (“78”), then the window size (“5”), then the output 
dimension (“78”), next the Lut2.dat pathway, the mean.dat pathway, the 
winLimits.dat pathway, the window (“0”), the output dimension (“4”), and *.dat. 
When prompted, enter the data folder information pathway.  
 
C.3 Drawing the ROIs and obtaining the TAC in ImageJ 
 ImageJ was used to generate a TAC from a set of dynamic data through the 
Generate_TAC plugin.  
• In ImageJ go to “Plugins” and “Generate_TAC”, and select the folder containing 
the .img data.  
• Set the Image type to 32-bit real and the width and height to 78.  
• Select “Merge to Stack” then click “OK”.  
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• Select “Image”, “Stacks”, and “Z Project”, and change the Projection type to Sum 
Slices. The image that appears is the sum of all the dynamic images acquired.  
• Select the TAC-Stack box and click “Image”, “Transform”, “Rotate 90 degrees 
Right”.  
• On the SUM_TAC-Stack, draw the input, output, and lung ROI (in that order) 
using any of the drawing tools. In between each one click “Add” in the ROI 
manager box.  
• When all three ROIs are added, select the TAC-Stack, and “Show All” (ROI 
Manager) to ensure the ROIs correspond to the correct region on the images.  
• Then click “OK” in the “Action Required” box. A “Log” box will appear with all 
of the values corresponding to the arterial, venous, and lung time activity curves.  
• Save this as a .txt file. 
 
Figure C.1. Summed image of the lung with the regions of interest mask representing the 
(1) arterial input, (2) venous output, and (3) lung. This mask will be applied to each 
image to determine the corresponding time activity curve. 
1
2
3
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Appendix D: MATLAB Programs 
The following MATLAB programs were used to analyze the data and solve for 
the key parameter values that best fit the model to the lung time activity curves. The 
following MATLAB programs should be copied into the same directory as the data: 
variablesPDE1.m, Simulation_GUI.m, Simulation_GUI.fig, FitInput3.m, findCin1.m, 
Modular_Regression_MethodB1.m, SolvePDE_MethodB1.m, Cin_curve_MethodB1.m, 
hc_curve_MethodB1.m, and Cin_curve_DEM1.m. Start MATLAB and switch to the 
appropriate directory.  
 
D.1 variablesPDE1.m 
 variablesPDE1.m allows the user to specify the type of data being used 
(simulated or experimental). If simulated data is selected, a figure of the simulated 
curves, created by Simulation_GUI.m, (see Appendix D.3), is generated. If experimental 
data is selected, the user is prompted to enter several inputs, including flow, % albumin, 
and the amount injected. If real data is selected, variablesPDE1.m then calls the function 
FitInput3.m (see Appendix D.2). 
1. In the command window the following prompt appears: ‘Use Real Data (1) or 
Simulated Data (2)?’ Enter the number according to the data type being used and 
press ‘Enter’.  
2. For ‘1’: 
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2.1.  Enter the values for the ‘Flow’, ‘Data acquisition time interval’, ‘Injected dose 
(pre-DEM)’, ‘Injected dose (post-DEM)’, and ‘Percent albumin’ in the Lung 
Curve Parameter dialog box and press ‘OK’.  
2.2. A dialog box will appear allowing you to search for the pre-DEM data file 
(generated in ImageJ and saved as a .txt file). Once selected, another dialog box 
will appear allowing you to search for the post-DEM data file. 
2.3. A figure will appear with the pre- and post-DEM lung curves. Enter the time 
point at which the curve starts in the ‘Input Parameters’ dialog box and press 
‘OK’ (the figure is interactive, so the tools at the top may be used to determine an 
accurate starting point). 
2.4. variablesPDE1.m calls FitInput3.m (see Appendix D.2) and saves the values of 
the mean and variance for both the pre- and post-DEM curves. 
3. For ‘2’: 
3.1. A figure of the simulated pre- and post-DEM lung curves, previously generated 
in Simulation_GUI.m, is generated. 
 
D.2 FitInput3.m 
 FitInput3.m uses nonlinear regression to fit a gamma variate function to the pre- 
and post-DEM input curves independently.  
1. A figure of the pre-DEM input curve will appear.  
1.1. In the command window enter the time point at which the input curve starts, and 
press enter.  
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1.2. Then enter the time point at which the input curve ends, and press enter.  
1.3. Enter initial estimates for the mean, variance, t0, and dose of the pre-DEM curve 
in [ ] and press enter. Do not close the figure until ‘Yes’ is selected in step 2. 
2. A figure will appear showing the fit of the simulated curve to the pre-DEM input 
curve. If the fit is acceptable, click ‘Yes’ otherwise click ‘No’. If ‘No’ is selected, you 
will repeat step 1 until ‘Yes’ is selected. If ‘Yes’ is selected, you will move on to step 
3. 
3. A figure of the post-DEM input curve will appear. The same procedure is used for the 
post-DEM curve as for the pre-DEM curve (steps 1 and 2). Once ‘Yes’ is selected the 
function ends.  
 
D.3 Simulation_GUI.m 
 Simulation_GUI.m generates a graphical user interface in which the user is 
prompted to enter values for the lung curve, input curve, and capillary transit time 
parameters. The user is also prompted to enter values for the ‘free parameters’, which are 
the unknown values solved for in Modular_Regression_MethodB1.m. 
1. When the GUI appears, enter the desired curve parameters. 
2. Press Run. A figure will appear in the GUI dialog box of the pre- and post-DEM 
simulated curves.  
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D.4 Modular_Regression_MethodB1.m 
 Modular_Regression_MethodB1.m uses nonlinear regression to simultaneously fit 
two independent curves (measured 99mTc-HMPAO pre- and post-DEM TACs) to obtain 
the model parameters and the lung steady-state uptake value.  
1. Calls variablesPDE1.m and FitInput3.m or Simulation_GUI.m (follow steps in 
Appendices D.1 and D.2 or Appendix D.3). 
2. Prompt appears in command window asking what data will be used in 
Modular_Regression_MethodB1.m. Specify ‘1’ for real data or ‘2’ for simulated 
data. 
3. Nonlinear regression is performed, and a curve fit to the two independent curves 
will appear.  
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Appendix E: Data Processing Code 
E.1. Flow chart  
 
Figure E.1. Flow chart showing the process of the variablesPDE1.m function  
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Figure E.2. Flow chart showing the process of the FitInput3.m function 
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Figure E.3. Flow chart showing the overall code 
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E.2. Data fitting code 
E.2.1 variablesPDE1.m 
function [flow, F, injected0, K, in, h_t, volume, data1, tdata1, data2, 
tdata2, L2, albumin, data_time_acquisition] = variablesPDE1  
  
%% Variables 
  
k2 = 0.0;              % rate constant for conversion of reduced back 
to oxidized in tissue (1/sec) 
k1 = 0.0;             % rate constant for conversion of reduced back to 
oxidized in blood, (1/sec) 
Kd = 3/2; 
kGSHb = 0.0;              % kGSH rate constant in blood, (1/sec) 
L = 1;              % Length of capillary (cm) 
dt = 0.005;  
  
% hc(t) curve 
dose = 1.0;     % mCi Injected 
t0 = 0;       % x(4), Sec, 3.5 
  
% Volumes 
Va = 0.15;      % artery volume, mL 
Vc = 3.6;       % tissue volume, mL 
Vv = 0.15;      % vein volume, mL 
  
% User enters whether they're performing a simulation or optimization 
prompt0 = input('Use Real Data (1) or Simulated Data (2) parameters? 
'); 
if prompt0 == 1    
%% Optimization parameters 
% Dialog box for entering optimization parameters 
prompt = {'Flow (mL/min):','Data acquisition time interval 
(s):','Injected dose (Pre-DEM curve, mCi)','Injected dose (Post-DEM 
curve, mCi)','Percent albumin (%)'};%,'Baseline time point (Pre-DEM 
Curve, s)','Baseline time point (Post-DEM Curve, s)'}; 
dlg_title = 'Lung Curve Parameters'; 
num_lines = 1; 
defaultans = {'10','1','1.5','1.5','3'};%,'10','10'}; 
options.Resize = 'on'; 
options.WindowStyle = 'normal'; 
answer = inputdlg(prompt,dlg_title,num_lines,defaultans,options); 
flow = str2double(answer{1}); 
data_time_acquisition = str2double(answer{2}); 
injected1 = str2double(answer{3}); 
injected2 = str2double(answer{4}); 
P = str2double(answer{5}); 
  
  
% Select data files (Pre- and Post-DEM) to open 
[filename, pathname] = uigetfile('*.txt','Pick a data file');  
name = fullfile(pathname, filename); 
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data0 = load(name); 
[filename1, pathname1] = uigetfile('*.txt','Pick a data file');  
name1 = fullfile(pathname1, filename1); 
data00 = load(name1); 
tdata1 = 0:data_time_acquisition:(length(data0)*data_time_acquisition)-
0.5;     % Time corresponding with pre-DEM data acquisition time (s) 
tdata2 = 
0:data_time_acquisition:(length(data00)*data_time_acquisition)-0.5;    
% Time corresponding with post-DEM data acquisition time (s) 
  
% Figure of Pre- and Post-DEM Curves BEFORE normalization 
figure; plot(tdata1,data0(:,3),tdata2,data00(:,3)) 
xlabel('Time (s)') 
legend('Pre-DEM','Post-DEM') 
  
% Dialog box prompting user to enter the point at which the curve 
starts to increase (after the background) 
prompt = {'Pre-DEM lung curve starting time point (s): ','Post-DEM lung 
curve starting time point (s): '};  
dlg_title = 'Input Parameters'; 
num_lines = 1; 
defaultans = {'10','10'}; 
options.Resize = 'on'; 
options.WindowStyle = 'normal'; 
answer = inputdlg(prompt,dlg_title,num_lines,defaultans,options); 
input1 = str2double(answer{1}); 
input2 = str2double(answer{2}); 
  
t01 = input1; 
t02 = input2; 
  
% Spline curve acquired at 0.5 s interval to have 1s interval 
if data_time_acquisition == 0.5 
    data10 = data0*2;        
    tdata3 = 0:(length(data10)/2)-0.5; 
    tdata1 = 0:0.5:(length(data10)/2)-0.5;               
    data1 = spline(tdata1,data10(:,1),tdata3);  
    data2 = spline(tdata1,data10(:,2),tdata3);  
    data3 = spline(tdata1,data10(:,3),tdata3);  
    data11 = data00*2;  
    tdata4 = 0:(length(data11)/2)-0.5; 
    tdata2 = 0:0.5:(length(data11)/2)-0.5;               
    data4 = spline(tdata2,data11(:,1),tdata4); 
    data5 = spline(tdata2,data11(:,2),tdata4); 
    data6 = spline(tdata2,data11(:,3),tdata4); 
    data0 = [data1; data2; data3]'; 
    data00 = [data4; data5; data6]'; 
  
elseif data_time_acquisition == 1 
    tdata3 = 0:(length(data0))-1; 
    tdata4 = 0:(length(data00))-1; 
end 
  
tdata1 = 0:length(data0)-1; 
tdata2 = 0:length(data00)-1; 
max(tdata1) 
max(tdata2) 
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% Shift curve to have a baseline of 0 
data1 = (data0(:,3)-mean(data0(1:t01,3)))./injected1; 
data2 = (data00(:,3)-mean(data00(1:t02,3)))./injected2; 
figure; plot(tdata1,data1,tdata2,data2) 
  
data0 = (data0(:,1)-(1/data_time_acquisition))/injected1; 
data00 = (data00(:,1)-(1/data_time_acquisition))/injected2; 
figure; plot(data0); hold on; plot(data00) 
  
global vars 
vars.data_time_acquisition = data_time_acquisition; 
vars.tdata1 = tdata1;   % Pre-DEM time interval (s) 
vars.tdata2 = tdata2;   % Post-DEM time interval (s) 
vars.data0 = data0;     % Pre-DEM input curve  
vars.data00 = data00;   % Post-DEM input curve 
vars.data1 = data1;     % Pre-DEM lung curve 
vars.data2 = data2;   % Post-DEM lung curve 
vars.t01 = t01;     % Pre-DEM curve starting point, after background 
(s) 
vars.t02 = t02;     % Post-DEM curve starting point, after background 
(s) 
vars.injected1 = injected1;     % Amount injected pre-DEM curve (mCi) 
vars.injected2 = injected2;     % Amount injected post-DEM curve (mCi) 
  
% Call mean and variance of  
[mu0, sigmas0, t00, mu00, sigmas00, t04, new_t, new_input] = FitInput3; 
  
mu1 = mu0;          % (s) input mean pre-DEM 
sigmas1 = sigmas0;  % (s^2) input variance pre-DEM 
mu2 = mu00;         % (s) input mean post-DEM 
sigmas2 = sigmas00; % (s^2) input variance post-DEM 
  
mu = 2.45;    % (s) hc(t) mean 
sigmas = 4.05; % (s^2) hc(t) variance 
ts = 0.865;     % (s) arterial time shift 
ts_v = 0.865;   % (s) venous time shift 
mu = mu*(10/flow); 
sigmas = sigmas*((10/flow)^2); 
   
kGSHc1 = 0.0;               % Post-DEM curve rate constant for 
conversion of oxidized to reduced in the tissue (1/sec) 
kGSHc = 0.1;               % Pre-DEM curve rate constant for conversion 
of oxidized to reduced in the tissue (1/sec) 
kother = 0.05;              % rate constant for conversion of oxidized 
to reduced in tissue via GSH-independent pathway (1/sec) 
  
elseif prompt0 == 2 
%% Simulation Parameters 
% run Simulation_GUI 
load('2Curves_PDE_Sim','tdata','tdata1','tdata2','LAC2','LACn','flow','
mu1','mu2','mu','sigmas1','sigmas2','sigmas',... 
    
't01','t02','time1','time2','PS','kGSHc','kother','kGSHb','data_time_ac
quisition','Vc','P','dose1','dose2','injected1','injected2'); 
data1 = LACn(1:length(tdata1)); 
data2 = LACn(length(tdata1)+1:end); 
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figure; plot(tdata1,data1,tdata2,data2) 
xlabel('Time (s)') 
legend('Pre-DEM','Post-DEM') 
     
t01 = t01*data_time_acquisition; 
t02 = t02*data_time_acquisition; 
vars.t01 = t01; 
vars.t02 = t02; 
     
end 
  
in = [t01; t02; mu1; sigmas1; mu2; sigmas2]; 
  
F = flow/60; 
kGSHc1 = 0; 
Vb = F*mu;       % capillary blood volume, mL 
volume = [Va; Vb; Vc; Vv]; 
injected0 = [injected1; injected2]; 
L2 = [L; dt];  
albumin = [Kd;P]; 
h_t = [dose; t0; mu; sigmas; ts; ts_v]; 
K = [kGSHb; k1; kGSHc; kGSHc1; kother; k2]; 
  
  
vars.flow = flow; 
vars.data_time_acquisition = data_time_acquisition; 
vars.albumin = albumin;  
vars.K = K; 
vars.L2 = L2; 
vars.injected0 = injected0; 
vars.in = in; 
vars.h_t = h_t; 
vars.volume = volume; 
vars.L2 = L2; 
vars.albumin = albumin; 
 
 
E.2.2 FitInput3.m 
function [mu0, sigmas0, t00, mu00, sigmas00, t04,new_t,new_input] = 
FitInput3 
  
global vars 
data0 = vars.data0;     % Pre-DEM input data 
data00 = vars.data00;   % Post-DEM input data 
data_time_acquisition = vars.data_time_acquisition; 
tdata3 = vars.tdata1;   % Pre-DEM Time interval (s) 
tdata4 = vars.tdata2;   % Post-DEM Time interval (s) 
  
%% Pre-DEM Input Curve 
figure; plot(tdata3,data0(:,1)) 
  
% Dialog box for input curve parameters 
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choice = 1; 
while(choice) 
  
inputstart = input('At what time point does the input curve start? 
');%)/data_time_acquisition; 
endinput = input('At what time point does the input curve end? 
');%)/data_time_acquisition; 
  
x0 = input('Enter the initial estimates for the mean, variance, t0, and 
dose of the pre-DEM curve in brackets (i.e. [2 3 10 5]) '); 
  
% Pad input curve with zeros to reduce noise contribution 
in = data0(inputstart+1:endinput,1); 
s = length(data0(1:inputstart,1)); 
in = padarray(in, [s 0], 0 ,'pre'); 
new_input = padarray(in, [35 0], 0, 'post'); 
new_t = 0:(length(new_input)-1); 
  
figure; plot(new_t,new_input) 
%% Find the best fit values for the input using the truncated curves 
lb = [0 0 0 0];                 % Lower bounds for lsqcurvefit 
  
[x,resnorm,residual,exitflag,out,lambda,jacobian] = 
lsqcurvefit(@findCin1,x0,new_t,new_input',lb); %Truncated Curve 
['Mean = ', num2str(x(1)),', Var = ', num2str(x(2)), ', t0 = ', 
num2str(x(3)), ', dose = ', num2str(x(4))] 
resnorm 
     
mu0 = x(1); 
sigmas0 = x(2); 
t00 = x(3); 
dose1 = x(4); 
  
% Use fit values to generate fitted input curve 
for i = 1:length(new_t); 
    if (new_t(i) <= t00); 
        Cin(i) = 0.0; 
    else 
        Cin(i) = dose1*((new_t(i) - t00)^(((mu0^2)/(sigmas0))-
1))*(exp(-(new_t(i)-t00)/((sigmas0)/mu0))); 
    end 
end 
  
figure 
plot(new_t,new_input,new_t,Cin,'--') 
axis([0 inf 0 inf]) 
xlabel('Time (sec)') 
ylabel('Counts/pixel/mCi Injected') 
title('Input curve fit WITHOUT DEM') 
  
% If the curves fits the data, select yes and exit the loop, otherwise 
% select no and enter different initial guesses; repeat until the fit 
is acceptable 
choice = menu('Does the new curve fit the original input curve (yes or 
no)?', 'No', 'Yes') 
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if choice == 2 
    break  
end 
end 
  
%% Post-DEM Curve 
figure; plot(tdata4,data00(:,1)) 
  
choice1 = 1; 
while(choice1) 
  
inputstart1 = input('At what time point does the input curve start? 
');%)/data_time_acquisition; 
endinput1 = input('At what time point does the input curve end? 
');%)/data_time_acquisition; 
  
x01 = input('Enter the initial estimates for the mean, variance, t0, 
and dose of the post-DEM curve in brackets (i.e. [2 2 8 0.1]) '); 
  
% Pad curve with zeros at beginning and end to reduce noise 
contribution 
input1 = data00(inputstart1+1:endinput1,1)        % New data 
s1 = length(data00(1:inputstart1)) 
input1 = padarray(input1, [s1 0], 0 ,'pre'); 
new_input1 = padarray(input1, [35 0], 0, 'post'); 
new_t1 = 
0:data_time_acquisition:(length(new_input1)*data_time_acquisition)-0.5; 
  
figure; plot(new_t1,new_input1) 
  
%% Find the best fit values for the input using the truncated curves 
[x1,resnorm,residual,exitflag,out,lambda,jacobian] = 
lsqcurvefit(@findCin1,x01,new_t1,new_input1',lb); %Truncated Curve 
['Mean 1= ', num2str(x1(1)),', Var = ', num2str(x1(2)), ', t0 = ', 
num2str(x1(3)), ', dose = ', num2str(x1(4))] 
resnorm 
  
mu00 = x1(1); 
sigmas00 = x1(2); 
t04 = x1(3); 
dose2 = x1(4); 
  
% Use new fit values to generate fitted input curve 
for i = 1:length(new_t1); 
    if (new_t1(i) <= t04); 
        Cin1(i) = 0.0; 
    else 
        Cin1(i) = dose2*((new_t1(i) - t04)^(((mu00^2)/(sigmas00))-
1))*(exp(-(new_t1(i)-t04)/((sigmas00)/mu00))); 
    end 
end 
  
figure 
plot(new_t1,new_input1,new_t1,Cin1,'--') 
axis([0 inf 0 inf]) 
xlabel('Time (sec)') 
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ylabel('Counts/pixel/mCi Injected') 
title('Input curve fit WITH DEM') 
  
choice1 = menu('Does the new curve fit the original input curve (yes or 
no)?', 'No', 'Yes') 
  
if choice1 == 2 
    break  
end 
end 
  
 
E.2.3 findCin1.m 
function [Cin] = findCin1(x1,new_t1); 
mu = x1(1); 
sigmas = x1(2); 
t0 = x1(3); 
dose = x1(4); 
  
%% Input Curve 
  
    for i = 1:length(new_t1) 
        if (new_t1(i) <= t0) 
            Cin(i) = 0.0; 
        else 
            Cin(i) = dose*((new_t1(i) - t0)^(((mu^2)/(sigmas))-
1))*(exp(-(new_t1(i)-t0)/((sigmas)/mu))); 
        end 
    end 
 
 
E.2.4 Simulation_GUI.m 
function varargout = Simulation_GUI(varargin) 
%SIMULATION_GUI MATLAB code file for Simulation_GUI.fig 
%      SIMULATION_GUI, by itself, creates a new SIMULATION_GUI or 
raises the existing 
%      singleton*. 
% 
%      H = SIMULATION_GUI returns the handle to a new SIMULATION_GUI or 
the handle to 
%      the existing singleton*. 
% 
%      SIMULATION_GUI('Property','Value',...) creates a new 
SIMULATION_GUI using the 
%      given property value pairs. Unrecognized properties are passed 
via 
%      varargin to Simulation_GUI_OpeningFcn.  This calling syntax 
produces a 
%      warning when there is an existing singleton*. 
% 
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%      SIMULATION_GUI('CALLBACK') and 
SIMULATION_GUI('CALLBACK',hObject,...) call the 
%      local function named CALLBACK in SIMULATION_GUI.M with the given 
input 
%      arguments. 
% 
%      *See GUI Options on GUIDE's Tools menu.  Choose "GUI allows only 
one 
%      instance to run (singleton)". 
% 
% See also: GUIDE, GUIDATA, GUIHANDLES 
  
% Edit the above text to modify the response to help Simulation_GUI 
  
% Last Modified by GUIDE v2.5 17-Feb-2018 09:34:40 
  
% Begin initialization code - DO NOT EDIT 
gui_Singleton = 1; 
gui_State = struct('gui_Name',       mfilename, ... 
                   'gui_Singleton',  gui_Singleton, ... 
                   'gui_OpeningFcn', @Simulation_GUI_OpeningFcn, ... 
                   'gui_OutputFcn',  @Simulation_GUI_OutputFcn, ... 
                   'gui_LayoutFcn',  [], ... 
                   'gui_Callback',   []); 
if nargin && ischar(varargin{1}) 
   gui_State.gui_Callback = str2func(varargin{1}); 
end 
  
if nargout 
    [varargout{1:nargout}] = gui_mainfcn(gui_State, varargin{:}); 
else 
    gui_mainfcn(gui_State, varargin{:}); 
end 
% End initialization code - DO NOT EDIT 
 
% --- Executes just before Simulation_GUI is made visible. 
function Simulation_GUI_OpeningFcn(hObject, eventdata, handles, 
varargin) 
% This function has no output args, see OutputFcn. 
% hObject    handle to figure 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
% varargin   unrecognized PropertyName/PropertyValue pairs from the 
%            command line (see VARARGIN) 
  
% Choose default command line output for Simulation_GUI 
handles.output = hObject; 
  
% Update handles structure 
guidata(hObject, handles); 
  
% UIWAIT makes Simulation_GUI wait for user response (see UIRESUME) 
% uiwait(handles.figure1); 
 
% --- Outputs from this function are returned to the command line. 
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function varargout = Simulation_GUI_OutputFcn(hObject, eventdata, 
handles) 
% varargout  cell array for returning output args (see VARARGOUT); 
% hObject    handle to figure 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
  
% Get default command line output from handles structure 
varargout{1} = handles.output; 
 
function PS_Callback(hObject, eventdata, handles) 
% hObject    handle to PS (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
  
% Hints: get(hObject,'String') returns contents of PS as text 
%        str2double(get(hObject,'String')) returns contents of PS as a 
double 
  
  
% --- Executes during object creation, after setting all properties. 
function PS_CreateFcn(hObject, eventdata, handles) 
% hObject    handle to PS (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    empty - handles not created until after all CreateFcns 
called 
  
% Hint: edit controls usually have a white background on Windows. 
%       See ISPC and COMPUTER. 
if ispc && isequal(get(hObject,'BackgroundColor'), 
get(0,'defaultUicontrolBackgroundColor')) 
    set(hObject,'BackgroundColor','white'); 
end 
 
function Vc_Callback(hObject, eventdata, handles) 
% hObject    handle to Vc (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
  
% Hints: get(hObject,'String') returns contents of Vc as text 
%        str2double(get(hObject,'String')) returns contents of Vc as a 
double 
 
% --- Executes during object creation, after setting all properties. 
function Vc_CreateFcn(hObject, eventdata, handles) 
% hObject    handle to Vc (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    empty - handles not created until after all CreateFcns 
called 
  
% Hint: edit controls usually have a white background on Windows. 
%       See ISPC and COMPUTER. 
if ispc && isequal(get(hObject,'BackgroundColor'), 
get(0,'defaultUicontrolBackgroundColor')) 
    set(hObject,'BackgroundColor','white'); 
end 
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function kGSHc_Callback(hObject, eventdata, handles) 
% hObject    handle to kGSHc (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
  
% Hints: get(hObject,'String') returns contents of kGSHc as text 
%        str2double(get(hObject,'String')) returns contents of kGSHc as 
a double 
 
% --- Executes during object creation, after setting all properties. 
function kGSHc_CreateFcn(hObject, eventdata, handles) 
% hObject    handle to kGSHc (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    empty - handles not created until after all CreateFcns 
called 
  
% Hint: edit controls usually have a white background on Windows. 
%       See ISPC and COMPUTER. 
if ispc && isequal(get(hObject,'BackgroundColor'), 
get(0,'defaultUicontrolBackgroundColor')) 
    set(hObject,'BackgroundColor','white'); 
end 
  
function kother_Callback(hObject, eventdata, handles) 
% hObject    handle to kother (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
  
% Hints: get(hObject,'String') returns contents of kother as text 
%        str2double(get(hObject,'String')) returns contents of kother 
as a double 
  
% --- Executes during object creation, after setting all properties. 
function kother_CreateFcn(hObject, eventdata, handles) 
% hObject    handle to kother (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    empty - handles not created until after all CreateFcns 
called 
  
% Hint: edit controls usually have a white background on Windows. 
%       See ISPC and COMPUTER. 
if ispc && isequal(get(hObject,'BackgroundColor'), 
get(0,'defaultUicontrolBackgroundColor')) 
    set(hObject,'BackgroundColor','white'); 
end 
  
function dose1_Callback(hObject, eventdata, handles) 
% hObject    handle to dose1 (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
  
% Hints: get(hObject,'String') returns contents of dose1 as text 
%        str2double(get(hObject,'String')) returns contents of dose1 as 
a double 
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% --- Executes during object creation, after setting all properties. 
function dose1_CreateFcn(hObject, eventdata, handles) 
% hObject    handle to dose1 (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    empty - handles not created until after all CreateFcns 
called 
  
% Hint: edit controls usually have a white background on Windows. 
%       See ISPC and COMPUTER. 
if ispc && isequal(get(hObject,'BackgroundColor'), 
get(0,'defaultUicontrolBackgroundColor')) 
    set(hObject,'BackgroundColor','white'); 
end 
  
function dose2_Callback(hObject, eventdata, handles) 
% hObject    handle to dose2 (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
  
% Hints: get(hObject,'String') returns contents of dose2 as text 
%        str2double(get(hObject,'String')) returns contents of dose2 as 
a double 
  
% --- Executes during object creation, after setting all properties. 
function dose2_CreateFcn(hObject, eventdata, handles) 
% hObject    handle to dose2 (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    empty - handles not created until after all CreateFcns 
called 
  
% Hint: edit controls usually have a white background on Windows. 
%       See ISPC and COMPUTER. 
if ispc && isequal(get(hObject,'BackgroundColor'), 
get(0,'defaultUicontrolBackgroundColor')) 
    set(hObject,'BackgroundColor','white'); 
end 
  
function time1_Callback(hObject, eventdata, handles) 
% hObject    handle to time1 (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
  
% Hints: get(hObject,'String') returns contents of time1 as text 
%        str2double(get(hObject,'String')) returns contents of time1 as 
a double 
  
% --- Executes during object creation, after setting all properties. 
function time1_CreateFcn(hObject, eventdata, handles) 
% hObject    handle to time1 (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    empty - handles not created until after all CreateFcns 
called 
  
% Hint: edit controls usually have a white background on Windows. 
%       See ISPC and COMPUTER. 
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if ispc && isequal(get(hObject,'BackgroundColor'), 
get(0,'defaultUicontrolBackgroundColor')) 
    set(hObject,'BackgroundColor','white'); 
end 
  
  
function time2_Callback(hObject, eventdata, handles) 
% hObject    handle to time2 (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
  
% Hints: get(hObject,'String') returns contents of time2 as text 
%        str2double(get(hObject,'String')) returns contents of time2 as 
a double 
  
  
% --- Executes during object creation, after setting all properties. 
function time2_CreateFcn(hObject, eventdata, handles) 
% hObject    handle to time2 (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    empty - handles not created until after all CreateFcns 
called 
  
% Hint: edit controls usually have a white background on Windows. 
%       See ISPC and COMPUTER. 
if ispc && isequal(get(hObject,'BackgroundColor'), 
get(0,'defaultUicontrolBackgroundColor')) 
    set(hObject,'BackgroundColor','white'); 
end 
  
function data_time_acquisition_Callback(hObject, eventdata, handles) 
% hObject    handle to data_time_acquisition (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
  
% Hints: get(hObject,'String') returns contents of 
data_time_acquisition as text 
%        str2double(get(hObject,'String')) returns contents of 
data_time_acquisition as a double 
   
% --- Executes during object creation, after setting all properties. 
function data_time_acquisition_CreateFcn(hObject, eventdata, handles) 
% hObject    handle to data_time_acquisition (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    empty - handles not created until after all CreateFcns 
called 
  
% Hint: edit controls usually have a white background on Windows. 
%       See ISPC and COMPUTER. 
if ispc && isequal(get(hObject,'BackgroundColor'), 
get(0,'defaultUicontrolBackgroundColor')) 
    set(hObject,'BackgroundColor','white'); 
end 
  
function flow_Callback(hObject, eventdata, handles) 
% hObject    handle to flow (see GCBO) 
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% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
  
% Hints: get(hObject,'String') returns contents of flow as text 
%        str2double(get(hObject,'String')) returns contents of flow as 
a double 
  
  
% --- Executes during object creation, after setting all properties. 
function flow_CreateFcn(hObject, eventdata, handles) 
% hObject    handle to flow (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    empty - handles not created until after all CreateFcns 
called 
  
% Hint: edit controls usually have a white background on Windows. 
%       See ISPC and COMPUTER. 
if ispc && isequal(get(hObject,'BackgroundColor'), 
get(0,'defaultUicontrolBackgroundColor')) 
    set(hObject,'BackgroundColor','white'); 
end 
  
function injected1_Callback(hObject, eventdata, handles) 
% hObject    handle to injected1 (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
  
% Hints: get(hObject,'String') returns contents of injected1 as text 
%        str2double(get(hObject,'String')) returns contents of 
injected1 as a double 
  
 % --- Executes during object creation, after setting all properties. 
function injected1_CreateFcn(hObject, eventdata, handles) 
% hObject    handle to injected1 (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    empty - handles not created until after all CreateFcns 
called 
  
% Hint: edit controls usually have a white background on Windows. 
%       See ISPC and COMPUTER. 
if ispc && isequal(get(hObject,'BackgroundColor'), 
get(0,'defaultUicontrolBackgroundColor')) 
    set(hObject,'BackgroundColor','white'); 
end 
  
function injected2_Callback(hObject, eventdata, handles) 
% hObject    handle to injected2 (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
  
% Hints: get(hObject,'String') returns contents of injected2 as text 
%        str2double(get(hObject,'String')) returns contents of 
injected2 as a double 
  
% --- Executes during object creation, after setting all properties. 
function injected2_CreateFcn(hObject, eventdata, handles) 
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% hObject    handle to injected2 (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    empty - handles not created until after all CreateFcns 
called 
  
% Hint: edit controls usually have a white background on Windows. 
%       See ISPC and COMPUTER. 
if ispc && isequal(get(hObject,'BackgroundColor'), 
get(0,'defaultUicontrolBackgroundColor')) 
    set(hObject,'BackgroundColor','white'); 
end 
  
function kGSHb_Callback(hObject, eventdata, handles) 
% hObject    handle to kGSHb (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
  
% Hints: get(hObject,'String') returns contents of kGSHb as text 
%        str2double(get(hObject,'String')) returns contents of kGSHb as 
a double 
  
% --- Executes during object creation, after setting all properties. 
function kGSHb_CreateFcn(hObject, eventdata, handles) 
% hObject    handle to kGSHb (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    empty - handles not created until after all CreateFcns 
called 
  
% Hint: edit controls usually have a white background on Windows. 
%       See ISPC and COMPUTER. 
if ispc && isequal(get(hObject,'BackgroundColor'), 
get(0,'defaultUicontrolBackgroundColor')) 
    set(hObject,'BackgroundColor','white'); 
end 
  
function P_Callback(hObject, eventdata, handles) 
% hObject    handle to P (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
  
% Hints: get(hObject,'String') returns contents of P as text 
%        str2double(get(hObject,'String')) returns contents of P as a 
double  
% --- Executes during object creation, after setting all properties. 
function P_CreateFcn(hObject, eventdata, handles) 
% hObject    handle to P (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    empty - handles not created until after all CreateFcns 
called 
  
% Hint: edit controls usually have a white background on Windows. 
%       See ISPC and COMPUTER. 
if ispc && isequal(get(hObject,'BackgroundColor'), 
get(0,'defaultUicontrolBackgroundColor')) 
    set(hObject,'BackgroundColor','white'); 
end 
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function t01_Callback(hObject, eventdata, handles) 
% hObject    handle to t01 (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
  
% Hints: get(hObject,'String') returns contents of t01 as text 
%        str2double(get(hObject,'String')) returns contents of t01 as a 
double 
   
% --- Executes during object creation, after setting all properties. 
function t01_CreateFcn(hObject, eventdata, handles) 
% hObject    handle to t01 (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    empty - handles not created until after all CreateFcns 
called 
  
% Hint: edit controls usually have a white background on Windows. 
%       See ISPC and COMPUTER. 
if ispc && isequal(get(hObject,'BackgroundColor'), 
get(0,'defaultUicontrolBackgroundColor')) 
    set(hObject,'BackgroundColor','white'); 
end 
  
function t02_Callback(hObject, eventdata, handles) 
% hObject    handle to t02 (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
  
% Hints: get(hObject,'String') returns contents of t02 as text 
%        str2double(get(hObject,'String')) returns contents of t02 as a 
double  
  
% --- Executes during object creation, after setting all properties. 
function t02_CreateFcn(hObject, eventdata, handles) 
% hObject    handle to t02 (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    empty - handles not created until after all CreateFcns 
called 
  
% Hint: edit controls usually have a white background on Windows. 
%       See ISPC and COMPUTER. 
if ispc && isequal(get(hObject,'BackgroundColor'), 
get(0,'defaultUicontrolBackgroundColor')) 
    set(hObject,'BackgroundColor','white'); 
end 
  
function mu_Callback(hObject, eventdata, handles) 
% hObject    handle to mu (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
  
% Hints: get(hObject,'String') returns contents of mu as text 
%        str2double(get(hObject,'String')) returns contents of mu as a 
double 
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% --- Executes during object creation, after setting all properties. 
function mu_CreateFcn(hObject, eventdata, handles) 
% hObject    handle to mu (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    empty - handles not created until after all CreateFcns 
called 
  
% Hint: edit controls usually have a white background on Windows. 
%       See ISPC and COMPUTER. 
if ispc && isequal(get(hObject,'BackgroundColor'), 
get(0,'defaultUicontrolBackgroundColor')) 
    set(hObject,'BackgroundColor','white'); 
end 
  
function sigmas_Callback(hObject, eventdata, handles) 
% hObject    handle to sigmas (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
  
% Hints: get(hObject,'String') returns contents of sigmas as text 
%        str2double(get(hObject,'String')) returns contents of sigmas 
as a double 
  
% --- Executes during object creation, after setting all properties. 
function sigmas_CreateFcn(hObject, eventdata, handles) 
% hObject    handle to sigmas (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    empty - handles not created until after all CreateFcns 
called 
  
% Hint: edit controls usually have a white background on Windows. 
%       See ISPC and COMPUTER. 
if ispc && isequal(get(hObject,'BackgroundColor'), 
get(0,'defaultUicontrolBackgroundColor')) 
    set(hObject,'BackgroundColor','white'); 
end 
  
function mu1_Callback(hObject, eventdata, handles) 
% hObject    handle to mu1 (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
  
% Hints: get(hObject,'String') returns contents of mu1 as text 
%        str2double(get(hObject,'String')) returns contents of mu1 as a 
double 
  
% --- Executes during object creation, after setting all properties. 
function mu1_CreateFcn(hObject, eventdata, handles) 
% hObject    handle to mu1 (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    empty - handles not created until after all CreateFcns 
called 
  
% Hint: edit controls usually have a white background on Windows. 
%       See ISPC and COMPUTER. 
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if ispc && isequal(get(hObject,'BackgroundColor'), 
get(0,'defaultUicontrolBackgroundColor')) 
    set(hObject,'BackgroundColor','white'); 
end 
  
function sigmas1_Callback(hObject, eventdata, handles) 
% hObject    handle to sigmas1 (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
  
% Hints: get(hObject,'String') returns contents of sigmas1 as text 
%        str2double(get(hObject,'String')) returns contents of sigmas1 
as a double 
  
% --- Executes during object creation, after setting all properties. 
function sigmas1_CreateFcn(hObject, eventdata, handles) 
% hObject    handle to sigmas1 (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    empty - handles not created until after all CreateFcns 
called 
  
% Hint: edit controls usually have a white background on Windows. 
%       See ISPC and COMPUTER. 
if ispc && isequal(get(hObject,'BackgroundColor'), 
get(0,'defaultUicontrolBackgroundColor')) 
    set(hObject,'BackgroundColor','white'); 
end 
function mu2_Callback(hObject, eventdata, handles) 
% hObject    handle to mu2 (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
  
% Hints: get(hObject,'String') returns contents of mu2 as text 
%        str2double(get(hObject,'String')) returns contents of mu2 as a 
double 
   
% --- Executes during object creation, after setting all properties. 
function mu2_CreateFcn(hObject, eventdata, handles) 
% hObject    handle to mu2 (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    empty - handles not created until after all CreateFcns 
called 
  
% Hint: edit controls usually have a white background on Windows. 
%       See ISPC and COMPUTER. 
if ispc && isequal(get(hObject,'BackgroundColor'), 
get(0,'defaultUicontrolBackgroundColor')) 
    set(hObject,'BackgroundColor','white'); 
end 
  
function sigmas2_Callback(hObject, eventdata, handles) 
% hObject    handle to sigmas2 (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
  
% Hints: get(hObject,'String') returns contents of sigmas2 as text 
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%        str2double(get(hObject,'String')) returns contents of sigmas2 
as a double 
  
% --- Executes during object creation, after setting all properties. 
function sigmas2_CreateFcn(hObject, eventdata, handles) 
% hObject    handle to sigmas2 (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    empty - handles not created until after all CreateFcns 
called 
  
% Hint: edit controls usually have a white background on Windows. 
%       See ISPC and COMPUTER. 
if ispc && isequal(get(hObject,'BackgroundColor'), 
get(0,'defaultUicontrolBackgroundColor')) 
    set(hObject,'BackgroundColor','white'); 
end 
   
% --- Executes on button press in Run. 
function Run_Callback(hObject, eventdata, handles) 
% hObject    handle to Run (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
  
% declare global variables 
global flow 
global mu1 
global mu2 
global mu 
global sigmas1 
global sigmas2 
global sigmas 
global t01 
global t02 
global time1 
global time2 
global PS 
global kGSHc 
global kother 
global kGSHb 
global data_time_acquisition 
global Vc 
global P 
global dose1 
global dose2 
global injected1 
global injected2 
   
% turn off variable editors so values can't be changed while graph is 
being calculated 
set(handles.flow, 'Enable', 'off'); 
set(handles.mu1, 'Enable', 'off'); 
set(handles.mu2, 'Enable', 'off'); 
set(handles.mu, 'Enable', 'off'); 
set(handles.sigmas1, 'Enable', 'off'); 
set(handles.sigmas2, 'Enable', 'off'); 
set(handles.sigmas, 'Enable', 'off'); 
set(handles.t01, 'Enable', 'off'); 
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set(handles.t02, 'Enable', 'off'); 
set(handles.time1, 'Enable', 'off'); 
set(handles.time2, 'Enable', 'off'); 
set(handles.PS, 'Enable', 'off'); 
set(handles.kGSHc, 'Enable', 'off'); 
set(handles.kother, 'Enable', 'off'); 
set(handles.kGSHb, 'Enable', 'off'); 
set(handles.data_time_acquisition, 'Enable', 'off'); 
set(handles.Vc, 'Enable', 'off'); 
set(handles.P, 'Enable', 'off'); 
set(handles.dose1, 'Enable', 'off'); 
set(handles.dose2, 'Enable', 'off'); 
set(handles.injected1, 'Enable', 'off'); 
set(handles.injected2, 'Enable', 'off'); 
  
% assign variables from user input 
flow = str2double( get(handles.flow, 'string'));                % time 
point at which output is no longer zero = str2double( get(handles.flow, 
'string'))/60;            % blood flow in/out of the system (constant) 
in seconds 
mu1 = str2double( get(handles.mu1, 'string'));                  % first 
constant in gamma function (changes shape of curve) 
mu2 = str2double( get(handles.mu2, 'string'));                  % 
constant in exponential portion of gamma function ("") 
mu = str2double( get(handles.mu, 'string'));                  % 
constant in exponential portion of gamma function ("") 
sigmas1 = str2double( get(handles.sigmas1, 'string'));% normalized 
amount of radio-tracer and HMPAO injected 
sigmas2 = str2double( get(handles.sigmas2, 'string'));            % ? 
scaling constant (at this point) 
sigmas = str2double( get(handles.sigmas, 'string'));        % rate 
constant for conversion from oxidized ==> reduced state in tissue (no 
GSH) 
t01 = str2double( get(handles.t01, 'string'));          % rate constant 
for conversion from oxidized ==> reduced state in tissue (w/ GSH) 
t02 = str2double( get(handles.t02, 'string'));                % rate 
constant for conversion from reduced ==> oxidized state in tissue 
time1 = str2double( get(handles.time1, 'string'));          % rate 
constant for conversion from oxidized ==> reduced state in blood (w/ 
GSH) 
time2 = str2double( get(handles.time2, 'string'));                % 
rate constant for conversion from reduced ==> oxidized state in blood  
PS = str2double( get(handles.PS, 'string'));    
kGSHc = str2double( get(handles.kGSHc, 'string'));          % rate 
constant for conversion from oxidized ==> reduced state in tissue (w/ 
GSH) 
kother = str2double( get(handles.kother, 'string'));                % 
rate constant for conversion from reduced ==> oxidized state in tissue 
kGSHb = str2double( get(handles.kGSHb, 'string'));          % rate 
constant for conversion from oxidized ==> reduced state in blood (w/ 
GSH) 
data_time_acquisition = str2double( get(handles.data_time_acquisition, 
'string'));                % rate constant for conversion from reduced 
==> oxidized state in blood  
Vc = str2double( get(handles.Vc, 'string'));    
P = str2double( get(handles.P, 'string'));          % rate constant for 
conversion from oxidized ==> reduced state in tissue (w/ GSH) 
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dose1 = str2double( get(handles.dose1, 'string'));                % 
rate constant for conversion from reduced ==> oxidized state in tissue 
dose2 = str2double( get(handles.dose2, 'string'));          % rate 
constant for conversion from oxidized ==> reduced state in blood (w/ 
GSH) 
injected1 = str2double( get(handles.injected1, 'string'));                
% rate constant for conversion from reduced ==> oxidized state in blood  
injected2 = str2double( get(handles.injected2, 'string'));    
  
  
%% Capillary parameters 
% define remaining variables  
mu = mu*(10/flow) 
mu1 = mu1*(10/flow) 
mu2 = mu2*(10/flow) 
sigmas = sigmas*((10/flow)^2) 
sigmas1 = sigmas1*((10/flow)^2) 
sigmas2 = sigmas2*((10/flow)^2) 
% sigmas = ((1.5)*sqrt(sigmas))^2; 
% sigmas1 = ((1.5)*sqrt(sigmas1))^2; 
% sigmas2 = ((1.5)*sqrt(sigmas2))^2; 
% PS = (nthroot((1.5),(2/3)))*PS; 
  
kGSHc1 = 0;             % rate constant for DEM curve conversion of 
oxidized to reduced in the tissue (1/sec) 
F = flow/60; 
Vb = F*mu;             % vascular volume (ml) 
k2 = 0.0;              % rate constant for conversion of reduced back 
to oxidized in tissue (1/sec) 
k1 = 0.0;             % rate constant for conversion of reduced back to 
oxidized in blood, (1/sec) 
Kd = 3/2;               % Dissociation rate constant, ratio of forward 
and inverse rate constants for albumin binding (1/sec) 
L = 1;              % Length of capillary (cm) 
dt = 0.005;         % step size (s) 
  
ts = 1*(10/flow);   % arterial time shift 
ts_v = 1*(10/flow); % venous time shift 
  
% hc(t) curve 
dose = 1.0;     % mCi Injected 
t0 = 0;       % x(4), Sec, 3.5 
   
%% Capillary curve parameters 
t = 0:dt:(time1-data_time_acquisition);         % pre-DEM time interval 
(s) 
t1 = 0:dt:(time2-data_time_acquisition);        % post-DEM time 
interval (s) 
tdata1 = 0:data_time_acquisition:(time1*data_time_acquisition)-0.5; 
tdata2 = 0:data_time_acquisition:(time2*data_time_acquisition)-0.5; 
  
[tc,hc,H,whc,dx,N] = hc_curve_MethodB1(t,t0,dose,mu,sigmas,F,dt,L); 
[C1, Cin, Cin2, C3, Cinmean_t, varCin, Ca_mean_t, varCa] = 
Cin_curve_MethodB1(t,F,t01,ts,dose1,mu1,sigmas1,dt); 
[C2, Cin1, Cin3, C4, Cinmean_t1, varCin1, Ca_mean_t1, varCa1] = 
Cin_curve_DEM1(t1,F,t02,ts,dose2,mu2,sigmas2,dt); 
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nx = round(1./dx);       % Number of nodes in the x-direction  
x = 0:dx:L; 
  
%% Capillary Curves 
x = 0:dx:L; 
nx = round(1/dx); 
  
% Create the solution matrix 
C = zeros(length(x),length(t),4); 
  
% Initial conditions (t=0)  
C(:,1,1) = 0;  
C(:,1,2) = 0; 
C(:,1,3) = 0; 
C(:,1,4) = 0; 
  
% Boundary conditions (x=0)  
C(1,:,1) = C1; 
C(1,:,2) = C3;     
C(1,:,3) = 0; 
C(1,:,4) = 0; 
  
Qbweight = zeros(1,length(t)); 
Rbweight = zeros(1,length(t)); 
Qcweight = zeros(1,length(t)); 
Rcweight = zeros(1,length(t)); 
  
for n = 1:(length(t)-1) 
    for i = 2:(length(x)-1) 
        C(i,n+1,1) = C(i-1,n,1)+((PS*dt)/(2*Vb))*(C(i,n,3)+C(i-1,n,3)-
C(i,n,1)/(1+(P/Kd))-C(i-1,n,1)/(1+(P/Kd)))-
((kGSHb*dt)/2)*(C(i,n,1)/(1+(P/Kd))+C(i-
1,n,1)/(1+(P/Kd)))+((k1*dt)/2)*(C(i,n,2)+C(i-1,n,2));      % Oxidized 
blood 
        C(i,n+1,2) = C(i-
1,n,2)+((kGSHb*dt)/2)*(C(i,n,1)/(1+(P/Kd))+C(i-1,n,1)/(1+(P/Kd)))-
((k1*dt)/2)*(C(i,n,2)+C(i-1,n,2));        % Reduced blood       
        C(i,n+1,3) = ((PS*dt)/(2*Vc))*(C(i,n,1)/(1+(P/Kd))+C(i-
1,n,1)/(1+(P/Kd))-C(i,n,3)-C(i-1,n,3))+C(i,n,3)-
((kGSHc*dt)/2)*(C(i,n,3)+C(i-1,n,3))-((kother*dt)/2)*(C(i,n,3)+C(i-
1,n,3))+((k2*dt)/2)*(C(i,n,4)+C(i-1,n,4));     %Oxidized tissue                                      
% Oxidized tissue 
        C(i,n+1,4) = ((kGSHc*dt)/2)*(C(i,n,3)+C(i-
1,n,3))+((kother*dt)/2)*(C(i,n,3)+C(i-1,n,3))-
((k2*dt)/2)*(C(i,n,4)+C(i-1,n,4))+C(i,n,4);        % reduced tissue 
         
        Qbweight(n) = Qbweight(n)+(H(i)*C(i,n,1));   %solving for a 
multiple capillaries (i.e. when i= 1:N) 
        Rbweight(n) = Rbweight(n)+(H(i)*C(i,n,2)); 
        Qcweight(n) = Qcweight(n)+(H(i)*C(i,n,3)); 
        Rcweight(n) = Rcweight(n)+(H(i)*C(i,n,4)); 
    end 
end 
  
aQb = trapz(t,Qbweight); 
aRb = trapz(t,Rbweight); 
tQo = t.*Qbweight; 
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tQout = (trapz(t,tQo))/aQb; 
vQo = ((t-tQout).^2).*Qbweight.*dt; 
vQbout = sum(vQo)/aQb; 
tRo = t.*Rbweight; 
tRout = (trapz(t,tRo))/aRb; 
  
ns_v = round(ts_v/dt); 
%% Oxidized blood  
for i = 1:length(t) 
    if (i <= ns_v) 
        Cv_Qb(i) = 0.0; 
    else 
        Cv_Qb(i) = Qbweight(i-ns_v); 
    end 
    Qv_mean_t(i) = t(i)*Cv_Qb(i)*dt;     
end 
  
%% Find the mean and variance of the oxidized blood curve 
areaQb = trapz(t,Cv_Qb);               % Find the area under the 
oxidized blood curve  
Qv_mean_t = sum(Qv_mean_t)/areaQb;    % Sec, mean transit time of the 
oxidized blood curve 
varQv = ((t-Qv_mean_t).^2).*Cv_Qb.*dt;       
varQv = sum(varQv)/areaQb;           % Sec^2, variance of oxidized 
blood curve 
  
['MeanCin = ', num2str(Cinmean_t),', VarCin = ', num2str(varCin), ', 
MeanArtery = ', num2str(Ca_mean_t), ', VarArtery = ', num2str(varCa),', 
Mean Capillary = ',num2str(tQout),', Var Capillary = 
',num2str(vQbout),', Mean Venous = ',num2str(Qv_mean_t),', Var Venous = 
',num2str(varQv)]; 
%% Reduced blood 
for i = 1:length(t) 
    if (i <= ns_v) 
        Cv_Rb(i) = 0.0; 
    else Cv_Rb(i) = Rbweight(i-ns_v); 
    end 
        Rbmean_t(i) = t(i)*Cv_Rb(i)*dt;     
end 
  
%% Find the mean and variance of the reduced blood curve 
areaRv = trapz(t,Cv_Rb);               % Find the area under the 
reduced blood curve  
Rb_mean_t = sum(Rbmean_t)/areaRv;    % Sec, mean transit time of the 
reduced blood curve 
varRv = ((t-Rb_mean_t).^2).*Cv_Rb.*dt;       
varRv = sum(varRv)/areaRv;           % Sec^2, variance of reduced blood 
curve 
  
mean_lung = Qv_mean_t - Cinmean_t;   % sec, mean transit time of lung 
Qbweight- Cin (out-in) 
  
%% Cumulative sum 
LAC = zeros(length(t),1); 
for i = 1:(length(t)-1) 
  LAC(1) = Cin(1)-Cv_Qb(1); 
  LAC(i+1) = LAC(i)+(Cin(i+1)-Cv_Qb(i+1)); 
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end   
  
LAC = F*dt*LAC; 
  
%% Spline Curve 
yy1 = spline(t,LAC,tdata1); 
  
% Add noise to spline curve 
noise1 = max(yy1).*0.025;     %Amount of noise added 
LACn1 = yy1 + noise1.*randn(size(yy1)); % Noisy Signal 
  
%% DEM Curve 
%Create the solution matrix 
C = zeros(length(x),length(t1),4); 
  
% Initial conditions (t=0)  
C(:,1,1) = 0;  
C(:,1,2) = 0; 
C(:,1,3) = 0; 
C(:,1,4) = 0; 
  
% Boundary conditions (x=0)  
C(1,:,1) = C2; 
C(1,:,2) = C4;     
C(1,:,3) = 0; 
C(1,:,4) = 0; 
  
Qbweight1 = zeros(1,length(t1)); 
Rbweight1 = zeros(1,length(t1)); 
Qcweight1 = zeros(1,length(t1)); 
Rcweight1 = zeros(1,length(t1)); 
  
for n = 1:(length(t1)-1) 
    for i = 2:(length(x)-1); 
        C(i,n+1,1) = C(i-1,n,1)+((PS*dt)/(2*Vb))*(C(i,n,3)+C(i-1,n,3)-
C(i,n,1)/(1+(P/Kd))-C(i-1,n,1)/(1+(P/Kd)))-
((kGSHb*dt)/2)*(C(i,n,1)/(1+(P/Kd))+C(i-
1,n,1)/(1+(P/Kd)))+((k1*dt)/2)*(C(i,n,2)+C(i-1,n,2));      % Oxidized 
blood 
        C(i,n+1,2) = C(i-
1,n,2)+((kGSHb*dt)/2)*(C(i,n,1)/(1+(P/Kd))+C(i-1,n,1)/(1+(P/Kd)))-
((k1*dt)/2)*(C(i,n,2)+C(i-1,n,2));        % Reduced blood       
        C(i,n+1,3) = ((PS*dt)/(2*Vc))*(C(i,n,1)/(1+(P/Kd))+C(i-
1,n,1)/(1+(P/Kd))-C(i,n,3)-C(i-1,n,3))+C(i,n,3)-
((kGSHc1*dt)/2)*(C(i,n,3)+C(i-1,n,3))-((kother*dt)/2)*(C(i,n,3)+C(i-
1,n,3))+((k2*dt)/2)*(C(i,n,4)+C(i-1,n,4));     %Oxidized tissue                                      
% Oxidized tissue 
        C(i,n+1,4) = ((kGSHc1*dt)/2)*(C(i,n,3)+C(i-
1,n,3))+((kother*dt)/2)*(C(i,n,3)+C(i-1,n,3))-
((k2*dt)/2)*(C(i,n,4)+C(i-1,n,4))+C(i,n,4);        % reduced tissue 
         
        Qbweight1(n) = Qbweight1(n)+(H(i)*C(i,n,1));   %solving for a 
multiple capillaries (i.e. when i= 1:N) 
        Rbweight1(n) = Rbweight1(n)+(H(i)*C(i,n,2)); 
        Qcweight1(n) = Qcweight1(n)+(H(i)*C(i,n,3)); 
        Rcweight1(n) = Rcweight1(n)+(H(i)*C(i,n,4)); 
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    end 
end 
  
aQb1 = trapz(t1,Qbweight1); 
aRb1 = trapz(t1,Rbweight1); 
tQo1 = t1.*Qbweight1; 
tQout1 = (trapz(t1,tQo1))/aQb1; 
vQo1 = ((t1.^2).*Qbweight1); 
vQbout1 = ((trapz(t1,vQo1))-(tQout1.^2))/aQb1; 
tRo1 = t1.*Rbweight1; 
tRout1 = (trapz(t1,tRo1))/aRb1; 
  
%% Oxidized venous blood  
for i = 1:length(t1) 
    if (i <= ns_v) 
        Cv_Qb1(i) = 0.0; 
    else Cv_Qb1(i) = Qbweight1(i-ns_v); 
    end 
        Qv_mean_t1(i) = t1(i)*Cv_Qb1(i)*dt;     
end 
  
%% Find the mean and variance of the oxidized blood curve 
areaQv1 = trapz(t1,Cv_Qb1);               % Find the area under the 
oxidized blood curve  
Qv_mean_t1 = sum(Qv_mean_t1)/areaQv1;   % Sec, mean transit time of the 
oxidized blood curve 
varQv1 = ((t1-Qv_mean_t1).^2).*Cv_Qb1.*dt;       
varQv1 = sum(varQv1)/areaQv1;           % Sec^2, variance of oxidized 
blood curve 
  
%% Reduced venous blood 
for i = 1:length(t1) 
    if (i <= ns_v) 
        Cv_Rb1(i) = 0.0; 
    else Cv_Rb1(i) = Rbweight1(i-ns_v); 
    end 
    Rvmean_t1(i) = t1(i)*Cv_Rb1(i)*dt;     
end 
  
%% Find the mean and variance of the reduced blood curve 
areaRv1 = trapz(t1,Cv_Rb1);               % Find the area under the 
reduced blood curve  
Rv_mean_t1 = sum(Rvmean_t1)/areaRv1;    % Sec, mean transit time of the 
reduced blood curve 
varRv1 = ((t1-Rv_mean_t1).^2).*Cv_Rb1.*dt;       
varRv1 = sum(varRv1)/areaRv1;           % Sec^2, variance of reduced 
blood curve 
  
mean_lung1 = Qv_mean_t1 - Cinmean_t1;   % sec, mean transit time of 
lung Qbweight- Cin (out-in) 
  
%% Cumulative sum 
LAC1 = zeros(length(t1),1); 
  
for i = 1:(length(t1)-1) 
  LAC1(1) = Cin1(1)-Cv_Qb1(1); 
  LAC1(i+1) = LAC1(i)+(Cin1(i+1)-Cv_Qb1(i+1)); 
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end   
  
LAC1 = F*dt*LAC1; 
  
['MeanCin = ', num2str(Cinmean_t1),', VarCin = ', num2str(varCin1), ', 
MeanArtery = ', num2str(Ca_mean_t1), ', VarArtery = ', 
num2str(varCa1),', Mean Capillary = ',num2str(tQout1),', Var Capillary 
= ',num2str(vQbout1),', Mean Venous = ',num2str(Qv_mean_t1),', Var 
Venous = ',num2str(varQv1)] 
  
%% Spline curve 
yy2 = spline(t1,LAC1,tdata2); 
  
% Add noise to spline curve 
noise2 = max(yy2).*0.025;     %Amount of noise added 
LACn2 = yy2 + noise2.*randn(size(yy2)); % Noisy Signal  
  
%% Combine with and without DEM curves  
LAC2 = [yy1 yy2]; 
LACn = [LACn1 LACn2]; 
tdata = 0:length(LAC2)-1;              % data 
  
% Save curves and variables 
save('2Curves_PDE_Sim','tdata','tdata1','tdata2','LAC2','LACn','flow','
mu1','mu2','mu','sigmas1','sigmas2','sigmas',... 
    
't01','t02','time1','time2','PS','kGSHc','kother','kGSHb','data_time_ac
quisition','Vc','P','dose1','dose2','injected1','injected2'); 
  
plot(tdata,LAC2,tdata,LACn) 
xlabel('Time (sec)') 
ylabel('Counts/pixel/mCi Injected') 
title('Lung Activity Curves') 
legend('Without noise','With Noise') 
  
set(handles.flow, 'Enable', 'on'); 
set(handles.mu1, 'Enable', 'on'); 
set(handles.mu2, 'Enable', 'on'); 
set(handles.mu, 'Enable', 'on'); 
set(handles.sigmas1, 'Enable', 'on'); 
set(handles.sigmas2, 'Enable', 'on'); 
set(handles.sigmas, 'Enable', 'on'); 
set(handles.t01, 'Enable', 'on'); 
set(handles.t02, 'Enable', 'on'); 
set(handles.time1, 'Enable', 'on'); 
set(handles.time2, 'Enable', 'on'); 
set(handles.PS, 'Enable', 'on'); 
set(handles.kGSHc, 'Enable', 'on'); 
set(handles.kother, 'Enable', 'on'); 
set(handles.kGSHb, 'Enable', 'on'); 
set(handles.data_time_acquisition, 'Enable', 'on'); 
set(handles.Vc, 'Enable', 'on'); 
set(handles.P, 'Enable', 'on'); 
set(handles.PS, 'Enable', 'on'); 
set(handles.dose1, 'Enable', 'on'); 
set(handles.dose2, 'Enable', 'on'); 
set(handles.injected1, 'Enable', 'on'); 
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set(handles.injected2, 'Enable', 'on'); 
 
  
E.2.5 Modular_Regression_MethodB1.m 
% % Use nonlinear regression to simultaneously fit 2 data curves using 
Method B (solve for longest capillary transit time) to solve PDEs 
  
global vars 
[flow, F, injected0, K, in, h_t, volume, data1, tdata1, data2, tdata2, 
L2, albumin, data_time_acquisition] = variablesPDE1;  
vars.flow = flow; 
vars.F = F;  
vars.injected0 = injected0; 
vars.K = K; 
vars.in = in; 
vars.h_t = h_t; 
vars.volume = volume; 
vars.data1 = data1; 
vars.tdata1 = tdata1; 
vars.data2 = data2; 
vars.tdata2 = tdata2; 
vars.L2 = L2; 
vars.albumin = albumin; 
vars.data_time_acquisition = data_time_acquisition; 
injected1 = injected0(1);            % mCi, Amount of mCi injected 
(based on experimental data) 
injected2 = injected0(2);            % mCi, Amount of mCi injected 
(based on experimental data) 
  
prompt0 = input('Modular Regression: Use Real Data (1) or Simulated 
Data (2)? '); 
if prompt0 == 1    
%% Import and modify multiple real data curves (with and w/out DEM) 
data = [data1; data2]; 
figure 
tdata = 0:length(data)-1;              % data 
plot(tdata,data)  
  
%% Simulated data Curve 
elseif prompt0 == 2 
load('2Curves_PDE_Sim','tdata','LAC2','LACn')   % load from 
PDE_Simulation.m 
figure; plot(tdata,LAC2,tdata,LACn) 
data = LACn'; 
end 
  
%% Nonlinear regression 
  
x0 = [2.5 0.6 8.0 0.35 8 2.0]; 
lb = [0 0 0 0 0 0]; 
ub = [inf inf inf inf inf inf]; 
options = optimoptions('lsqcurvefit','OptimalityTolerance',1e-
3,'FunctionTolerance',1e-3,'StepTolerance',1e-
3,'MaxFunctionEvaluations',60,'MaxIterations',60) 
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[x, resnorm, residual, exitflag, output, lambda, jacobian] = 
lsqcurvefit(@SolvePDE_MethodB1, x0, tdata, data', lb, ub, options); 
x 
['PS = ', num2str(x(1)), ', kGSHc = ', num2str(x(2)), ', dose1 = ', 
num2str(x(3)), ', kother = ', num2str(x(4)), ', dose2 = ', 
num2str(x(5)), ', Vc = ', num2str(x(6))] 
resnorm 
  
[hh, p, stats] = runstest(residual)      % Runs test to check 
randomness of fit 
  
% Correlation Coefficient 
cc = zeros(length(x0),length(x0)); 
NP = length(x0);  
h = inv(jacobian'*jacobian); 
for i = 1:NP; 
    for j = 1:NP; 
        cc(i,j) = h(i,j)/((h(i,i)*h(j,j))^0.5); 
    end 
end   
cc 
  
% Confidence intervals (95% confidence, alpha = 0.05) 
s_2 = resnorm/(length(tdata)-NP); 
for i = 1:NP 
    seb(i) = ((s_2)^0.5)*(h(i,i)^0.5); 
end 
alpha = 0.05; 
tt_dis = -tinv(alpha/2,length(tdata)-length(x0)); 
seb = seb.*tt_dis; 
seb 
  
%% Cin curve for single capillary without DEM 
% Cin curve parameters 
  
PS = x(1); 
kGSHc = x(2); 
dose1 = x(3);  
kother = x(4); 
dose2 = x(5); 
Vc = x(6); 
x1 = x; 
  
%% Input curve parameters 
t01 = in(1); 
t02 = in(2); 
mu1 = in(3); 
sigmas1 = in(4); 
mu2 = in(5); 
sigmas2 = in(6); 
  
%% Capillary parameters 
dt = L2(2); 
L = L2(1); 
kGSHb = K(1); 
k1 = K(2); 
kGSHc1 = K(4); 
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k2 = K(6); 
Kd = albumin(1); 
P = albumin(2); 
dose = h_t(1); 
t0 = h_t(2); 
  
%% Capillary curve parameters 
ts = h_t(5); 
ts_v = h_t(6); 
mu = h_t(3);          % sec, Mean of capillary 
sigmas = h_t(4); %(mu*0.7)^2;        %  sec^2, Variance of capillary 
Vb = volume(2); 
  
%% Cin (input) curve for single capillary without DEM, gamma variate 
function 
t = 0:dt:(length(data1)-1);    % @ 1 sec acquisition, Sec, time for Cin 
curve 
t1 = 0:dt:(length(data2)-1);      % @ 1 sec acquisition, Sec, time for 
Cin curve 
  
[tc,hc,H,whc,dx,N] = hc_curve_MethodB1(t,t0,dose,mu,sigmas,F,dt,L); 
[C1, Cin, Cin2, C3, Cinmean_t, varCin, Ca_mean_t, varCa] = 
Cin_curve_MethodB1(t,F,t01,ts,dose1,mu1,sigmas1,dt); 
[C2, Cin1, Cin3, C4, Cinmean_t1, varCin1, Ca_mean_t1, varCa1] = 
Cin_curve_DEM1(t1,F,t02,ts,dose2,mu2,sigmas2,dt); 
  
%% Capillary Curves 
x = 0:dx:L; 
nx = round(1/dx); 
  
% Create the solution matrix 
C = zeros(length(x),length(t),4); 
  
% Initial conditions (t=0)  
C(:,1,1) = 0;   % Oxidized blood 
C(:,1,2) = 0;   % Reduced blood 
C(:,1,3) = 0;   % Oxidized tissue 
C(:,1,4) = 0;   % Reduced tissue 
  
% Boundary conditions (x=0)  
C(1,:,1) = C1; 
C(1,:,2) = C3;     
C(1,:,3) = 0; 
C(1,:,4) = 0; 
  
Qbweight = zeros(1,length(t)); 
Rbweight = zeros(1,length(t)); 
Qcweight = zeros(1,length(t)); 
Rcweight = zeros(1,length(t)); 
  
for n = 1:(length(t)-1) 
    for i = 2:(length(x)-1) 
        C(i,n+1,1) = C(i-1,n,1)+((PS*dt)/(2*Vb))*(C(i,n,3)+C(i-1,n,3)-
C(i,n,1)/(1+(P/Kd))-C(i-1,n,1)/(1+(P/Kd)))-
((kGSHb*dt)/2)*(C(i,n,1)/(1+(P/Kd))+C(i-
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1,n,1)/(1+(P/Kd)))+((k1*dt)/2)*(C(i,n,2)+C(i-1,n,2));      % Oxidized 
blood 
        C(i,n+1,2) = C(i-
1,n,2)+((kGSHb*dt)/2)*(C(i,n,1)/(1+(P/Kd))+C(i-1,n,1)/(1+(P/Kd)))-
((k1*dt)/2)*(C(i,n,2)+C(i-1,n,2));        % Reduced blood       
        C(i,n+1,3) = ((PS*dt)/(2*Vc))*(C(i,n,1)/(1+(P/Kd))+C(i-
1,n,1)/(1+(P/Kd))-C(i,n,3)-C(i-1,n,3))+C(i,n,3)-
((kGSHc*dt)/2)*(C(i,n,3)+C(i-1,n,3))-((kother*dt)/2)*(C(i,n,3)+C(i-
1,n,3))+((k2*dt)/2)*(C(i,n,4)+C(i-1,n,4));     %Oxidized tissue                                      
% Oxidized tissue 
        C(i,n+1,4) = ((kGSHc*dt)/2)*(C(i,n,3)+C(i-
1,n,3))+((kother*dt)/2)*(C(i,n,3)+C(i-1,n,3))-
((k2*dt)/2)*(C(i,n,4)+C(i-1,n,4))+C(i,n,4);        % reduced tissue 
         
        Qbweight(n) = Qbweight(n)+(H(i)*C(i,n,1));   %solving for a 
multiple capillaries (i.e. when i= 1:N) 
        Rbweight(n) = Rbweight(n)+(H(i)*C(i,n,2)); 
        Qcweight(n) = Qcweight(n)+(H(i)*C(i,n,3)); 
        Rcweight(n) = Rcweight(n)+(H(i)*C(i,n,4)); 
    end 
end 
  
figure 
plot(t,Qbweight,t,Rbweight,t,Qcweight,t,Rcweight) 
  
aQb = trapz(t,Qbweight); 
aRb = trapz(t,Rbweight); 
tQo = t.*Qbweight; 
tQout = (trapz(t,tQo))/aQb; 
vQo = ((t-tQout).^2).*Qbweight.*dt; 
vQbout = sum(vQo)/aQb; 
tRo = t.*Rbweight; 
tRout = (trapz(t,tRo))/aRb; 
  
ns_v = round(ts_v/dt); 
%% Oxidized blood  
for i = 1:length(t) 
    if (i <= ns_v) 
        Cv_Qb(i) = 0.0; 
    else Cv_Qb(i) = Qbweight(i-ns_v); 
    end 
    Qv_mean_t(i) = t(i)*Cv_Qb(i)*dt;     
end 
  
%% Find the mean and variance of the oxidized blood curve 
areaQb = trapz(t,Cv_Qb);               % Find the area under the 
oxidized blood curve  
Qv_mean_t = sum(Qv_mean_t)/areaQb;    % Sec, mean transit time of the 
oxidized blood curve 
varQv = ((t-Qv_mean_t).^2).*Cv_Qb.*dt;       
varQv = sum(varQv)/areaQb;           % Sec^2, variance of oxidized 
blood curve 
  
['MeanCin = ', num2str(Cinmean_t),', VarCin = ', num2str(varCin), ', 
MeanArtery = ', num2str(Ca_mean_t), ', VarArtery = ', num2str(varCa),', 
Mean Capillary = ',num2str(tQout),', Var Capillary = 
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',num2str(vQbout),', Mean Venous = ',num2str(Qv_mean_t),', Var Venous = 
',num2str(varQv)]; 
%% Reduced blood 
for i = 1:length(t) 
    if (i <= ns_v) 
        Cv_Rb(i) = 0.0; 
    else Cv_Rb(i) = Rbweight(i-ns_v); 
    end 
        Rbmean_t(i) = t(i)*Cv_Rb(i)*dt;     
end 
  
%% Find the mean and variance of the reduced blood curve 
areaRv = trapz(t,Cv_Rb);               % Find the area under the 
reduced blood curve  
Rb_mean_t = sum(Rbmean_t)/areaRv;    % Sec, mean transit time of the 
reduced blood curve 
varRv = ((t-Rb_mean_t).^2).*Cv_Rb.*dt;       
varRv = sum(varRv)/areaRv;           % Sec^2, variance of reduced blood 
curve 
  
mean_lung = Qv_mean_t - Cinmean_t;   % sec, mean transit time of lung 
Qbweight- Cin (out-in) 
  
%% Cumulative sum 
LAC = zeros(length(t),1); 
for i = 1:(length(t)-1) 
  LAC(1) = Cin(1)-Cv_Qb(1); 
  LAC(i+1) = LAC(i)+(Cin(i+1)-Cv_Qb(i+1)); 
end   
  
LAC = F*dt*LAC; 
  
%% Spline Curve 
yy1 = spline(t,LAC,tdata1); 
  
%% DEM Curve 
%Create the solution matrix 
C = zeros(length(x),length(t1),4); 
  
% Initial conditions (t=0)  
C(:,1,1) = 0;  
C(:,1,2) = 0; 
C(:,1,3) = 0; 
C(:,1,4) = 0; 
  
% Boundary conditions (x=0)  
C(1,:,1) = C2; 
C(1,:,2) = C4;     
C(1,:,3) = 0; 
C(1,:,4) = 0; 
  
Qbweight1 = zeros(1,length(t1)); 
Rbweight1 = zeros(1,length(t1)); 
Qcweight1 = zeros(1,length(t1)); 
Rcweight1 = zeros(1,length(t1)); 
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for n = 1:(length(t1)-1) 
    for i = 2:(length(x)-1); 
        C(i,n+1,1) = C(i-1,n,1)+((PS*dt)/(2*Vb))*(C(i,n,3)+C(i-1,n,3)-
C(i,n,1)/(1+(P/Kd))-C(i-1,n,1)/(1+(P/Kd)))-
((kGSHb*dt)/2)*(C(i,n,1)/(1+(P/Kd))+C(i-
1,n,1)/(1+(P/Kd)))+((k1*dt)/2)*(C(i,n,2)+C(i-1,n,2));      % Oxidized 
blood 
        C(i,n+1,2) = C(i-
1,n,2)+((kGSHb*dt)/2)*(C(i,n,1)/(1+(P/Kd))+C(i-1,n,1)/(1+(P/Kd)))-
((k1*dt)/2)*(C(i,n,2)+C(i-1,n,2));        % Reduced blood       
        C(i,n+1,3) = ((PS*dt)/(2*Vc))*(C(i,n,1)/(1+(P/Kd))+C(i-
1,n,1)/(1+(P/Kd))-C(i,n,3)-C(i-1,n,3))+C(i,n,3)-
((kGSHc1*dt)/2)*(C(i,n,3)+C(i-1,n,3))-((kother*dt)/2)*(C(i,n,3)+C(i-
1,n,3))+((k2*dt)/2)*(C(i,n,4)+C(i-1,n,4));     %Oxidized tissue                                      
% Oxidized tissue 
        C(i,n+1,4) = ((kGSHc1*dt)/2)*(C(i,n,3)+C(i-
1,n,3))+((kother*dt)/2)*(C(i,n,3)+C(i-1,n,3))-
((k2*dt)/2)*(C(i,n,4)+C(i-1,n,4))+C(i,n,4);        % reduced tissue 
         
        Qbweight1(n) = Qbweight1(n)+(H(i)*C(i,n,1));   %solving for a 
multiple capillaries (i.e. when i= 1:N) 
        Rbweight1(n) = Rbweight1(n)+(H(i)*C(i,n,2)); 
        Qcweight1(n) = Qcweight1(n)+(H(i)*C(i,n,3)); 
        Rcweight1(n) = Rcweight1(n)+(H(i)*C(i,n,4)); 
    end 
end 
  
  
aQb1 = trapz(t1,Qbweight1); 
aRb1 = trapz(t1,Rbweight1); 
tQo1 = t1.*Qbweight1; 
tQout1 = (trapz(t1,tQo1))/aQb1; 
vQo1 = ((t1.^2).*Qbweight1); 
vQbout1 = ((trapz(t1,vQo1))-(tQout1.^2))/aQb1; 
tRo1 = t1.*Rbweight1; 
tRout1 = (trapz(t1,tRo1))/aRb1; 
  
%% Oxidized venous blood  
for i = 1:length(t1) 
    if (i <= ns_v) 
        Cv_Qb1(i) = 0.0; 
    else Cv_Qb1(i) = Qbweight1(i-ns_v); 
    end 
        Qv_mean_t1(i) = t1(i)*Cv_Qb1(i)*dt;     
end 
  
%% Find the mean and variance of the oxidized blood curve 
areaQv1 = trapz(t1,Cv_Qb1);               % Find the area under the 
oxidized blood curve  
Qv_mean_t1 = sum(Qv_mean_t1)/areaQv1;   % Sec, mean transit time of the 
oxidized blood curve 
varQv1 = ((t1-Qv_mean_t1).^2).*Cv_Qb1.*dt;       
varQv1 = sum(varQv1)/areaQv1;           % Sec^2, variance of oxidized 
blood curve 
  
  
%% Reduced venous blood 
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for i = 1:length(t1) 
    if (i <= ns_v) 
        Cv_Rb1(i) = 0.0; 
    else Cv_Rb1(i) = Rbweight1(i-ns_v); 
    end 
    Rvmean_t1(i) = t1(i)*Cv_Rb1(i)*dt;     
end 
  
%% Find the mean and variance of the reduced blood curve 
areaRv1 = trapz(t1,Cv_Rb1);               % Find the area under the 
reduced blood curve  
Rv_mean_t1 = sum(Rvmean_t1)/areaRv1;    % Sec, mean transit time of the 
reduced blood curve 
varRv1 = ((t1-Rv_mean_t1).^2).*Cv_Rb1.*dt;       
varRv1 = sum(varRv1)/areaRv1;           % Sec^2, variance of reduced 
blood curve 
  
mean_lung1 = Qv_mean_t1 - Cinmean_t1;   % sec, mean transit time of 
lung Qbweight- Cin (out-in) 
  
%% Cumulative sum 
LAC1 = zeros(length(t1),1); 
  
for i = 1:(length(t1)-1) 
  LAC1(1) = Cin1(1)-Cv_Qb1(1); 
  LAC1(i+1) = LAC1(i)+(Cin1(i+1)-Cv_Qb1(i+1)); 
end   
  
LAC1 = F*dt*LAC1; 
  
['MeanCin = ', num2str(Cinmean_t1),', VarCin = ', num2str(varCin1), ', 
MeanArtery = ', num2str(Ca_mean_t1), ', VarArtery = ', 
num2str(varCa1),', Mean Capillary = ',num2str(tQout1),', Var Capillary 
= ',num2str(vQbout1),', Mean Venous = ',num2str(Qv_mean_t1),', Var 
Venous = ',num2str(varQv1)] 
  
%% Spline curve 
yy2 = spline(t1,LAC1,tdata2); 
  
%% Combine with and without DEM curves  
LAC2 = [yy1 yy2]; 
tdata5 = 0:(length(LAC2)-1);   
  
rmse = sqrt(mean((data-LAC2).^2)); 
m1 = mean(LAC2(60:end)); 
m2 = mean(data(60:end)); 
SS_err = abs((m1-m2)/m2) 
  
figure 
plot(t,Cin,t,C1,t,Qbweight,t,Rbweight,t,Qcweight,t,Rcweight,t,Cv_Qb) 
xlabel('Time (sec)') 
ylabel('Counts/pixel/mCi Injected') 
legend('Cin','Artery','Oxidized Blood','Reduced Blood','Oxidized 
Tissue','Reduced Tissue','Oxidized Vein') 
title(sprintf('Without DEM, BSA = %f, Kd = %f',P, Kd)) 
axis([0 60 0 inf]) 
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figure 
plot(t1,Cin1,t1,C2,t1,Qbweight1,t1,Rbweight1,t1,Qcweight1,t1,Rcweight1,
t1,Cv_Qb1) 
xlabel('Time (sec)') 
ylabel('Counts/pixel/mCi Injected') 
legend('Cin','Artery','Oxidized Blood','Reduced Blood','Oxidized 
Tissue','Reduced Tissue','Oxidized Vein') 
title(sprintf('With DEM, BSA = %f, Kd = %f',P, Kd)) 
axis([0 60 0 inf]) 
  
figure  
plot(tdata,data,tdata5,LAC2,'--') 
xlabel('Time (sec)') 
ylabel('Counts/pixel/mCi Injected') 
legend('Data','Optimization') 
title('Simulation with and without DEM, 3% BSA, 10 mL/min') 
axis([0 inf 0 inf]) 
  
figure 
plot(tdata1,data1,tdata2,data2,tdata1,yy1,tdata2,yy2) 
xlabel('Time (sec)') 
ylabel('Counts/pixel/I.D.') 
title('Control, HMPAO, pre- and post-DEM Data and Fit') 
legend('Pre-DEM Data','Post-DEM Data','Pre-DEM Fit','Post-DEM Fit') 
axis([0 80 0 inf]) 
  
J1 = (jacobian(:,1))/(max(jacobian(:,1))); 
J2 = (jacobian(:,2))/(max(jacobian(:,2))); 
J4 = (jacobian(:,4))/(max(jacobian(:,4))); 
J6 = (jacobian(:,6))/(max(jacobian(:,6))); 
  
figure; plot(J1(1:75)); hold on; plot(J2(1:75)); hold on; 
plot(J4(1:75)); hold on; plot(J6(1:75)) 
hold off 
legend('PS','k_{2}','k_{3}','V_{c}') 
xlabel('Time (sec)') 
ylabel('Normalized S(t)') 
title('S(t) for model parameters- Control pre-DEM') 
set(gca,'fontsize',16) 
axis([0 inf 0 inf]) 
  
figure; plot(J1(76:end)); hold on; plot(J2(76:end)); hold on; 
plot(J4(76:end)); hold on; plot(J6(76:end)) 
hold off 
legend('PS','k_{2}','k_{3}','V_{c}') 
xlabel('Time (sec)') 
ylabel('Normalized S(t)') 
title('S(t) for model parameters- Control post-DEM') 
set(gca,'fontsize',16) 
axis([0 inf 0 inf]) 
  
figure; plot(tdata(1:75),data(1:75),tdata(76:end)-
74.5,data(76:end),tdata1,yy1,'--',tdata2,yy2,'--') 
xlabel('Time (sec)') 
ylabel('Counts/pixel/I.D.')  
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legend('Pre-DEM Simulated Data','Post-DEM Simulated Data','Pre-DEM 
Simulation Fit','Post-DEM Simultation Fit') 
set(gca,'fontsize',16) 
axis([0 inf 0 inf] 
 
 
 
E.2.6 SolvePDE_MethodB1.m 
% Nonlinear regression function called by Modular_Regression_MethodB.m 
to simultaneously fit 2 data curves using Method B (solve for longest 
capillary transit time) to solve PDEs 
%  
function LAC2 = SolvePDE_MethodB1(x,tdata)  
   
PS = x(1); 
kGSHc = x(2); 
kother = x(4); 
dose1 = x(3); 
dose2 = x(5); 
Vc = x(6); 
  
global vars 
flow = vars.flow; 
F = flow/60; 
K = vars.K; 
in = vars.in; 
h_t = vars.h_t; 
volume = vars.volume; 
data1 = vars.data1; 
tdata1 = vars.tdata1; 
data2 = vars.data2; 
tdata2 = vars.tdata2; 
L2 = vars.L2; 
albumin = vars.albumin; 
  
t01 = in(1); 
t02 = in(2); 
mu1 = in(3); 
sigmas1 = in(4); 
mu2 = in(5); 
sigmas2 = in(6); 
  
L = L2(1); 
dt = L2(2); 
kGSHb = K(1); 
k1 = K(2); 
kGSHc1 = K(4); 
k2 = K(6); 
Kd = albumin(1); 
P = albumin(2); 
dose = h_t(1); 
t0 = h_t(2); 
Vb = volume(2); 
ts = h_t(5); 
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ts_v = h_t(6); 
mu = h_t(3);          % sec, Mean of capillary 
sigmas = h_t(4); %(mu*0.7)^2;        %  sec^2, Variance of capillary 
t = 0:dt:(length(data1)-1);    % @ 1 sec acquisition, Sec, time for Cin 
curve 
t1 = 0:dt:(length(data2)-1);      % @ 1 sec acquisition, Sec, time for 
Cin curve 
  
for j=1:length(t) 
    if (t(j) <= t01) 
    Cin(j) = 0.0; 
    else 
    Cin(j) = ((t(j) - t01)^(((mu1^2)/(sigmas1))-1))*(exp(-(t(j)-
t01)/((sigmas1)/mu1)));     % Input curve, gamma variate function 
    end 
    Cinmean_t(j) = t(j)*Cin(j)*dt; 
  
end 
  
%% Find the mean and variance of the Cin curve 
areaCin = trapz(t,Cin);       % Find the area under the Cin curve  
Cinmean_t = sum(Cinmean_t)/areaCin;  % Sec, mean transit time of Cin 
curve 
varCin = ((t-Cinmean_t).^2).*Cin.*dt;       
varCin = sum(varCin)/areaCin;    % Sec^2, variance of Cin curve 
  
Cin = Cin/trapz(t,Cin); 
Cin = dose1*Cin./F;         % Normalize the area under the Cin curve to 
dose/flow 
Cin2 = Cin*0;       % Percent of reduced HMPAO that enters the 
capillary region 
Cin = Cin*1;        % Percent of oxidized HMPAO that enters the 
capillary region 
  
%% Artery curve- shift the Cin curve by time ts  
ns = round(ts/dt);     % sec, divide the time shift by the step size 
for i = 1:length(t) 
    if (i <= ns) 
        C1(i) = 0.0; 
    else C1(i) = Cin(i-ns);     % C1 is the artery curve 
    end 
    Camean_t(i) = t(i)*C1(i)*dt;     
  
end 
  
%% Find the mean and variance of the artery curve 
areaCa = trapz(t,C1);               % Find the area under the artery 
curve  
Ca_mean_t = sum(Camean_t)/areaCa;    % Sec, mean transit time of the 
artery curve 
varCa = ((t-Ca_mean_t).^2).*C1.*dt;       
varCa = sum(varCa)/areaCa;           % Sec^2, variance of artery curve 
  
for i = 1:length(t) 
    if (i <= ns) 
        C3(i) = 0.0; 
    else C3(i) = Cin2(i-ns);     % C1 is the artery curve 
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    end 
    Camean_t2(i) = t(i)*C3(i)*dt;     
end 
  
%% Find the point on the gamma variate function curve that corresponds 
with 0.01*max of the curve and find the time point (idx) that 
corresponds with that curve value 
hc2 = zeros(1,length(t)); 
% Create capillary gamma variate curve 
for j=1:length(t) 
    if (t(j) <= t0) 
    hc2(j) = 0.0; 
    else 
    hc2(j) = dose*((t(j) - t0)^(((mu^2)/(sigmas))-1))*(exp(-(t(j)-
t0)/((sigmas)/mu))); 
    end 
end 
  
% Normalize the area under the curve 
abc = trapz(t(1:length(t)),hc2);    % Determine area under the curve 
hc2 = hc2./abc;      % Scale the area to 1 
hc2 = hc2./F;        % Scale the area to 1/Flow 
  
% Find the time point that corresponds with 0.985*(max of curve) 
tcmax = 0.015*max(hc2);           
for i = round(mu/dt):length(t) 
    if (hc2(i)<=tcmax) 
        idx = t(i); 
        break  
    else  
        continue 
    end  
end 
idx = round(idx/dt);  
  
%% Create the hc curve, which corresponds with N (number of 
capillaries) mean transit times 
hc1 = zeros(1,idx); 
for j=1:idx 
    if (t(j) <= t0) 
    hc1(j) = 0.0; 
    else 
    hc1(j) = dose*((t(j) - t0)^(((mu^2)/(sigmas))-1))*(exp(-(t(j)-
t0)/((sigmas)/mu))); 
    end 
end 
  
% Scale the area under the hc1 curve to 1 
ab = trapz(t(1:idx),hc1);    % Determine area under the curve 
hc1 = hc1./ab;               % Scale the area to 1 
thc = idx*dt; 
  
% Find the mean transit time interval for N capillaries by dividing the 
max time point by the number of capillaries  
dx = dt/max(thc); 
N = round(1/dx); 
tc = 0:dt:max(thc); 
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tc = tc(2:end); 
  
% Find the hc values that correspond with the N mean transit times 
hc = zeros(1,N); 
for j=1:length(tc) 
    if (tc(j) <= t0) 
    hc(j) = 0.0; 
    else 
    hc(j) = dose*((tc(j) - t0)^(((mu^2)/(sigmas))-1))*(exp(-(tc(j)-
t0)/((sigmas)/mu))); 
    end 
end 
  
%Scale the area under the hc curve to 1 
ab = trapz(tc,hc);    % Determine area under the curve 
hc = hc./ab;      % Scale the area to 1 
  
% Normalize the area of the summed hc values to 1 
area = sum(hc); 
area = area*dt; 
hc = hc/area; 
whc = hc*dt; 
  
dthc2 = max(thc)/(2*N); 
tc2 = 0:dthc2:max(thc); 
  
dx = dt/max(thc);      % step size between nodes, different for each 
mean transit time 
nx = round(1./dx);       % Number of nodes in the x-direction  
x = 0:dx:L; 
  
% Find the weights 
hctc = spline(tc,hc,tc2); 
H = zeros(length(tc),1); 
for i = 1:(length(tc)); 
    if (tc(i) <= t0) 
        H(i) = 0.0; 
    else   
    H(i) = (dt/2)*((hctc((2*i)-1))+hctc((2*i)+1)); 
    end 
end 
  
%% Capillary Curves 
x = 0:dx:L; 
nx = round(1/dx); 
  
% Create the solution matrix 
C = zeros(length(x),length(t),4); 
  
% Initial conditions (t=0)  
C(:,1,1) = 0;  
C(:,1,2) = 0; 
C(:,1,3) = 0; 
C(:,1,4) = 0; 
  
% Boundary conditions (x=0)  
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C(1,:,1) = C1; 
C(1,:,2) = C3;     
C(1,:,3) = 0; 
C(1,:,4) = 0; 
  
Qbweight = zeros(1,length(t)); 
Rbweight = zeros(1,length(t)); 
Qcweight = zeros(1,length(t)); 
Rcweight = zeros(1,length(t)); 
  
for n = 1:(length(t)-1) 
    for i = 2:(length(x)-1); 
        C(i,n+1,1) = C(i-1,n,1)+((PS*dt)/(2*Vb))*(C(i,n,3)+C(i-1,n,3)-
C(i,n,1)/(1+(P/Kd))-C(i-1,n,1)/(1+(P/Kd)))-
((kGSHb*dt)/2)*(C(i,n,1)/(1+(P/Kd))+C(i-
1,n,1)/(1+(P/Kd)))+((k1*dt)/2)*(C(i,n,2)+C(i-1,n,2));      % Oxidized 
blood 
        C(i,n+1,2) = C(i-
1,n,2)+((kGSHb*dt)/2)*(C(i,n,1)/(1+(P/Kd))+C(i-1,n,1)/(1+(P/Kd)))-
((k1*dt)/2)*(C(i,n,2)+C(i-1,n,2));        % Reduced blood       
        C(i,n+1,3) = ((PS*dt)/(2*Vc))*(C(i,n,1)/(1+(P/Kd))+C(i-
1,n,1)/(1+(P/Kd))-C(i,n,3)-C(i-1,n,3))+C(i,n,3)-
((kGSHc*dt)/2)*(C(i,n,3)+C(i-1,n,3))-((kother*dt)/2)*(C(i,n,3)+C(i-
1,n,3))+((k2*dt)/2)*(C(i,n,4)+C(i-1,n,4));     %Oxidized tissue                                      
% Oxidized tissue 
        C(i,n+1,4) = ((kGSHc*dt)/2)*(C(i,n,3)+C(i-
1,n,3))+((kother*dt)/2)*(C(i,n,3)+C(i-1,n,3))-
((k2*dt)/2)*(C(i,n,4)+C(i-1,n,4))+C(i,n,4);        % reduced tissue 
         
        Qbweight(n) = Qbweight(n)+(H(i)*C(i,n,1));   %solving for a 
multiple capillaries (i.e. when i= 1:N) 
        Rbweight(n) = Rbweight(n)+(H(i)*C(i,n,2)); 
        Qcweight(n) = Qcweight(n)+(H(i)*C(i,n,3)); 
        Rcweight(n) = Rcweight(n)+(H(i)*C(i,n,4)); 
    end 
end 
  
aQb = trapz(t,Qbweight); 
aRb = trapz(t,Rbweight); 
tQo = t.*Qbweight; 
tQout = (trapz(t,tQo))/aQb; 
vQo = ((t-tQout).^2).*Qbweight.*dt; 
vQbout = sum(vQo)/aQb; 
tRo = t.*Rbweight; 
tRout = (trapz(t,tRo))/aRb; 
ns_v = round(ts_v/dt); 
  
%% Oxidized blood  
for i = 1:length(t) 
    if (i <= ns_v) 
        Cv_Qb(i) = 0.0; 
    else Cv_Qb(i) = Qbweight(i-ns_v); 
    end 
    Qv_mean_t(i) = t(i)*Cv_Qb(i)*dt;     
end 
  
%% Find the mean and variance of the oxidized blood curve 
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areaQb = trapz(t,Cv_Qb);               % Find the area under the 
oxidized blood curve  
Qv_mean_t = sum(Qv_mean_t)/areaQb;    % Sec, mean transit time of the 
oxidized blood curve 
varQv = ((t-Qv_mean_t).^2).*Cv_Qb.*dt;       
varQv = sum(varQv)/areaQb;           % Sec^2, variance of oxidized 
blood curve 
  
['MeanCin = ', num2str(Cinmean_t),', VarCin = ', num2str(varCin), ', 
MeanArtery = ', num2str(Ca_mean_t), ', VarArtery = ', num2str(varCa),', 
Mean Capillary = ',num2str(tQout),', Var Capillary = 
',num2str(vQbout),', Mean Venous = ',num2str(Qv_mean_t),', Var Venous = 
',num2str(varQv)]; 
%% Reduced blood 
for i = 1:length(t) 
    if (i <= ns_v) 
        Cv_Rb(i) = 0.0; 
    else Cv_Rb(i) = Rbweight(i-ns_v); 
    end 
        Rbmean_t(i) = t(i)*Cv_Rb(i)*dt;     
end 
  
%% Find the mean and variance of the reduced blood curve 
areaRv = trapz(t,Cv_Rb);               % Find the area under the 
reduced blood curve  
Rb_mean_t = sum(Rbmean_t)/areaRv;    % Sec, mean transit time of the 
reduced blood curve 
varRv = ((t-Rb_mean_t).^2).*Cv_Rb.*dt;       
varRv = sum(varRv)/areaRv;           % Sec^2, variance of reduced blood 
curve 
  
mean_lung = Qv_mean_t - Cinmean_t;   % sec, mean transit time of lung 
Qbweight- Cin (out-in) 
  
%% Cumulative sum 
LAC = zeros(length(t),1); 
for i = 1:(length(t)-1) 
  LAC(1) = Cin(1)-Cv_Qb(1); 
  LAC(i+1) = LAC(i)+(Cin(i+1)-Cv_Qb(i+1)); 
end   
  
LAC = F*dt*LAC; 
  
%% Spline Curve 
yy1 = spline(t,LAC,tdata1); 
  
%% DEM Curve 
% Cin (input) curve for single capillary with DEM 
  
for j=1:length(t1) 
    if (t1(j) <= t02) 
    Cin1(j) = 0.0; 
    else 
    Cin1(j) =((t1(j) - t02)^(((mu2^2)/(sigmas2))-1))*(exp(-(t1(j)-
t02)/((sigmas2)/mu2))); 
    end 
    Cinmean_t1(j) = t1(j)*Cin1(j)*dt; 
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end 
  
%% Find the mean and variance of the Cin curve 
areaCin1 = trapz(t1,Cin1);       % Find the area under the Cin curve  
Cinmean_t1 = sum(Cinmean_t1)/areaCin1;  % Sec, mean transit time of Cin 
curve 
varCin1 = ((t1-Cinmean_t1).^2).*Cin1.*dt;       
varCin1 = sum(varCin1)/areaCin1;    % Sec^2, variance of Cin curve 
  
Cin1 = Cin1/trapz(t1,Cin1); 
Cin1 = dose2*Cin1./F;           % Normalize the area under the Cin 
curve to dose/flow 
Cin3 = Cin1*0;       % Percent of reduced HMPAO that enters the 
capillary region 
Cin1 = Cin1*1;       % Percent of oxidized HMPAO that enters the 
capillary region 
  
%% Artery curve- shift the Cin curve by time ts  
for i = 1:length(t1) 
    if (i <= ns) 
        C2(i) = 0.0; 
    else C2(i) = Cin1(i-ns);        % C2 is the artery curve 
    end 
    Camean_t1(i) = t1(i)*C2(i)*dt;     
end 
  
%% Find the mean and variance of the artery curve 
areaCa1 = trapz(t1,C2);               % Find the area under the artery 
curve  
Ca_mean_t1 = sum(Camean_t1)/areaCa1;    % Sec, mean transit time of the 
artery curve 
varCa1 = ((t1-Ca_mean_t1).^2).*C2.*dt;       
varCa1 = sum(varCa1)/areaCa1;           % Sec^2, variance of artery 
curve 
  
for i = 1:length(t1) 
    if (i <= ns) 
        C4(i) = 0.0; 
    else C4(i) = Cin3(i-ns);     % C1 is the artery curve 
    end 
    Camean_t3(i) = t1(i)*C4(i)*dt;     
end 
  
%Create the solution matrix 
C = zeros(length(x),length(t1),4); 
  
% Initial conditions (t=0)  
C(:,1,1) = 0;  
C(:,1,2) = 0; 
C(:,1,3) = 0; 
C(:,1,4) = 0; 
  
% Boundary conditions (x=0)  
C(1,:,1) = C2; 
C(1,:,2) = C4;     
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C(1,:,3) = 0; 
C(1,:,4) = 0; 
  
Qbweight1 = zeros(1,length(t1)); 
Rbweight1 = zeros(1,length(t1)); 
Qcweight1 = zeros(1,length(t1)); 
Rcweight1 = zeros(1,length(t1)); 
  
for n = 1:(length(t1)-1) 
    for i = 2:(length(x)-1); 
        C(i,n+1,1) = C(i-1,n,1)+((PS*dt)/(2*Vb))*(C(i,n,3)+C(i-1,n,3)-
C(i,n,1)/(1+(P/Kd))-C(i-1,n,1)/(1+(P/Kd)))-
((kGSHb*dt)/2)*(C(i,n,1)/(1+(P/Kd))+C(i-
1,n,1)/(1+(P/Kd)))+((k1*dt)/2)*(C(i,n,2)+C(i-1,n,2));      % Oxidized 
blood 
        C(i,n+1,2) = C(i-
1,n,2)+((kGSHb*dt)/2)*(C(i,n,1)/(1+(P/Kd))+C(i-1,n,1)/(1+(P/Kd)))-
((k1*dt)/2)*(C(i,n,2)+C(i-1,n,2));        % Reduced blood       
        C(i,n+1,3) = ((PS*dt)/(2*Vc))*(C(i,n,1)/(1+(P/Kd))+C(i-
1,n,1)/(1+(P/Kd))-C(i,n,3)-C(i-1,n,3))+C(i,n,3)-
((kGSHc1*dt)/2)*(C(i,n,3)+C(i-1,n,3))-((kother*dt)/2)*(C(i,n,3)+C(i-
1,n,3))+((k2*dt)/2)*(C(i,n,4)+C(i-1,n,4));     %Oxidized tissue                                      
% Oxidized tissue 
        C(i,n+1,4) = ((kGSHc1*dt)/2)*(C(i,n,3)+C(i-
1,n,3))+((kother*dt)/2)*(C(i,n,3)+C(i-1,n,3))-
((k2*dt)/2)*(C(i,n,4)+C(i-1,n,4))+C(i,n,4);        % reduced tissue 
         
        Qbweight1(n) = Qbweight1(n)+(H(i)*C(i,n,1));   %solving for a 
multiple capillaries (i.e. when i= 1:N) 
        Rbweight1(n) = Rbweight1(n)+(H(i)*C(i,n,2)); 
        Qcweight1(n) = Qcweight1(n)+(H(i)*C(i,n,3)); 
        Rcweight1(n) = Rcweight1(n)+(H(i)*C(i,n,4)); 
    end 
end 
  
  
aQb1 = trapz(t1,Qbweight1); 
aRb1 = trapz(t1,Rbweight1); 
tQo1 = t1.*Qbweight1; 
tQout1 = (trapz(t1,tQo1))/aQb1; 
vQo1 = ((t1.^2).*Qbweight1); 
vQbout1 = ((trapz(t1,vQo1))-(tQout1.^2))/aQb1; 
tRo1 = t1.*Rbweight1; 
tRout1 = (trapz(t1,tRo1))/aRb1; 
  
%% Oxidized venous blood  
for i = 1:length(t1) 
    if (i <= ns_v) 
        Cv_Qb1(i) = 0.0; 
    else Cv_Qb1(i) = Qbweight1(i-ns_v); 
    end 
        Qv_mean_t1(i) = t1(i)*Cv_Qb1(i)*dt;     
end 
  
%% Find the mean and variance of the oxidized blood curve 
areaQv1 = trapz(t1,Cv_Qb1);               % Find the area under the 
oxidized blood curve  
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Qv_mean_t1 = sum(Qv_mean_t1)/areaQv1;   % Sec, mean transit time of the 
oxidized blood curve 
varQv1 = ((t1-Qv_mean_t1).^2).*Cv_Qb1.*dt;       
varQv1 = sum(varQv1)/areaQv1;           % Sec^2, variance of oxidized 
blood curve 
  
  
%% Reduced venous blood 
for i = 1:length(t1) 
    if (i <= ns_v) 
        Cv_Rb1(i) = 0.0; 
    else Cv_Rb1(i) = Rbweight1(i-ns_v); 
    end 
    Rvmean_t1(i) = t1(i)*Cv_Rb1(i)*dt;     
end 
  
%% Find the mean and variance of the reduced blood curve 
areaRv1 = trapz(t1,Cv_Rb1);               % Find the area under the 
reduced blood curve  
Rv_mean_t1 = sum(Rvmean_t1)/areaRv1;    % Sec, mean transit time of the 
reduced blood curve 
varRv1 = ((t1-Rv_mean_t1).^2).*Cv_Rb1.*dt;       
varRv1 = sum(varRv1)/areaRv1;           % Sec^2, variance of reduced 
blood curve 
  
mean_lung1 = Qv_mean_t1 - Cinmean_t1;   % sec, mean transit time of 
lung Qbweight- Cin (out-in) 
  
%% Cumulative sum 
LAC1 = zeros(length(t1),1); 
  
for i = 1:(length(t1)-1) 
  LAC1(1) = Cin1(1)-Cv_Qb1(1); 
  LAC1(i+1) = LAC1(i)+(Cin1(i+1)-Cv_Qb1(i+1)); 
end   
  
LAC1 = F*dt*LAC1; 
  
['MeanCin = ', num2str(Cinmean_t1),', VarCin = ', num2str(varCin1), ', 
MeanArtery = ', num2str(Ca_mean_t1), ', VarArtery = ', 
num2str(varCa1),', Mean Capillary = ',num2str(tQout1),', Var Capillary 
= ',num2str(vQbout1),', Mean Venous = ',num2str(Qv_mean_t1),', Var 
Venous = ',num2str(varQv1)] 
  
%% Spline curve 
yy2 = spline(t1,LAC1,tdata2); 
  
%% Combine with and without DEM curves  
LAC2 = [yy1 yy2]; 
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E.2.7 Cin_curve_MethodB1.m 
% 5/4/17 
% This function creates the Cin curve and the artery curve for the lung 
WITHOUT DEM used in the PDE 
% simulation 
  
function [C1, Cin, Cin2, C3, Cinmean_t, varCin, Ca_mean_t, varCa] = 
Cin_curve_MethodB1(t,F,t01,ts,dose1,mu1,sigmas1,dt) 
%% Cin (input) curve for single capillary without DEM, gamma variate 
function 
  
for j=1:length(t) 
    if (t(j) <= t01) 
    Cin(j) = 0.0; 
    else 
    Cin(j) = dose1*((t(j) - t01)^(((mu1^2)/(sigmas1))-1))*(exp(-(t(j)-
t01)/((sigmas1)/mu1)));     % Input curve, gamma variate function 
    end 
    Cinmean_t(j) = t(j)*Cin(j)*dt; 
end 
  
%% Find the mean and variance of the Cin curve 
areaCin = trapz(t,Cin);       % Find the area under the Cin curve  
Cinmean_t = sum(Cinmean_t)/areaCin;  % Sec, mean transit time of Cin 
curve 
varCin = ((t-Cinmean_t).^2).*Cin.*dt;       
varCin = sum(varCin)/areaCin;    % Sec^2, variance of Cin curve 
  
Cin = Cin/trapz(t,Cin); 
Cin = dose1*Cin./F;         % Normalize the area under the Cin curve to 
dose/flow 
Cin2 = Cin*0;       % Percent of reduced HMPAO that enters the 
capillary region 
Cin = Cin*1;        % Percent of oxidized HMPAO that enters the 
capillary region 
  
%% Artery curve- shift the Cin curve by time ts to represent the 
percent of oxidized HMPAO that enters the capillary region 
ns = round(ts/dt);     % sec, divide the time shift by the step size 
for i = 1:length(t) 
    if (i <= ns) 
        C1(i) = 0.0; 
    else C1(i) = Cin(i-ns);     % C1 is the artery curve 
    end 
    Camean_t(i) = t(i)*C1(i)*dt;     
  
end 
  
%% Find the mean and variance of the artery curve 
areaCa = trapz(t,C1);               % Find the area under the artery 
curve  
Ca_mean_t = sum(Camean_t)/areaCa;    % Sec, mean transit time of the 
artery curve 
varCa = ((t-Ca_mean_t).^2).*C1.*dt;       
 145 
varCa = sum(varCa)/areaCa;           % Sec^2, variance of artery curve 
  
%% Artery curve- shift the Cin curve by time ts to represent the 
percent of reduced HMPAO that enters the capillary region 
for i = 1:length(t) 
    if (i <= ns) 
        C3(i) = 0.0; 
    else C3(i) = Cin2(i-ns);     % C1 is the artery curve 
    end 
    Camean_t2(i) = t(i)*C3(i)*dt;     
end 
 
E.2.8 hc_curve_MethodB1.m 
% 5/4/17 
% This function finds the hc curve that gives the mean transit time 
distribution used in the PDE simulation  
  
function [tc,hc,H,whc,dx,N] = 
hc_curve_MethodB1(t,t0,dose,mu,sigmas,F,dt,L) 
  
%% Find the point on the gamma variate function curve that corresponds 
with 0.01*max of the curve and find the time point (idx) that 
corresponds with that curve value 
hc2 = zeros(1,length(t)); 
% Create capillary gamma variate curve 
for j=1:length(t) 
    if (t(j) <= t0) 
    hc2(j) = 0.0; 
    else 
    hc2(j) = ((t(j) - t0)^(((mu^2)/(sigmas))-1))*(exp(-(t(j)-
t0)/((sigmas)/mu))); 
    end 
end 
  
% Normalize the area under the curve 
abc = trapz(t(1:length(t)),hc2);    % Determine area under the curve 
hc2 = hc2./abc;      % Scale the area to 1 
hc2 = hc2./F;        % Scale the area to 1/Flow 
  
% Find the time point that corresponds with 0.985*(max of curve) 
tcmax = 0.015*max(hc2);           
for i = round(mu/dt):length(t) 
    if (hc2(i)<=tcmax) 
        idx = t(i); 
        break  
    else  
        continue 
    end  
end 
idx         % Time value that corresponds with curve 
idx = round(idx/dt);  
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%% Create the hc curve, which corresponds with N (number of 
capillaries) mean transit times 
hc1 = zeros(1,idx); 
for j=1:idx 
    if (t(j) <= t0) 
    hc1(j) = 0.0; 
    else 
    hc1(j) = dose*((t(j) - t0)^(((mu^2)/(sigmas))-1))*(exp(-(t(j)-
t0)/((sigmas)/mu))); 
    end 
end 
  
% Scale the area under the hc1 curve to 1 
ab = trapz(t(1:idx),hc1);    % Determine area under the curve 
hc1 = hc1./ab;               % Scale the area to 1 
thc = idx*dt;  
  
% Find the mean transit time interval for N capillaries by dividing the 
max time point by the number of capillaries  
dx = dt/max(thc); 
N = round(1/dx); 
tc = 0:dt:max(thc); 
tc = tc(2:end); 
  
% Find the hc values that correspond with the N mean transit times 
hc = zeros(1,N); 
for j=1:length(tc) 
    if (tc(j) <= t0) 
    hc(j) = 0.0; 
    else 
    hc(j) = dose*((tc(j) - t0)^(((mu^2)/(sigmas))-1))*(exp(-(tc(j)-
t0)/((sigmas)/mu))); 
    end 
end 
  
  
%Scale the area under the hc curve to 1 
ab = trapz(tc,hc);    % Determine area under the curve 
hc = hc./ab;      % Scale the area to 1 
  
% Normalize the area of the summed hc values to 1 
area = sum(hc); 
area = area*dt; 
hc = hc/area; 
whc = hc*dt; 
  
dthc2 = max(thc)/(2*N); 
tc2 = 0:dthc2:max(thc); 
  
dx = dt/max(thc);      % step size between nodes, different for each 
mean transit time 
nx = round(1./dx);       % Number of nodes in the x-direction  
x = 0:dx:L; 
  
% Find the weights 
hctc = spline(tc,hc,tc2); 
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H = zeros(length(tc),1); 
for i = 1:(length(tc)); 
    if (tc(i) <= t0) 
        H(i) = 0.0; 
    else   
    H(i) = (dt/2)*((hctc((2*i)-1))+hctc((2*i)+1)); 
    end 
end 
sum(H); 
  
 
E.2.9 Cin_curve_DEM1.m 
% 5/4/17 
% This function finds the Cin curve and the artery curve for the lung 
WITH DEM used in the PDE 
% simulation 
  
function [C2, Cin1, Cin3, C4, Cinmean_t1, varCin1, Ca_mean_t1, varCa1] 
= Cin_curve_DEM1(t1,F,t02,ts,dose2,mu2,sigmas2,dt) 
%% Cin (input) curve for single capillary with DEM 
ns = round(ts/dt); 
  
for j=1:length(t1) 
    if (t1(j) <= t02) 
    Cin1(j) = 0.0; 
    else 
    Cin1(j) =((t1(j) - t02)^(((mu2^2)/(sigmas2))-1))*(exp(-(t1(j)-
t02)/((sigmas2)/mu2))); 
    end 
    Cinmean_t1(j) = t1(j)*Cin1(j)*dt; 
end 
  
%% Find the mean and variance of the Cin curve 
areaCin1 = trapz(t1,Cin1);       % Find the area under the Cin curve  
Cinmean_t1 = sum(Cinmean_t1)/areaCin1;  % Sec, mean transit time of Cin 
curve 
varCin1 = ((t1-Cinmean_t1).^2).*Cin1.*dt;       
varCin1 = sum(varCin1)/areaCin1;    % Sec^2, variance of Cin curve 
  
Cin1 = Cin1/trapz(t1,Cin1); 
Cin1 = dose2*Cin1./F;           % Normalize the area under the Cin 
curve to dose/flow 
Cin3 = Cin1*0;       % Percent of reduced HMPAO that enters the 
capillary region 
Cin1 = Cin1*1;       % Percent of oxidized HMPAO that enters the 
capillary region 
  
%% Artery curve- shift the Cin curve by time ts  
for i = 1:length(t1) 
    if (i <= ns) 
        C2(i) = 0.0; 
    else C2(i) = Cin1(i-ns);        % C2 is the artery curve 
    end 
    Camean_t1(i) = t1(i)*C2(i)*dt;     
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end 
  
%% Find the mean and variance of the artery curve 
areaCa1 = trapz(t1,C2);               % Find the area under the artery 
curve  
Ca_mean_t1 = sum(Camean_t1)/areaCa1;    % Sec, mean transit time of the 
artery curve 
varCa1 = ((t1-Ca_mean_t1).^2).*C2.*dt;       
varCa1 = sum(varCa1)/areaCa1;           % Sec^2, variance of artery 
curve 
  
for i = 1:length(t1) 
    if (i <= ns) 
        C4(i) = 0.0; 
    else C4(i) = Cin3(i-ns);     % C1 is the artery curve 
    end 
    Camean_t3(i) = t1(i)*C4(i)*dt;     
end 
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